


Given that this protocol had clearly surpassed our previously published work and given the ubiquity of the dibenzofurans with multiple methoxy groups, we challenged our methodology with highly electron-rich diarylether precursors, reminiscent of naturally occurring dibenzofuran scaffolds. To a methodology relying on a CMD/AMLA mechanism, we suspected these substrates would represent a significant challenge given the associated sterics and electronics.²² Two disubstituted precursors were prepared and excellent yields were observed for both the dimethyl (**43**) and dimethoxy (**44**) dibenzofuran scaffolds. Surprisingly, even the trimethoxy derivative (**45**) could be afforded in a superb yield of 90%. The ceiling of the systems tolerance was found with the tetramethoxy-substituted derivative **46** where a lower yield of 42% was observed. Nevertheless, this is a good, usable yield considering the electronic and steric challenges that this substrate poses.

**Scheme 49** Substrate scope of dibenzofurans synthesised

The structures of the electron-rich derivatives **44** (Figure 4) and **45** (Figure 5) were confirmed by X-ray diffraction analysis of single crystals. These single crystals were obtained by vapour diffusion from a saturated solution of dichloromethane and toluene respectively, in hexane.




Figure 4 Crystal structure of the dimethoxy dibenzofuran **44**





Figure 5 Crystal structure of the trimethoxy dibenzofuran **45**


2.7. Investigation into ‘Ligandless’ Conditions

As outlined in the Introduction to this Chapter, the use of quaternary organic salts with transition-metal catalysis is a well reported means of increasing reaction efficiency. In the case of Pd metal, the function of quaternary ammonium salts is relatively well understood, particularly in the context of the Heck-Mizoroki reaction, as described earlier. These quaternary salts are known to stabilise Pd-clusters or form catalytically active species with Pd-precursors. Work by Hong,⁷⁹ Hull⁷⁰ and Muzart¹⁰¹ all show how different Pd-catalysts can be reacted with quaternary ammonium salts to yield anionic Pd-species, which are catalytically active (Scheme 50). Hong and co-workers demonstrated how the isolated

anionic Pd-species remains catalytically active, even in the absence of additional ammonium salt, for the C–H functionalisation reaction depicted in Scheme 51.



Scheme 50 The different anionic Pd-species synthesised from quaternary ammonium salts




Entry	[Pd]	NR ₄ X	Yield ^a
1	Pd(OAc) ₂	Bu ₄ NBr	>99%
2	PdBr ₂	Bu ₄ NBr	91%
3	PdBr ₄ (Bu ₄ N) ₂	Bu ₄ NBr	46%
4	PdBr ₄ (Bu ₄ N) ₂	-	92%


^aYield determined by gas chromatography

Scheme 51 The catalytic activity of the anionic Pd-species developed by Hong

Inspired by these bodies of work, we looked to independently generate an anionic Pd-species corresponding to our reaction conditions. Using conditions similar to Hull and co-workers,⁷⁰ two equivalents of NBu₄OAc were added to one equivalent of Pd(OAc)₂ in dry acetone. The solution was then added to dry diethyl ether to crash out the desired palladate species **50** (Scheme 52). Once the palladate species was isolated, it was trialled in the model reaction. Using 5 mol% of the suspected palladate complex, and one equivalent of NBu₄OAc, the model diarylether **2** could be successfully ring closed in 34% yield (Scheme 53). This reaction demonstrates the catalytic activity of the proposed palladate species and thus, supports the hypothesis that this ammonium stabilised Pd-species is an active catalytic species in this system.




Scheme 52 The synthesis of the ammonium acetate palladate complex



Scheme 53 The catalytic capability of the palladate complex in our reaction

The strong precedent for quaternary ammonium salts stabilising Pd-clusters, or forming Pd nanoparticles, was a strong rationale for the conception of this project. We had also observed during the optimisation studies that the reaction performed well without the presence of phosphine ligand (70%, Table 1, Entry 1). Intrinsically, we wondered if an increase of quaternary ammonium salt would allow for higher yields to be achieved in the absence of any phosphine. Additionally, as the stoichiometry of the NBu₄OAc increases, the requirement for solvent is circumvented as the quaternary salt becomes molten upon heating, allowing the reaction to be performed ‘neat’. Pleasingly, with 2.5 mol% palladium and 5 equivalents of NBu₄OAc, a 81% yield was obtained. By doubling the NBu₄OAc equivalents to 10, a 93% isolated yield was obtained for this reaction, highlighting the potentially stabilising effect that these ammonium salts can have on palladium.

These conditions allow for excellent yields of electron-rich dibenzofurans to be obtained without the requirement for organic solvent, phosphine ligand or inorganic base. It is this potential role of NBu₄OAc acting as the reactions base, ‘solvent’ and ligand which makes the synergistic use of ammonium salts with palladium catalysis so powerful.




Entry	NBu ₄ OAc (equiv.)	Solvent	Yield ^a
1	2	1,4-dioxane	70%
2	5	Neat	81%
3	10	Neat	[93%]

^a Yield refers to ¹H NMR yield using 1,3,5-trimethoxybenzene as an internal standard
 Isolated yields are indicated by square brackets

Table 4 The use of NBu₄OAc to remove the requirement for phosphine ligands

Another potential role of organic salts in palladium-catalysis involves the reoxidation of catalytically inactive Pd-black to the active monomeric Pd-species. Work by de Vries⁸⁰ exhibits how halide salts can re-oxidise palladium black to allow improved catalyst turnover in the Heck reaction. Similarly, Sanford describes a Pd-catalysed reaction where the addition of a specific ligand can rescue off-cycle catalyst to keep the reaction turning over and improve the overall yield.¹⁰² In our previous methodology to access dibenzofurans, we noticed rapid formation of Pd-black as outlined in Section 2.2. We decided to investigate whether our NBu₄OAc could potential rescue some of the catalytically inactive Pd-black by oxidising the metal back to Pd (II). The Pd-catalyst (Pd(OAc)₂) was firstly stirred in 1,4-dioxane at 125 °C for 4 hours to degrade the metal to Pd-black, which was visibly observable. After this 4 hour period, the model substrate **2** was added to the flask, alongside 2 equivalents of NBu₄OAc, and left stir at reaction temperature for a further 24 hours. Interestingly, we saw a 15% conversion to the desired dibenzofuran **3**. When the parallel reaction was performed with K₂CO₃ as a base, only trace amounts of product was observed in the ¹H NMR spectrum. This experiment is not definitive but is certainly indicative towards the ability of NBu₄OAc to

rescue active palladium catalysts, pointing towards another function of this organic salt in our reaction.




Entry	Base	Yield ^a
1	NBu ₄ OAc	15%
2	K ₂ CO ₃	<1%

^aYield refers to ¹H NMR spectroscopy yield using 1,3,5-trimethoxybenzene as an internal standard

Table 5 Investigation into the potential of Pd (II) regeneration from Pd-black


Liu and co-workers previously reported studies on the role of quaternary organic salts in copper-catalysed carbon–nitrogen bond formation.⁸⁶ In this report, the tetraalkylammonium or phosphonium cations undergo conductivity measurements to exhibit how these species are readily ionised in organic solvent. The authors showcase how the solubility and relative ionizations of these organic bases facilitates the reaction. Accordingly, we looked to demonstrate that the success of NBu₄OAc in our protocol could not be attributed solely to improved solubility. A reaction scheme was designed where using our standard ligand and catalyst, we could employ an inorganic acetate base (KOAc) with a crown ether additive to provide improved solubility of the acetate anion (Scheme 54). However, when the crude NMR was analysed, no dibenzofuran product was observed. From this, we can rationalise that either i) the quaternary ammonium species is fundamental to the reactions success or ii) at some point in the catalytic cycle, an anionic species is formed which requires charge stabilisation which is inhibited by the presence of the crown ether additive. Regardless, we believe that the power of NBu₄OAc within the protocol is not solely a result of improved reaction homogeneity and solubility. Corresponding reactions were trialled with NMe₄OAc but they did not yield the same level of ring closure as achieved with NBu₄OAc (Table 2).




Scheme 54 The investigation into improved solubility of acetate anions using 18-C-6 additive

2.8. Mechanistic Considerations

As described previously, the mechanism of aryl-aryl bond formation by intramolecular direct arylation can occur by a variety of postulated mechanistic pathways (Scheme 55). This is dependent on reaction conditions and the substrate being considered. The predominant mechanistic pathway concerns a concerted metalation deprotonation CMD step and is depicted in Scheme 56. Our newly developed conditions allow previously unsuccessful substrate classes, in particular electron-rich diarylethers, to work exceedingly well by utilising NBu_4OAc . Considering this, we wondered could we gain a mechanistic insight into this transformation by comparing the reactivity and selectivity using our conditions with that using the standard conditions that facilitate a CMD step.




Scheme 55 The potential mechanistic pathways available for diaryl ethers in forming dibenzofurans



Scheme 56 General CMD mechanism for Pd-catalysed direct arylation


Several potential reaction schemes were devised to investigate mechanistic differences between our newly developed conditions and existing literature protocols. The premise and results of each of these will be outlined below. However, many of the pathways explored proved to be inconclusive and these will be discussed before the successful attempts.

Firstly, a competition experiment between the *p*-F (**6**) and *p*-OMe (**30**) substrates was analysed (Scheme 57). Both substrates were added to the same flask under the standard reaction conditions. It was hypothesised that one of the electron-rich or electron-poor *ortho*-protons would react faster than the other. This preferential rate of reaction, dependent on the electronics of the arene, would ideally indicate a mechanism type for our conditions. When this approach was trialled at the standard temperature of 125 °C, the reaction rate was too fast and no preferential ring closure could be observed. Accordingly, the temperature was lowered to 100 °C to capture slower reaction progression. However, even with this reduced reactivity, the NMR shifts of the newly formed products **36** and **42** coincided with the signals of the diarylether starting materials.




Scheme 57 The competition experiment between *p*-F and *p*-OMe under our protocol

We then synthesised a diarylether substrate where a competition experiment could be performed on the one molecule in an intramolecular competition experiment. By using the 3-fluoro-5-methoxy phenyl boronic acid (**51**) and 2-bromophenol starting materials, the desired model compound (**52**) could be synthesised in moderate yield (Scheme 58). This substrate was designed to have one *ortho*-proton influenced by electron donating properties, and the alternative *ortho*-proton influenced by electron withdrawing properties.




Scheme 58 The synthesis of a bifunctionalised model substrate for a competition experiment

Similarly, this substrate was subjected to the developed reaction conditions, where the products afforded (**53** and **54**) would be analysed to compare the arene site selectivity in the intramolecular ring closure (Scheme 59). The reaction was given the standard time of 24 hours to react but unfortunately, the crude NMR obtained gave a complex mixture of multiple products and was not definitive.



Scheme 59 Intramolecular competition experiment

In a similar fashion, we investigated the use of a *meta*-substituted diarylether precursor. It was hoped that the discrimination displayed towards one of the *ortho*-C–H bonds would allow us to decipher a viable mechanistic switch from standard CMD-type conditions, to our ammonium salt conditions. The *m*-fluorinated boronic acid **55** was coupled with 2-bromophenol to yield the desired model diarylether starting material **56** (Scheme 60).



Scheme 60 The synthesis of the *meta*-fluorinated diarylether

Subsequently, this precursor was subjected to literature ‘CMD-type’ conditions (obtained from Fagnou¹⁹) and the standard protocol we had developed using NBu₄OAc. The two potential products shown in Figure 6 have different ¹⁹F NMR signals and so, ¹⁹F qNMR was used as a measure of the relative ratios of product formed.¹⁰³ Using the ‘CMD-type’ conditions (Table 6, Entry 1) the ratio of *m*:*o* product was found to be 60:40. When our ammonium salt conditions were applied, the ratio of *m*:*o* product was found to be 70:30 (Table 6, Entry 2). This result is too small a difference to be considered a potential indicator for an alternative mechanism at play between these protocols. A large discrimination was seen between the *m*- and *o*-products for the *m*-substituted diarylether **11**, giving a ratio of 97:3 respectively (Scheme 61). However, the steric influence of this methoxy substituent is the likely factor.






Figure 6 The relative ¹⁹F NMR shifts for each product



Entry	Ligand	Base	Solvent	Ratio ^a 58 : 57
1	P ^t Bu ₂ Me.HBF ₄	K ₂ CO ₃	DMA	40 : 60
2	PCy ₃ .HBF ₄	NBu ₄ OAc	1,4-dioxane	30 : 70


^a Ratio determined by ¹⁹F NMR spectroscopy

Table 6 The electronic bias of different Pd-catalysed intramolecular direct arylation conditions for diarylethers



Scheme 61 The electronic bias between *o* and *m* protons of a *m*-OMe substituted diarylether

Finally, in an attempt to directly compare literature CMD conditions to our protocol, the reaction reported by Fagnou and co-workers shown in Table 7 was examined.⁴⁴ Using this *meta*-fluorinated benzyloxy ether (**60**), Fagnou reports an electronic bias where the proton *ortho* to the fluorine atom (**61**) was preferential activated in a ratio of 4.3:1, when $\text{PCy}_3\cdot\text{HBF}_4$ was employed as the ligand. When our conditions were applied to this substrate, a 1:1 ratio of both products was observed (Table 7). This change in selectivity may suggest a mechanistic switch for our protocol. However, it should be highlighted that when the phosphine ligand was changed in Fagnou's system, we observed varying ratios of the two constitutional isomers.



Entry	Base	Solvent	Ratio ^a 61 : 62
1	K ₂ CO ₃	DMA	4.3 : 1
2	NBu ₄ OAc	1,4-dioxane	1 : 1




^a Ratio determined by ¹H NMR spectroscopy

Table 7 The electronic bias of different Pd-catalysed intramolecular direct arylation conditions

2.9. Application to Six-Membered Ring Systems

Previously, within the McGlacken Group, the intramolecular direct arylation of benzyloxy ether substrates was investigated (Scheme 62).¹⁰⁴ With this work, the position of the halide


is fundamental to the success of the ring closure. Fagnou and co-workers previously described an excellent means of forming these benzochromene structures *via* intramolecular direct arylation.¹⁰⁵ Using this Pd-catalysed process, a range of steric and electronic effects was comprehensively explored. Catalytic loadings could be reduced to as low as 0.1 mol% while still retaining excellent yields of product. Additionally, the ethereal oxygen linker could be replaced with a nitrogen or carbon atom. Within the McGlacken Group, similar results were seen when the reaction was trialled with an alternative phosphine ligand. However, when the halide atom is on the phenolic fragment of the starting material, these conditions fail to yield any product. Furthermore, it was observed that when 'CMD-type' conditions were employed, only dehalogenated starting material was furnished.

Fagnou*McGlacken**McGlacken*

Scheme 62 Synthesis of benzochromenes performed by Fagnou and within the McGlacken Group

To date, the intramolecular direct arylation of benzyl ethers where the halide resides on the phenolic fragment, is unreported. With the successful use of NBu_4OAc to effect ring closure

in dibenzofuran, we envisaged that this benzyl ether ring closure could be facilitated by the addition of quaternary ammonium salts. Using a variety of Pd catalysts and phosphine ligands, a number of reaction conditions were investigated for this substrate (Table 8). Using 5 mol% of Pd(OAc)₂, 10 mol% of P^tBu₃.HBF₄ and two equivalents of NBu₄OAc, the desired benzochromene could be generated in 55% yield after 48 h (Table 8, Entry 1). Unfortunately however, this result was not reproducible and the product yield varied significantly when the reaction was repeated. Alternative catalyst/ligand loadings, palladium catalysts, phosphine ligands, solvents and solvents were investigated alongside reaction temperature and time. Unfortunately, none of these initial attempts could provide good yields of the desired product. The use of added pivalic acid did not increase the yield of the reaction, despite the prominence found with employing pivalic acid as a key proton shuttle in CMD-type palladium-catalysed reactions (Table 8, Entry 4). The use of silver salt additives was also investigated, on the pretence that in C–H Activation events silver salts are well documented to facilitate key steps in the catalytic cycle. Unfortunately, the addition of silver carbonate did not increase the product yield (Table 8, Entry 7). Dimethylacetamide (DMA) (Table 8, Entries 8-10) and hexafluoro isopropanol (HFIP) (Table 8, Entry 12) were also trialled as solvents in the reaction, given the success observed when employing these solvents in C–H activation reactions. DMA gave good conversion to our desired benzochromene but disappointingly, only trace amounts of product were observed when HFIP was used as the reaction solvent. It is worth highlighting that in nearly all experiments, a moderate yield of the difficult-to-access benzochromene was observed, setting a proof-of-principle for further optimisation.



Entry	<i>Pd(OAc)₂</i> (mol%)	Ligand (mol%)	Additive (equiv.)	Base	Solvent	Time (h)	Yield ^a
1	5	P ^t Bu ₃ .HBF ₄ (10)	-	NBu ₄ OAc	dioxane	48	55%
2	2.5	P ^t Bu ₃ .HBF ₄ (05)	-	NBu ₄ OAc	dioxane	24	34%
3	2.5	PCy ₃ .HBF ₄ (05)	-	NBu ₄ OAc	dioxane	24	16%
4	5	P ^t Bu ₃ .HBF ₄ (10)	PivOH ^b	NBu ₄ OAc	dioxane	24	21%
5	5	P ^t Bu ₃ .HBF ₄ (10)	-	KOAc	dioxane	24	10%
6	5	P(<i>p</i> FC ₆ H ₄) ₃ (10)	-	NBu ₄ OAc	dioxane	24	15%
7	5	P ^t Bu ₃ .HBF ₄ (10)	Ag ₂ CO ₃ ^b	NBu ₄ OAc	dioxane	24	24%
8	5	P ^t Bu ₃ .HBF ₄ (10)	-	NBu ₄ OAc	DMA ^c	24	39%
9	5	PCy ₃ .HBF ₄ (10)	-	NBu ₄ OAc	DMA	24	43%
10	Pd(OPiv) ₂	PCy ₃ .HBF ₄ (10)	-	NBu ₄ OAc	DMA	24	18%
11	PdCl ₂ (MeCN) ₂	P ^t Bu ₃ .HBF ₄ (10)	-	NBu ₄ OAc	dioxane	24	23%
12	5	PCy ₃ .HBF ₄ (10)	-	NBu ₄ OAc	HFIP	24	6%
13	5	PCy ₃ .HBF ₄ (10)	-	NBu ₄ OAc ^d	DMA	24	15%

^a Yield refers to ¹H NMR yield which is calculated using 1,3,5-trimethoxybenzene as an internal standard



^b 30 mol% of the additive used

^c Reaction performed at 140 °C

^d 5 equivalents of base used

Table 8 Optimisation for the synthesis of benzochromene using NBu₄OAc


Given the moderate success of DMA as a solvent for the reaction, a variety of phosphine ligands were screened in the reaction (Scheme 63). SPhos proved to be an excellent ligand when employed with NBu_4OAc , producing the product in 74% yield. However, like previous experiments with this reaction type, the yield varied significantly upon repetition.



^a Yield refers to ^1H NMR yield which is calculated using 1,3,5-trimethoxybenzene as an internal standard

Scheme 63 Effect of ligand screening on the benzochromene synthesis

As a final attempt to enable this intramolecular direct arylation, we postulated that the tetrabutylphosphonium acetate that was developed during the dibenzofuran investigation, could produce higher yields in the reaction. Thus, two equivalents of PBU_4OAc were used in DMA with our standard conditions (Scheme 64). However, only poor conversion to the product was observed.




Scheme 64 The use of PBu_4OAc in the intramolecular ring closure of benzoxyethers


Thus far, only poor to moderate yields of the benzochromene scaffold have been obtained from the intramolecular direct arylation of benzyloxy substrates with a halogenated phenol. The good yields obtained have been found to be somewhat irreproducible and inconsistent. However, to the best of our knowledge, this is the first time that this particular substrate has been successfully ring closed, albeit in moderate yields. The formation of any product, irrespective of the yield, showcases the potential for quaternary ammonium salts to facilitate difficult Pd-catalysed transformations. Further work is required to find a consistent reaction system that produces good yields of the desired substrate.

2.10. Application to Indoloquinoline Substrates

Many polycyclic alkaloids are found in traditional herbal medicines which have contributed to the discovery of new therapeutic agents.¹⁰⁶ The indoloquinoline structure is one such alkaloid found in the West African Climbing Shrub *Cryptolepis sanguinolenta*.^{107,108} The roots of this plant have been used by traditional African healers for centuries in the treatment of a multitude of afflictions.^{106,109} The indoloquinoline structure is termed a privileged scaffold due to the breadth of its therapeutic use. 11*H*-Indolo[3,2-*c*]quinoline (**66**) is an isomeric analogue of other naturally occurring indoloquinolines such as isocryptolepine, neocryptolepine and cryptolepine. An indoloquinoline scaffold is characterised by an indole and quinoline fused ring system. One can envisage a key C–H activation step to create this tetracyclic motif.



Previous work within the McGlacken group described a Pd-catalysed approach to yield a range of benzofuroquinolines.¹¹⁰ Within this work, a two-step procedure was reported where a Buchwald-Hartwig amination and subsequent intramolecular direct arylation was detailed (Scheme 65). Initially, the brominated quinoline (**67**) and aniline (**68**) starting materials underwent a Buchwald-Hartwig amination to yield the diarylamine intermediate **69**. This intermediate then underwent a C–H activation event to yield the desired indoloquinoline product **66** in 61% yield over two-steps (Scheme 65).



Scheme 65 The synthesis of indoloquinoline via Buchwald-Hartwig coupling and subsequent direct arylation


At the time of this work, this indoloquinoline product was sent for biological evaluation for quorum sensing and yielded promising results as an antibacterial agent. Consequently, a more efficient route to target was desired as a range of these indoloquinolines would have to be synthesised. As depicted in Scheme 65, both steps share the features of high

temperature and Pd-catalysis. Given our success of employing NBu₄OAc with Pd-catalysis in the synthesis of dibenzofurans, it was postulated that the organic base may improve this synthetic route. An initial problem with this route is the requirement for NMP in the C–H Activation step. NMP was required as the solvent to get acceptable yields of the desired product. However, NMP is highly toxic and required multiple steps of column chromatography to be removed. It is well documented that NMP can act as a ligand for Pd species in solution. It was thought that this potential ligation, or the increased solubility of Pd complexes in NMP relative to dioxane, was why NMP was required to obtain high yields of product.

However, it was hypothesised that the use of NBu₄OAc may allow the transformation to occur in dioxane, removing the prerequisite for extensive purification. Pleasingly, when NBu₄OAc was trialled in the reaction, complete consumption of starting material was observed after six hours. This success created parallels between both steps, namely; Pd catalyst, carboxylate base, dioxane solvent, inert atmosphere and high temperature. Accordingly, a one-pot approach employing NBu₄OAc was attempted (Scheme 66). Pleasingly, with 3.5 equivalents of NBu₄OAc, the indoloquinoline could be generated in 98% yield in one-pot, with dioxane as the solvent (Table 9, Entry 1). The catalyst and ligand loading was lowered to 2.5 and 5 mol% respectively, but a drop in yield to 81% was observed (Table 9, Entry 2). Using loadings of 5 and 10 mol% for the catalyst and ligand, the loading of NBu₄OAc could be reduced to 2 equivalents while retaining the high yield of 98% (Table 9, Entry 3). Similarly, an excellent yield of 90% was achieved when the ligand loading was lowered to 6 mol% (Table 9, Entry 4). Interestingly, NBu₄OAc also enabled changing the solvent to cyclopentylmethyl ether (CPME) (Table 9, Entry 5 and 6). CPME is classed as a green solvent^{94,95} and is a significant advancement from the original solvent of NMP. Furthermore, it was found that the reaction did not require an inert atmosphere under these conditions. Using 5 and 6 mol% of the catalyst and phosphine respectively, with 2 equivalents of NBu₄OAc in CPME, the reaction could proceed in air to give an 86% isolated yield of the desired product (Table 9, Entry 8). However, it is worth noting that when the reaction was trialled in non-anhydrous solvent (Table 9, Entry 7), or in the absence of phosphine (Table 9, Entry 9) the yield was reduced.

To conclude, the indoloquinoline scaffold can be synthesised in excellent yields in one-pot from simple starting materials when NBu₄OAc is employed in the reaction. Many previous syntheses utilise harsh reaction conditions, hazardous reagents or multi-step protocols to access these scaffolds. When using an excess of quaternary ammonium salt, a one-pot

procedure can be carried out to achieve high yields of the desired product without the need for phosphine ligand or additional solvent.




Scheme 66 The one-pot optimisation of the synthesis of indoloquinoline

Entry	$\text{Pd}_2(\text{dba})_3$ (mol%)	XantPhos (mol%)	NBu_4OAc (equiv.)	Time (h)	Solvent (dried)	Atmosphere	Yield ^a
1	5	10	3.5	30	dioxane	N ₂	98% ^a
2	2.5	5	3.5	30	dioxane	N ₂	81% ^a
3	5	10	2	30	dioxane	N ₂	98% ^a
4	5	6	2	30	dioxane	N ₂	90% ^a
5	5	10	2	30	CPME	N ₂	93% ^a
6	5	6	2	30	CPME	N ₂	90% ^a
7	5	10	2	30	CPME ^b	N ₂	32% ^a
8	5	6	2	30	CPME	Air	[86%]
9	5	0	2	48	CPME	Air	17% ^a

^a Yield refers to ¹H NMR yield which is calculated using 1,3,5-trimethoxybenzene as an internal standard
^b Refers to non-anhydrous solvent used in the reaction

Table 9 The optimisation of the one-pot synthesis of indoloquinoline

As showcased with the synthesis of dibenzofurans the use of excess quaternary ammonium salt can obviate the requirement for phosphine ligands. A similar investigation was performed with the one-pot synthesis of indoloquinoline (Scheme 67). To our delight, the desired tetracyclic product was formed in an excellent yield of 94% when 5 mol% of Pd catalyst was used with 10 equivalents of NBu₄OAc. As discussed earlier, NBu₄OAc can be identified as an ionic liquid and so, when adding 10 equivalents of the salt to the reaction, the need for a solvent is removed. In this case, the NBu₄OAc performs as the base, solvent and potentially a ligand in the system.



Scheme 67 The use of excess NBu_4OAc to allow removal of phosphine

2.11. Conclusions and Future Work

The intramolecular cyclisation of electron-rich diarylethers and diarylamines was successfully demonstrated. In the case of diarylether substrates, a range of dibenzofuran scaffolds were furnished in excellent yields by employing NBu_4OAc in the Pd-catalysed C–H Activation event. A protocol where excess NBu_4OAc could act as the base, solvent and ligand furnished the desired dibenzofuran in 93% yield. Investigations into the role of the NBu_4OAc salt were explored. It was postulated that the quaternary ammonium salt can possibly stabilise palladium colloids, rescue off-cycle palladium or form active palladate species. These palladium-ammonium interactions are attributed to the successful C–H Activation performed on these difficult electron-rich substrates. Furthermore, the protocol was extended to indoloquinolines. A one-pot Buchwald-Hartwig, C–H activation procedure was devised where halogenated quinolines and anilines could be coupled using Pd-catalysis and NBu_4OAc . This improved protocol reduces the steps required to access indoloquinolines. Additionally, the requirement for hazardous reagents like NMP are circumvented when NBu_4OAc was employed.

Future work on this project will involve synthesising a range of indoloquinolines to be biologically evaluated for their antibacterial properties. A key goal of future work is to better understand the palladium-ammonium complex which enables the transformation to take place.

3. Experimental

3.1. General Procedures

All solvents and reagents purchased from Sigma Aldrich, Fluorochem/Doug Discovery, Alfa Aesar, Tokyo Chemical Industry and Strem were used as obtained from commercial sources and without purification, unless otherwise noted. All experiments performed under inert conditions were done so under an atmosphere of nitrogen atmosphere, using flame-dried glassware and Schlenk set-up. When required, solvents were dried using activated 3 Å molecular sieves (20% w/v) and stored inertly in a Young's flask.


Wet flash column chromatography was carried out using Kieselgel 60 Å (35-70 µm) silica gel (Merck). Thin Layer Chromatography (TLC) was carried out on pre-coated silica gel plates (Merck 60 PF254). Visualisation was achieved by UV light and staining with potassium permanganate staining. Melting points (m.p) were recorded on a uni-melt Thomas Hoover Capillary melting point apparatus or an Electrothermal IA9300 Digital Melting Point apparatus.

NMR spectra were run in CDCl₃ using tetramethylsilane (TMS) as the internal standard at 25 °C, unless otherwise specified. ¹H NMR (600 MHz spectra), ¹H NMR (500 MHz) spectra, ¹H NMR (400 MHz) spectra and ¹H NMR (300 MHz) spectra were recorded on Bruker Avance 600, Bruker Avance 500, Bruker Avance 400 and Bruker Avance 300 NMR spectrometers respectively. ¹³C (150 MHz) spectra, ¹³C (125 MHz) spectra, ¹³C (100 MHz) spectra and ¹³C (75.5 MHz) spectra were recorded on Bruker Avance 600, Bruker Avance 500, Bruker Avance 400 and Bruker Avance 300 NMR spectrometers respectively in proton decoupled mode. ¹⁹F NMR (376 MHz) and ¹⁹F NMR (282 MHz) spectra were recorded on a Bruker Avance 400 and Bruker Avance 300 NMR spectrometers respectively in proton decoupled mode. All spectra were recorded at University College Cork. Chemical shifts δ_H and δ_C are expressed as parts per million (ppm), positive shift being downfield from TMS; coupling constants (*J*) are expressed in hertz (Hz) as observed and are uncorrected. Splitting patterns in ¹H NMR spectra are designated as s (singlet), br s (broad singlet), d (doublet), dd (doublet of doublets), dt (doublet of triplets), t (triplet), q (quartet) and m (multiplet). For ¹³C NMR spectra, the number of attached protons for each signal was determined using the DEPT pulse sequence run in the DEPT-90 and DEPT-135 modes. ¹H-¹H COSY, HSQC, and HMBC experiments were performed to aid the NMR assignment of novel chemical structures.

Nominal mass spectra (LRMS) were recorded on a Waters Quattro Micro Triple Quadrupole spectrometer (QAA1202) in ESI mode using 50% acetonitrile–water containing 0.1% formic acid as eluent. Samples were prepared in acetonitrile. High resolution mass spectra (HRMS) were recorded on a Waters LCT Premier Time of Flight (ToF LC-MS) spectrometer (KD160) or a Waters Vion IMS mass spectrometer (SAA055 K) with Waters Acquity I-class UPLC in electrospray ionisation (ESI) mode using 50% acetonitrile–water containing 0.1% formic acid as eluent and Leucine Enkephalin as a reference solution. Samples (max. 1 mg/mL) were dissolved in acetonitrile, methanol, water or 10% DMSO/acetonitrile.

The Microanalysis Laboratory, National University of Ireland, Cork, performed elemental analysis using a Perkin-Elmer 240 and Exeter Analytical CE440 elemental analysers.


^1H NMR spectra, ^{13}C spectra, and LRMS analyses were recorded for all previously reported compounds. For novel compounds, in addition to the aforementioned analyses, HRMS and 2D ^1H NMR spectra were also obtained. Crystal structures were also obtained for select substrates.

2-bromo-4-methoxy-1-phenoxybenzene (2)

2-bromo-4-methoxy phenol (406 mg, 2 mmol, 1 equiv.), phenyl boronic acid (487 mg, 4 mmol, 2 equiv.), Cu(OAc)₂ (1 equiv.) and triethylamine (1.4 mL, 5 equiv.) were added to a 250 mL round-bottom flask containing DCM (20 mL) and 3 Å molecular sieves.

The resulting mixture was stirred at room temperature until TLC analysis indicated complete consumption of starting material (48 h). The reaction mixture was then filtered through Celite® using hexanes (60 mL). The filtrate was then concentrated *in vacuo* and the resulting residue was purified by silica gel chromatography (7:3 hexane:DCM, gradient to 100% hexane) to yield the title product as a white solid (386 mg, 69%). M.P: 63 °C (lit. 61–62 °C).¹¹¹


¹H NMR (300 MHz, CDCl₃) δ_H: 7.34 – 7.26 (m, 2H), 7.17 (d, *J* = 3.0 Hz, 1H), 7.09 – 6.94 (m, 2H), 6.93 – 6.78 (m, 3H), 3.80 (s, 3H) ppm. ¹³C NMR (75 MHz, CDCl₃) δ_C: 157.9, 156.6, 146.6, 129.6, 122.5, 118.5, 116.7, 116.1, 114.6, 55.9 ppm. HRMS (ESI-TOF) *m/z*: [M]⁺ calcd. for C₁₃H₁₁BrO₂: 279.0015, found: 279.0022.

2-bromo-4-fluoro-1-phenoxybenzene (5)

2-bromo-4-fluorophenol (382mg, 2 mmol, 1 equiv.), phenyl boronic acid (488 mg, 4 mmol, 2 equiv.), Cu(OAc)₂ (1 equiv., 2 mmol) and triethylamine (1.4 mL, 5 equiv., 10 mmol) were added to a 250 mL round-bottom flask containing DCM (20 mL) and 3 Å


molecular sieves. The resulting mixture was stirred at room temperature until TLC analysis indicated complete consumption of starting material (48 h). The reaction mixture was then filtered through Celite® using hexanes (60 mL). The filtrate was then concentrated *in vacuo* and the resulting residue was purified by silica gel chromatography (7:3 DCM:Hexane) to yield the title product as a white solid (214 mg, 40%). MP: 63 °C (lit 60 – 61 °C). Characterisation data is consistent with the literature.⁴⁵

¹H NMR (400 MHz, CDCl₃) δ_H: 7.44 – 7.31 (m, 3H), 7.16 – 7.10 (m, 1H), 7.07 – 6.93 (m, 4H) ppm. ¹³C NMR (125 MHz, CDCl₃) δ_C: 158.7 (d, *J*_{C-F} = 246 Hz), 157.2, 149.8 (d, *J*_{C-F} = 3.0 Hz), 129.8, 123.3, 121.8 (d, *J*_{C-F} = 9.0 Hz), 120.7 (d, *J*_{C-F} = 26 Hz), 117.5, 115.6 (d, *J*_{C-F} = 23.0 Hz), 115.5 ppm. δ_F (376 MHz, CDCl₃): -117.2 ppm

1-bromo-2-(4-fluorophenoxy)benzene (6)


2-bromophenol (346 mg, 2 mmol, 1 equiv.), 4-fluorobenzene boronic acid (560 mg, 4 mmol, 2 equiv.), Cu(OAc)₂ (363 mg, 1 equiv., 2 mmol) and triethylamine (1.4 mL, 5 equiv., 10 mmol) were added to a 250 mL round-bottom flask containing DCM (20 mL) and 3 Å molecular sieves. The resulting mixture was stirred at room temperature until TLC analysis indicated complete consumption of starting material (48 h). The reaction mixture was then filtered through Celite® using hexanes (60 mL). The filtrate was then concentrated *in vacuo* and the resulting residue was purified by silica gel chromatography (7:3 hexane:DCM) to yield the title product as a colourless oil (374 mg, 70%). Characterisation data is consistent with the literature.⁴⁵

¹H NMR (400 MHz, CDCl₃) δ_H: 7.62 (dd, *J* = 8.0, 1.4 Hz, 1H), 7.29 – 7.22 (m, 1H), 7.08 – 6.87 (m, 6H) ppm. ¹³C NMR (100 MHz, CDCl₃) δ_C: 158.8 (d, *J*_{C-F} = 243 Hz), 154.0, 152.7 (d, *J*_{C-F} = 2.4 Hz), 133.9, 128.7, 124.9, 119.9 (2 x CH, d, *J*_{C-F} = 11.5 Hz), 119.7, 116.3 (2 x CH, d, *J*_{C-F} = 23.5 Hz), 114.5 ppm. δ_F (282 MHz, CDCl₃): -119.9 ppm. HRMS (ESI-TOF) *m/z*: [M+Na]⁺ calcd. for C₁₂H₈BrFONa: 288.9634, found: 288.9625.

3-bromo-4-phenoxy pyridine (7)

A mixture of 3-bromo-4-chloro pyridine (0.3 g, 1.56 mmol, 1 equiv.) and phenol (0.586 g, 6.23 mmol, 5 equiv.) were added to a 250 mL round bottomed flask and stirred neat at 130 °C in an oil bath until TLC analysis indicated complete consumption of starting material. The cooled reaction mixture was then diluted with 10% aq. NaOH (5 mL) and stirred at room temperature for 1 hour. The aqueous phase was extracted with DCM (3 x 10 mL). The combined organics were washed with 6M NaOH (3 x 10 mL), water (10 mL) and brine (10 mL) and then dried with MgSO₄, filtered and concentrated *in vacuo*. The crude product was passed through a short pad of silica (hexanes:EtOAc, 3:1) to yield the title product as a yellow oil (0.345 g, 88%).


¹H NMR (300 MHz, CDCl₃) δ_H: 8.70 (bs, 1H), 8.30 (bs, 1H), 7.49 – 7.40 (m, 2H), 7.31 – 7.24 (m, 1H), 7.14 – 7.07 (m, 2H), 6.62 (d, *J* = 5.6 Hz, 1H) ppm. ¹³C NMR (75 MHz, CDCl₃) δ_C: 161.4, 153.8, 153.3, 149.8, 130.3, 125.8, 120.6, 116.3 and 111.6 ppm. HRMS (ESI-TOF) *m/z*: [M]⁺ calcd. for C₁₁H₈BrNO: 249.9862, found: 249.9861.

1-(3-bromo-4-phenoxyphenyl)ethan-1-one (8)

2-bromophenol (0.126 mL, 1.2 mmol, 1 equiv.), 4-acetyl phenyl boronic acid (399 mg, 2.4 mmol, 2 equiv.), Cu(OAc)₂ (218 mg, 1 equiv., 1.2 mmol) and triethylamine (0.84 mL, 5 equiv., 10 mmol) were added to a 250 mL round-bottom flask containing DCM (12

mL) and 3 Å molecular sieves. The resulting mixture was stirred at room temperature until TLC analysis indicated complete consumption of starting material (24 h). The reaction mixture was then filtered through Celite® using hexanes (60 mL). The filtrate was then concentrated *in vacuo* and the resulting residue was purified by silica gel chromatography (100% DCM) to yield the title product as a white solid (105 mg, 30%). MP: 61 °C.


¹H NMR (300 MHz, CDCl₃) δ_H: 7.98 – 7.91 (m, 2H), 7.67 (dd, *J* = 7.9, 1.6 Hz, 1H), 7.35 (td, *J* = 15.6, 1.6 Hz, 1H), 7.16 – 7.06 (m, 2H), 6.97 – 6.91 (m, 2H), 2.57 (s, 3H) ppm ¹³C NMR (125 MHz, CDCl₃) δ_C: 196.6, 161.3, 152.0, 134.1, 132.1, 130.6, 129.0, 126.4, 122.4, 116.5, 115.9, 26.4 ppm. HRMS (ESI-TOF) *m/z*: [M]⁺ calcd. for C₁₄H₁₁BrO₂: 291.0015, found: 291.0027.

1-bromo-2-phenoxybenzene (9)

2-bromo phenol (0.117 mL, 1 mmol, 1 equiv.), phenyl boronic acid (244 mg, 2 mmol, 2 equiv.), Cu(OAc)₂ (181 mg, 1 mmol, 1 equiv.) and triethylamine (0.7 mL, 5 mmol, 5 equiv.) were added to a 250 mL round-


bottom flask containing DCM (10 mL) and 3 Å molecular sieves. The resulting mixture was stirred at room temperature until TLC analysis indicated complete consumption of starting material (20 h). The reaction mixture was then filtered through Celite® using hexanes (60 mL). The filtrate was then concentrated *in vacuo* and the resulting residue was purified by silica gel chromatography (100% Hexane) to yield the title product as a colourless oil (151 mg, 61% yield). Characterisation data is consistent with the literature.⁴⁹

¹H NMR (400 MHz, CDCl₃) δ_H: 7.63 (dd, *J* = 7.9, 1.4 Hz, 1H), 7.36 – 7.29 (m, 2H), 7.28 – 7.22 (m, 1H), 7.14 – 7.07 (m, 1H), 7.05 – 6.93 (m, 4H). ¹³C NMR (100 MHz, CDCl₃) δ_C: 156.9, 153.7, 133.8, 129.8, 129.7, 128.6, 124.9, 123.4, 120.6, 118.9, 118.1, 114.9 ppm. HRMS (ESI-TOF) *m/z*: [M]⁺ calcd. for 248.9909 found 248.9907.

1-bromo-2-(*m*-tolxyloxy)benzene (10)


2-bromo phenol (0.23 mL, 2 mmol, 1 equiv.), 3-tolyl boronic acid (544 mg, 4 mmol, 2 equiv.), Cu(OAc)₂ (363 mg, 2 mmol, 1 equiv.) and triethylamine (1.4 mL, 10 mmol, 5 equiv.) were added to a 250 mL round-bottom flask containing DCM (20 mL) and 3 Å molecular sieves. The resulting mixture was stirred at room temperature until TLC analysis indicated complete consumption of starting material (48 h). The reaction mixture was then filtered through Celite® using hexanes (60 mL). The filtrate was then concentrated *in vacuo* and the resulting residue was purified by silica gel chromatography (7:3 DCM:Hexane) to yield the title product as a clear oil (294 mg, 56%).

¹H NMR (300 MHz, CDCl₃) δ_H; 7.61 (dd, *J* = 7.9, 1.6 Hz, 1H), 7.28 – 7.15 (m, 2H), 7.01 – 6.85 (m, 3H), 6.84 – 6.71 (m, 2H), 2.32 (s, 3H) ppm. ¹³C NMR (75 MHz, CDCl₃) δ_C; 156.9, 153.8, 140.0, 133.8, 129.5, 128.6, 124.8, 124.3, 120.6, 118.9, 115.2, 114.9, 21.4 ppm. HRMS (ESI-TOF) *m/z*: [M+H]⁺ calculated for C₁₃H₁₁BrO: 263.0066 found 263.0070.

1-bromo-2-(3-methoxyphenoxy)benzene (11)

2-bromo phenol (0.105 mL, 1 mmol, 1 equiv.), 3-methoxy phenyl boronic acid (304 mg, 2 mmol, 2 equiv.), Cu(OAc)₂ (181 mg, 1 mmol, 1 equiv.) and triethylamine (0.7 mL, 5 mmol, 5 equiv.) were added to a 250 mL round-bottom flask containing DCM (10 mL) and 3 Å molecular sieves. The resulting mixture was stirred at room temperature until TLC analysis indicated complete consumption of starting material (24 h). The reaction mixture was then filtered through Celite® using hexanes (60 mL). The filtrate was then concentrated *in vacuo* and the resulting residue was purified by silica gel chromatography (1:1 Hexane:DCM) to yield the title product as a colourless oil (199 mg, 71%). Characterisation data consistent with the literature.⁴⁹


¹H NMR (300 MHz, CDCl₃) δ_H; 7.65 – 7.57 (m, 1H), 7.29 – 7.16 (m, 2H), 7.04 – 6.95 (m, 2H), 6.67 – 6.62 (m, 1H), 6.56 – 6.48 (m, 2H), 3.76 (s, 3H) ppm. ¹³C NMR (75 MHz, CDCl₃) δ_C; 161.0, 158.1, 153.5, 133.8, 130.2, 128.7, 125.2, 120.9, 115.0, 110.1, 109.0, 104.2, 55.4 ppm. HRMS (ESI-TOF) *m/z*: [M]⁺ calcd. for C₁₃H₁₁BrO₂: 279.0015, found: 279.0016.

2-(2-bromophenoxy)-1,4-dimethylbenzene (12)

2-bromo phenol (0.23 mL, 2 mmol, 1 equiv.), 2,5-dimethyl phenyl boronic acid (600 mg, 4 mmol, 2 equiv.), Cu(OAc)₂ (383 mg, 2 mmol, 1 equiv.) and triethylamine (1.4 mL, 10 mmol, 5 equiv.) were added to a 250 mL round-bottom flask containing DCM (20 mL) and 3 Å molecular

sieves. The resulting mixture was stirred at room temperature until TLC analysis indicated complete consumption of starting material (48 h). The reaction mixture was then filtered through Celite® using hexanes (60 mL). The filtrate was then concentrated *in vacuo* and the resulting residue was purified by silica gel chromatography (7:3 DCM:Hexane) to yield the title product as a yellow oil (189 mg, 34%).


¹H NMR (400 MHz, CDCl₃) δ_H; 7.61 (dd, *J* = 8.0, 1.3 Hz, 1H), 7.22 – 7.16 (m, 1H), 7.13 (d, *J* = 7.7 Hz, 1H), 6.93 (td, *J* = 7.7, 1.3 Hz, 1H), 6.88 (d, *J* = 8.0 Hz, 1H), 6.72 (dd, *J* = 8.0, 1.3 Hz, 1H), 6.65 (s, 1H), 2.27 (s, 3H) and 2.20 (s, 3H) ppm. ¹³C NMR (125 MHz, CDCl₃) δ_C; 154.4, 153.9, 137.1, 133.7, 131.2, 128.4, 126.3, 124.9, 123.7, 119.7, 118.1, 113.4, 20.9, 15.7 ppm. HRMS (ESI-TOF) *m/z*: [M]⁺ calcd. for C₁₄H₁₃BrO: 277.0222, found: 277.0221.

2-bromo-4-methoxy-1-(4-methoxyphenoxy)benzene (13)

2-bromo-4-methoxy phenol (305 mg, 1.5 mmol, 1 equiv.), *p*-methoxy phenyl boronic acid (456 mg, 3 mmol, 2 equiv.), Cu(OAc)₂ (272 mg, 1.5 mmol, 1 equiv.) and triethylamine


(1.05 mL, 7.5 mmol, 5 equiv.) were added to a 250 mL round-bottom flask containing DCM (15 mL) and 3 Å molecular sieves. The resulting mixture was stirred at room temperature until TLC analysis indicated complete consumption of starting material (48 h). The reaction mixture was then filtered through Celite® using hexanes (60 mL). The filtrate was then concentrated *in vacuo* and the resulting residue was purified by silica gel chromatography (8:2 CHCl₃:Hexane) to yield the title product as a colourless oil (88 mg, 19%).

¹H NMR (300 MHz, CDCl₃) δ_H; 7.15 (d, *J* = 2.9 Hz, 1H), 6.92 – 6.76 (m, 6H), 3.77 (apparent doublet, 6H) ppm. ¹³C NMR (75 MHz, CDCl₃) δ_C; 156.1, 155.4, 151.4, 147.9, 121.2, 119.5, 118.6, 118.5, 115.1, 114.8, 114.5, 55.9, 55.7 ppm. HRMS (ESI-TOF) *m/z*: [M]⁺ calcd. for C₁₄H₁₃BrO₃: 309.0121, found: 309.0115.

2-bromo-1-(3,4-dimethoxyphenoxy)-4-methoxybenzene (14)


2-bromo-4-methoxy phenol (406 mg, 2 mmol, 1 equiv.), 3,4-dimethoxy phenyl boronic acid (728 mg, 4 mmol, 2 equiv.), Cu(OAc)₂ (363 mg, 2 mmol, 1 equiv.) and triethylamine (1.4 mL, 10 mmol, 5 equiv.) were added to a 250 mL round-bottom flask containing DCM (20 mL) and 3 Å molecular sieves. The resulting mixture was stirred at room temperature until TLC analysis indicated complete consumption of starting material (48 h). The reaction mixture was then filtered through Celite® using hexanes (60 mL). The filtrate was then concentrated *in vacuo* and the resulting residue was purified by silica gel chromatography (1:1 Hexane:DCM) to yield the title product as an off-white solid (100 mg, 15%) MP: 92 – 93 ° C.

¹H NMR (300 MHz, CDCl₃) δ_H; 7.16 (d, *J* = 2.9 Hz, 1H), 6.94 – 6.87 (m, 1H), 6.84 – 6.87 (m, 2H), 6.61 (d, *J* = 2.8 Hz, 1H), 6.36 (dd, *J* = 8.7, 2.8 Hz, 1H), 3.85 – 3.82 (m, 6H), 3.79 (s, 3H) ppm. ¹³C NMR (75.5 MHz, CDCl₃) δ_C; 156.2, 151.7, 149.9, 147.6, 144.9, 121.3, 118.5, 115.2, 114.5, 111.7, 108.1, 102.8, 56.3, 55.9, 55.8 ppm. HRMS (ESI-TOF) *m/z*: [M]⁺ calcd. For C₁₅H₁₅BrO₄: 339.0226, found: 339.0222.

5-(2-bromo-4-methoxyphenoxy)-1,2,3-trimethoxybenzene (15)


2-bromo-4-methoxy phenol (264 mg, 1.3 mmol, 1 equiv.), 3,4,5-trimethoxy phenyl boronic acid (551 mg, 2.6 mmol, 2 equiv.), Cu(OAc)₂ (236 mg, 1.3 mmol, 1 equiv.) and triethylamine (0.9 mL, 6.5 mmol, 5 equiv.) were added to a 250 mL round-bottom flask containing DCM (13 mL) and 3 Å molecular sieves. The resulting mixture was stirred at room temperature until TLC analysis indicated complete consumption of starting material (24 h). The reaction mixture was then filtered through Celite® using hexanes (60 mL). The filtrate was then concentrated *in vacuo* and the resulting residue was purified by silica gel chromatography (100% DCM) to yield the title product as a white solid (85 mg, 12%) MP: 129 – 130 ° C.

¹H NMR (300 MHz, CDCl₃) δ_H; 7.17 (d, *J* = 2.9 Hz, 1H), 6.96 (d, *J* = 9.0 Hz, 1H), 6.84 (dd, *J* = 9.0, 2.9 Hz, 1H), 6.15, (s, 2H), 3.80 (s, 6H), 3.78 (s, 6H) ppm. ¹³C NMR (75 MHz, CDCl₃) δ_C; 156.4, 154.0, 153.8, 146.9, 133.7, 121.8, 118.4, 115.5, 114.5, 94.9, 60.9, 56.1 (Cx2), 55.8 ppm. HRMS (ESI-TOF) *m/z*: [M+H]⁺ calculated for C₁₆H₁₈BrO₅: 369.0332 found 369.0330.

1-bromo-2-(4-methoxyphenoxy)benzene (30)


Sodium hydride (1.2 equiv., 60%) was added to a flask evacuated and refilled with nitrogen before DMF (2 mL/mmol) was added on ice. *p*-methoxy phenol (323 mg, 2.6 mmol, 1 equiv.) was added dropwise to the mixture stirring at 0 ° C. Once the phenol was added the mixture was left stir on ice for 1 hour. 2-bromofluorobenzene (0.29 mL, 2.6 mmol, 1 equiv.) was then added dropwise and the resulting mixture was left stir at 120 ° C for 24 hours under a nitrogen atmosphere. After 24 hours the reaction mixture was cooled to room temperature and quenched with water (10 mL). The organic layer was extracted with diethyl ether (3 x 10 mL) and brine (1 x 10 mL) before being dried over MgSO₄. The mixture was then filtered and concentrated in vacuo. The resulting residue was purified by silica gel chromatography (9:1 Hexane:Ethyl acetate) to yield the title product as a yellow oil (515 mg, 71%). Characterisation data is consistent with the literature.¹¹²

¹H NMR (400 MHz, CDCl₃) δ_H: 7.59 (dd, *J* = 8.0, 1.5 Hz, 1H), 7.22 – 7.15 (m, 1H), 6.98 – 6.90 (m, 3H), 6.90 – 6.85 (m, 2H), 6.82 (dd, *J* = 8.0, 1.5 Hz, 1H), 3.79 (s, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃) δ_C: 156.0, 154.9, 149.9, 133.7, 128.5, 124.1, 120.3, 118.8, 114.9, 113.7, 55.7 ppm. HRMS (ESI-TOF) *m/z*: [M]⁺ calcd. for C₁₃H₁₁BrO₂: 279.0015, found: 279.0016.

2-methoxydibenzo[*b,d*][furan (3)


Diarylether **2** (70 mg, 0.25 mmol, 1 equiv.) or diarylether **30** (70 mg, 0.25 mmol, 1 equiv.) Pd(OAc)₂ (2.5 mol%), PCy₃·HBF₄ (5 mol%), NBu₄OAc (2 equiv.) and 1,4-dioxane (2 mL/mmol) were added to a sealed reaction vial equipped with a magnetic stir bar. The reaction mixture was stirred at 125 ° C for 24 hours in a multi-reaction heating mantle. After 24 hours the reaction mixture was cooled to room temperature and diluted with DCM (15 mL), filtered through a pad of Celite® and the solvent was concentrated under reduced pressure. The resulting residue was then purified by column chromatography using 100% CHCl₃ as eluent on silica gel to elute the title product as a white solid (**3** 47 mg, 95% and **42** 46 mg 93%). MP: 45 – 46 ° C (lit 46 – 47 ° C). Characterisation data consistent with the literature.¹¹³

¹H NMR (300 MHz, CDCl₃) δ_H: 7.92 (d, *J* = 7.7 Hz, 1H), 7.55 (d, *J* = 8.2 Hz, 1H), 7.50 – 7.40 (m, 3H), 7.33 (td, *J* = 7.5, 0.9 Hz, 1H), 7.06 (dd, *J* = 8.9, 2.6 Hz, 1H) and 3.92 (s, 3H) ppm. ¹³C NMR (75 MHz, CDCl₃) δ_C: 156.9, 155.9, 150.9, 127.1, 124.7, 124.5, 122.4, 120.6, 115.2, 112.1, 111.7, 103.8 and 56.0 ppm. HRMS (ESI-TOF) *m/z*: [M+H]⁺ calculated for C₁₃H₁₀O₂: 199.075356 found 199.07629.

dibenzo[*b,d*]furan (34)


Diarylether **9** (50 mg, 0.2 mmol, 1 equiv.), Pd(OAc)₂ (2.5 mol%), PCy₃.HBF₄ (5 mol%), NBu₄OAc (2 equiv.) and 1,4-dioxane (2 mL/mmol) were added to a sealed reaction vial equipped with a magnetic stir bar. The reaction mixture was stirred at 125 °C for 24 hours in a multi-reaction heating mantle. After 24 hours the reaction mixture was cooled to room temperature and diluted with DCM (15 mL), filtered through a pad of Celite® and the solvent was concentrated under reduced pressure. The resulting residue was then purified by column chromatography using 100% Hexane as eluent on silica gel to elute the title product as a white solid (29 mg, 86%). MP: 78 – 79 °C (lit 78 – 80 °C).⁵⁷ Characterisation data consistent with the literature.⁵⁹

¹H NMR (400 MHz, CDCl₃) δ_H: 7.35 (t, *J* = 7.5 Hz, 2H), 7.46 (t, *J* = 7.5 Hz, 2H), 7.59 (d, *J* = 8.2 Hz, 2H), 7.97 (d, *J* = 7.7 Hz, 2H) ppm. ¹³C NMR (100 MHz, CDCl₃) δ_C: 155.2, 126.1, 123.2, 121.6, 119.6, 110.6 ppm. HRMS (ESI-TOF) *m/z*: [M+H]⁺ calculated for C₁₂H₈O: 169.0647 found 169.0640.

2-fluorodibenzo[*b,d*]furan (35)


Diarylether **5** (187 mg, 0.7 mmol, 1 equiv.) or diarylether **6** (107 mg, 0.4 mmol, 1 equiv.) Pd(OAc)₂ (2.5 mol%), PCy₃.HBF₄ (5 mol%), NBu₄OAc (2 equiv.) and 1,4-dioxane (2 mL/mmol) were added to a sealed reaction vial equipped with a magnetic stir bar. The reaction mixture was stirred at 125 °C for 24 hours in a multi-reaction heating mantle. After 24 hours the reaction mixture was cooled to room temperature and diluted with DCM (15 mL), filtered through a pad of Celite® and the solvent was concentrated under reduced pressure. The resulting residue was then purified by column chromatography using 7:3 DCM:Hexane as eluent on silica gel to elute the title product as a white solid (**35** 115 mg, 87% and **36** 68 mg, 90%). MP: 89 °C (lit. 90 – 91 °C). Characterisation data is consistent with the literature.⁴⁹

¹H NMR (400 MHz, CDCl₃) δ_H: 7.90 (d, *J* = 7.7 Hz, 1H) 7.64 - 7.53 (m, 2H) 7.52 – 7.42 (m, 2H) 7.33 (t, *J* = 7.6 Hz, 1H) 7.15 (td, *J* = 9.0, 2.6 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ_C: 160.2 (*J*_{C-F} = 239.1 Hz), 157.8, 157.2, 152.2, 127.7, 125.2 (*J*_{C-F} = 10.2 Hz), 124.0 (*J*_{C-F} = 3.6 Hz), 122.7, 120.8, 114.5 (*J*_{C-F} = 25.9 Hz), 112.3 (*J*_{C-F} = 9.3 Hz), 111.9, 106.7 (*J*_{C-F} = 25.1 Hz) ppm. δ_F (376 MHz, CDCl₃) -120.5 ppm. HRMS (ESI-TOF) *m/z*: [M+Na]⁺ calculated for C₁₂H₇FO: 209.0373 found 209.0380.

1-(dibenzo[*b,d*]furan-2-yl)ethan-1-one (37)


Diarylether **8** (58 mg, 0.2 mmol, 1 equiv.), Pd(OAc)₂ (2.5 mol%), PCy₃.HBF₄ (5 mol%), NBu₄OAc (2 equiv.) and 1,4-dioxane (2 mL/mmol) were added to a sealed reaction vial equipped with a magnetic stir bar. The reaction mixture was stirred at 125 °C for 24 hours in a multi-reaction heating mantle. After 24 hours the reaction mixture was cooled to room temperature and diluted with DCM (15 mL), filtered through a pad of Celite® and the solvent was concentrated under reduced pressure. The resulting residue was then purified by column chromatography using 100% DCM as eluent on silica gel to elute the title product as a pale yellow solid (40 mg, 95%). MP: 80 – 81 °C (lit. 84 – 85.5 °C). Characterisation data consistent with the literature.¹¹⁴

¹H NMR (400 MHz, CDCl₃) δ_H: 8.59 (d, *J* = 1.6 Hz, 1H), 8.11 (dd, *J* = 8.6, 1.7 Hz, 1H), 8.01 (d, *J* = 7.7 Hz, 1H), 7.60 (d, *J* = 8.6 Hz, 2H), 7.51 (t, *J* = 7.7 Hz, 1H), 7.39 (t, *J* = 7.6 Hz, 1H), 2.71 (s, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃) δ_C: 197.3, 158.9, 156.9, 132.6, 128.0, 127.9, 124.6, 123.7, 123.4, 121.6, 120.9, 111.9, 111.6, 26.7 ppm. HRMS (ESI-TOF) *m/z*: [M+H]⁺ calculated for C₁₄H₁₀O₂: 211.0754 found 211.0755.

benzofuro[3,2-*c*]pyridine (38)


Diarylether **7** (88 mg, 0.35 mmol, 1 equiv.), Pd(OAc)₂ (2.5 mol%), PCy₃.HBF₄ (5 mol%), NBu₄OAc (2 equiv.) and 1,4-dioxane (2 mL/mmol) were added to a sealed reaction vial equipped with a magnetic stir bar. The reaction mixture was stirred at 125 °C for 24 hours in a multi-reaction heating mantle. After 24 hours the reaction mixture was cooled to room temperature and diluted with DCM (15 mL), filtered through a pad of Celite® and the solvent was concentrated under reduced pressure. The resulting residue was then purified by column chromatography using 100% DCM as eluent on silica gel to elute the title product as a clear oil (50 mg, 84%). Characterisation data is consistent with the literature.¹¹⁵

¹H NMR (400 MHz, CDCl₃) δ_H: 9.26 (s, 1H), 8.65 (d, *J* = 5.5 Hz, 1H), 8.02 (d, *J* = 7.7 Hz, 1H), 7.62 (d, *J* = 8.2 Hz, 1H), 7.56 – 7.47 (m, 2H), 7.42 (t, *J* = 7.7 Hz, 1H) ppm. ¹³C NMR (125 MHz, CDCl₃) δ_C: 160.9, 155.9, 147.4, 143.5, 128.3, 123.8, 121.6, 121.5, 121.1, 111.9, 107.4 ppm. HRMS (ESI-TOF) *m/z*: [M+H]⁺ calculated for C₁₁H₇NO: 170.0600 found 170.0611.

9H-carbazole (39)


2-bromo-*N*-phenylaniline **33** (62 mg, 0.25 mmol, 1 equiv.), Pd(OAc)₂ (2.5 mol%), PCy₃·HBF₄ (5 mol%), NBu₄OAc (2 equiv.) and 1,4-dioxane (2 mL/mmol) were added to a sealed reaction vial equipped with a magnetic stir bar. The reaction mixture was stirred at 125 °C for 24 hours in a multi-reaction heating mantle. After 24 hours the reaction mixture was cooled to room temperature and diluted with DCM (15 mL), filtered through a pad of Celite® and the solvent was concentrated under reduced pressure. The resulting residue was then purified by column chromatography using 100% Hexane as eluent on silica gel to elute the title product as a pale white solid (37.5 mg, 89%). MP: 246 °C. Characterisation data consistent with the literature.¹¹⁶

¹H NMR (300 MHz, (CD₃)₂SO) δ_H: 11.22 (bs, 1H), 8.10 (d, *J* = 7.9 Hz, 2H), 7.49 (m, 2H), 7.38 (ddd, *J* = 1.1, 7.4, 8.0 Hz, 2H), 7.16 (ddd, *J* = 1.1, 7.4, 8.0 Hz, 2H) ppm. ¹³C NMR (100 MHz, (CD₃)₂SO) δ_C: 140.1, 125.9, 122.8, 120.6, 118.9, 111.3 ppm; *m/z* (ES⁺): 168 [(M+H)]⁺, 100%.

3-methyldibenzo[*b,d*]furan (40)


Diarylether **10** (52 mg, 0.2 mmol, 1 equiv.), Pd(OAc)₂ (2.5 mol%), PCy₃·HBF₄ (5 mol%), NBu₄OAc (2 equiv.) and 1,4-dioxane (2 mL/mmol) were added to a sealed reaction vial equipped with a magnetic stir bar. The reaction mixture was stirred at 125 °C for 24 hours in a multi-reaction heating mantle. After 24 hours the reaction mixture was cooled to room temperature and diluted with DCM (15 mL), filtered through a pad of Celite® and the solvent was concentrated under reduced pressure. The resulting residue was then purified by column chromatography using 100% DCM as eluent on silica gel to elute the title product as a white solid (33 mg, 90%). MP: 61 – 62 °C (lit. 62 – 63 °C). Characterisation data is consistent with the literature.¹¹⁷

¹H NMR (400 MHz, CDCl₃) δ_H: 7.89 (d, *J* = 7.7 Hz, 1H), 7.81 (d, *J* = 7.8, 1H), 7.53 (d, *J* = 8.2 Hz, 1H), 7.44 – 7.35 (m, 2H), 7.31 (t, *J* = 7.8 Hz, 1H), 7.15 (d, *J* = 7.8 Hz, 1H), 2.52 (s, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃) δ_C: 156.6, 156.2, 137.6, 126.5, 124.3, 123.9, 122.5, 121.6, 120.3, 120.1, 111.9, 111.5, 21.9 ppm. HRMS (ESI-TOF) *m/z*: [M+Na]⁺ calculated for C₁₃H₁₀O: 205.0624 found 205.0630.

3-methoxydibenzo[*b,d*]furan (41)


Diarylether **11** (112 mg, 0.4 mmol, 1 equiv.), Pd(OAc)₂ (2.5 mol%), PCy₃.HBF₄ (5 mol%), NBu₄OAc (2 equiv.) and 1,4-dioxane (2 mL/mmol) were added to a sealed reaction vial equipped with a magnetic stir bar. The reaction mixture was stirred at 125 °C for 24 hours in a multi-reaction heating mantle. After 24 hours the reaction mixture was cooled to room temperature and diluted with DCM (15 mL), filtered through a pad of Celite® and the solvent was concentrated under reduced pressure. The resulting residue was then purified by column chromatography using 1:1 Hexane:DCM as eluent on silica gel to elute the title product as a pale yellow solid (74 mg, 94%). MP: 94 – 95 °C (lit. 95 – 96 °C). Characterisation data is consistent with the literature.¹¹⁷

¹H NMR (300 MHz, CDCl₃) δ_H: 7.85 (d, *J* = 7.4 Hz, 1H), 7.80 (d, *J* = 8.5 Hz, 1H), 7.52 (d, *J* = 8.1 Hz, 1H), 7.41 – 7.33 (m, 1H), 7.33 – 7.26 (m, 1H), 7.09 (d, *J* = 2.2 Hz, 1H), 6.94 (dd, *J* = 8.5, 2.2 Hz, 1H), 3.90 (s, 3H) ppm. ¹³C NMR (75 MHz, CDCl₃) δ_C: 160.3, 157.9, 156.7, 126.0, 124.7, 123.0, 121.3, 120.1, 117.7, 111.7, 111.3, 96.8, 56.0 ppm. HRMS (ESI-TOF) *m/z*: [M+H]⁺ calculated for C₁₃H₁₀O₂: 199.0753 found 199.0746.

1,4-dimethyldibenzo[*b,d*]furan (43)


Diarylether **12** (83 mg, 0.3 mmol, 1 equiv.), Pd(OAc)₂ (2.5 mol%), PCy₃.HBF₄ (5 mol%), NBu₄OAc (2 equiv.) and 1,4-dioxane (2 mL/mmol) were added to a sealed reaction vial equipped with a magnetic stir bar. The reaction mixture was stirred at 125 °C for 24 hours in a multi-reaction heating mantle. After 24 hours the reaction mixture was cooled to room temperature and diluted with DCM (15 mL), filtered through a pad of Celite® and the solvent was concentrated under reduced pressure. The resulting residue was then purified by column chromatography using 100% Hexane as eluent on silica gel to elute the title product as a clear oil (56 mg, 95%).

¹H NMR (300 MHz, CDCl₃) δ_H: 8.02 (d, *J* = 7.7 Hz, 1H), 7.59 (d, *J* = 8.2 Hz, 1H), 7.44 (t, *J* = 7.7, 1H), 7.33 (t, *J* = 7.6, 1H), 7.15 (d, *J* = 7.5 Hz, 1H), 7.01 (d, *J* = 7.5 Hz, 1H), 2.76 (s, 3H), 2.56 (s, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃) δ_C: 155.9, 154.9, 130.7, 127.8, 126.3, 125.3, 123.7, 122.5, 122.3, 122.2, 118.9, 111.5, 19.6, 14.9 ppm. HRMS (ESI-TOF) *m/z*: [M+H]⁺ calculated for C₁₄H₁₂O: 197.0960 found 197.0958.

2,8-dimethoxydibenzo[b,d]furan (44)


Diarylether **13** (74 mg, 0.24 mmol, 1 equiv.), Pd(OAc)₂ (2.5 mol%), PCy₃.HBF₄ (5 mol%), NBu₄OAc (2 equiv.) and 1,4-dioxane (2 mL/mmol) were added to a sealed reaction vial equipped with a magnetic stir bar. The reaction mixture was stirred at 125 °C for 24 hours in a multi-reaction heating mantle. After 24 hours the reaction mixture was cooled to room temperature and diluted with DCM (15 mL), filtered through a pad of Celite® and the solvent was concentrated under reduced pressure. The resulting residue was then purified by column chromatography using 7:3 DCM:Hexane as eluent on silica gel to elute the title product as a white solid (50 mg, 91%). MP: 89 °C. Characterisation data consistent with the literature.⁶¹

¹H NMR (600 MHz, CDCl₃) δ_H: 7.43 (d, *J* = 8.9 Hz, 2H), 7.37 (d, *J* = 2.7 Hz, 2H), 7.03 (dd, *J* = 8.9, 2.7 Hz), 3.91 (s, 6H) ppm. ¹³C NMR (151 MHz, CDCl₃) δ_C: 155.6, 151.6, 124.9, 115.2, 112.2, 103.5, 56.0 ppm. HRMS (ESI-TOF) *m/z*: [M+H]⁺ calculated for C₁₄H₁₂O₃: 229.0859 found 229.0865.

2,3,8-trimethoxydibenzo[b,d]furan (45)


Diarylether **14** (68 mg, 0.2 mmol, 1 equiv.), Pd(OAc)₂ (2.5 mol%), PCy₃.HBF₄ (5 mol%), NBu₄OAc (2 equiv.) and 1,4-dioxane (2 mL/mmol) were added to a sealed reaction vial equipped with a magnetic stir bar. The reaction mixture was stirred at 125 °C for 24 hours in a multi-reaction heating mantle. After 24 hours the reaction mixture was cooled to room temperature and diluted with DCM (15 mL), filtered through a pad of Celite® and the solvent was concentrated under reduced pressure. The resulting residue was then purified by column chromatography using 7:3 DCM:Hexane as eluent on silica gel to elute the title product as an off-white solid (47 mg, 90%). MP: 100 °C.

¹H NMR (300 MHz, CDCl₃) δ_H: 7.40 (d, *J* = 8.9 Hz, 1H), 7.32 (s, 1H), 7.29 (d, *J* = 2.6 Hz, 1H), 7.08 (s, 1H), 6.94 (dd, *J* = 8.9, 2.6 Hz, 1H), 3.98 (s, 3H), 3.96 (s, 3H), 3.89 (s, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃) δ_C: 155.8, 151.9, 151.0, 149.9, 146.1, 125.3, 115.8, 113.3, 111.8, 102.9, 102.2, 95.7, 56.6, 56.3, 56.0 ppm. HRMS (ESI-TOF) *m/z*: [M+H]⁺ calculated for C₁₅H₁₄O₄: 259.0964 found 259.0956.

1,2,3,8-tetramethoxydibenzo[*b,d*]furan (46)

Diarylether (55 mg, 0.15 mmol, 1 equiv.), Pd(OAc)₂ (2.5 mol%), PCy₃.HBF₄ (5 mol%), NBu₄OAc (2 equiv.) and 1,4-dioxane (2 mL/mmol) were added to a sealed reaction vial equipped with a magnetic stir bar. The reaction mixture was stirred at 125 °C for 24 hours in a multi-reaction heating mantle. After 24 hours the reaction mixture was cooled to room temperature and diluted with DCM (15 mL), filtered through a pad of Celite® and the solvent was concentrated under reduced pressure. The resulting residue was then purified by column chromatography using 7:3 DCM:Hexane as eluent on silica gel to elute the title product as a yellow solid (18 mg, 42%). MP: 61 – 62 °C.

¹H NMR (300 MHz, CDCl₃) δ_H: 7.50 (d, *J* = 2.7 Hz, 1H), 7.37 (d, *J* = 8.9 Hz, 1H), 6.94 (dd, *J* = 8.9, 2.7 Hz, 1H), 6.85 (s, 1H), 4.15 (s, 3H), 3.94 (s, 3H), 3.91 (apparent d, 6H) ppm. ¹³C NMR (75 MHz, CDCl₃) δ_C: 155.9, 154.3, 153.6, 150.6, 148.1, 137.8, 124.3, 112.9, 111.2, 110.7, 105.3, 91.3, 61.5, 61.0, 56.4, 56.1 ppm. HRMS (ESI-TOF) *m/z*: [M+H]⁺ calculated for C₁₆H₁₆O₅: 289.1071 found 289.1077.

11*H*-indolo[3,2-*c*]quinoline

To a screw-cap vial equipped with a magnetic stir bar was added 4-bromo quinoline (42 mg, 0.2 mmol, 1 equiv.), 2-bromo aniline (38 mg, 0.22 mmol, 1.1 equiv.), Pd(OAc)₂ (5 mol%), XantPhos (6 mol%) and NBu₄OAc (2 equiv.). 1,4-Dioxane or CPME (2 mL/mmol) was added and the reaction was heated to 120 °C for 30 hours. Upon reaction completion, the mixture was cooled and subsequently diluted with CH₂Cl₂ before being filtered through a pad of Celite®. The solvent was removed by rotary evaporation and the resulting residue was purified by silica gel column chromatography using DCM as eluent to afford the title product as an off-white solid (188 mg, 86%). Characterisation data is consistent with the literature.¹¹⁸

¹H NMR (300 MHz, DMSO-*d*₆) δ_H: 12.74 (bs, 1H), 9.60 (s, 1H), 8.52 (d, *J* = 7.8 Hz, 1H), 8.32 (d, *J* = 7.8 Hz, 1H), 8.14 (d, *J* = 8.1 Hz, 1H), 7.80 – 7.65 (m, 3H), 7.50 (t, *J* = 7.6 Hz, 1H) and 7.35 (t, *J* = 7.6 Hz, 1H) ppm. ¹³C NMR (75.5 MHz, DMSO-*d*₆) δ_C: 145.9, 145.3, 140.2, 139.2, 130.0, 128.4, 126.1, 125.9, 122.5, 122.3, 121.0, 120.5, 117.6, 114.8 and 112.3 ppm.

3.2. Crystal Data





Compound	6a	6b
Formula	C ₁₄ H ₁₂ O ₃	C ₁₅ H ₁₄ O ₄
$D_{calc.}/\text{g cm}^{-3}$	1.389	1.423
m/mm^{-1}	0.798	0.103
Formula Weight	228.24	258.26
Colour	clear colourless	clear colourless
Shape	prism-shaped	plate-shaped
Size/mm ³	0.33×0.06×0.04	0.36×0.16×0.04
T/K	100(2)	100(2)
Crystal System	orthorhombic	triclinic
Flack Parameter	0.13(14)	-
Hooft Parameter	0.12(11)	-
Space Group	$P2_12_12_1$	$P-1$
$a/\text{\AA}$	4.74800(10)	6.0439(2)
$b/\text{\AA}$	10.9125(2)	9.6768(3)
$c/\text{\AA}$	21.0717(4)	10.6997(3)
$a/^\circ$	90	88.835(2)
$b/^\circ$	90	78.123(3)
$g/^\circ$	90	79.937(2)
$V/\text{\AA}^3$	1091.78(4)	602.88(3)
Z	4	2
Z'	1	1
Wavelength/ $\text{\AA}$	1.54184	0.71073
Radiation type	Cu K α	Mo K α
$Q_{min}/^\circ$	4.196	1.945
$Q_{max}/^\circ$	76.711	28.498
Measured Refl's.	10527	30327
Indep't Refl's	2206	3043
Refl's $I \geq 2\sigma(I)$	2115	2531
R_{int}	0.0850	0.0413
Parameters	157	175
Restraints	0	0
Largest Peak	0.241	0.332

Deepest Hole	-0.261	-0.192
GooF	1.084	1.071
wR_2 (all data)	0.1177	0.1052
wR_2	0.1161	0.0994
R_1 (all data)	0.0434	0.0481
R_1	0.0421	0.0383

CCDC:

6a: CCDC-2244127

6b: CCDC-2238733



Crystal Analysis Experimental:

6a: Experimental. Single clear colourless prism-shaped crystals of **6a** recrystallised from DCM by slow evaporation. A suitable crystal with dimensions $0.33 \times 0.06 \times 0.04 \text{ mm}^3$ was selected and mounted on a MITIGEN holder with silicon oil on a ROD, Synergy Custom system, HyPix diffractometer. The crystal was kept at a steady $T = 100(2) \text{ K}$ during data collection. The structure was solved with the ShelXT 2014/5 (Sheldrick, 2014) solution program using dual methods and by using Olex2 1.5-alpha (Dolomanov *et al.*, 2009) as the graphical interface. The model was refined with ShelXL 2016/6 (Sheldrick, 2015) using full matrix least squares minimisation on F^2 .

6b: Single clear colourless plate-shaped crystals of **6b** recrystallised from toluene by slow evaporation. A suitable crystal with dimensions $0.36 \times 0.16 \times 0.04 \text{ mm}^3$ was selected and mounted on a MITIGEN holder with silicon oil on a ROD, Synergy Custom system, HyPix diffractometer. The crystal was kept at a steady $T = 100(2) \text{ K}$ during data collection. The structure was solved with the ShelXT 2014/5 (Sheldrick, 2014) solution program using dual methods and by using Olex2 1.5-alpha (Dolomanov *et al.*, 2009) as the graphical interface. The model was refined with ShelXL 2016/6 (Sheldrick, 2015) using full matrix least squares minimisation on F^2 .

4. References

- (1) Alberico, D.; Scott, M. E.; Lautens, M. *Chem. Rev.* **2007**, *107*, 174–238.
- (2) Mc Glacken, G. P.; Bateman, L. M. *Chem. Soc. Rev.* **2009**, *38*, 2447–2464.
- (3) Johansson Seechurn, C. C. C.; Kitching, M. O.; Colacot, T. J.; Snieckus, V. *Angew. Chem. Int. Ed.* **2012**, *51*, 5062–5085.
- (4) Heck, R. F. *Synlett* **2006**, 2855–2860.
- (5) Negishi, E.-I. *Acc. Chem. Res.* **1982**, *11*, 340 – 348.
- (6) Farina, V. *Org. Process Res.Dev.* **2023**, *27*, 831–846.
- (7) Gensch, T.; Hopkinson, M. N.; Glorius, F.; Wencel-Delord, J. *Chem. Soc. Rev.* **2016**, *45*, 2900–2936.
- (8) Labinger, J. A.; Bercaw Arnold, J. E.; Beckman, M. *Nature* **2002**, *417*, 507–514.
- (9) Godula, K.; Sames, D. *Science* **2006**, *312*, 67–72.
- (10) Fairlamb, I. J. S. in *Green and Sustainable Medicinal Chemistry: Methods, Tools and Strategies for the 21st Century Pharmaceutical Industry*, Royal Society Chemistry, UK, **2016**, pp. 129–139.
- (11) Xue, X. S.; Ji, P.; Zhou, B.; Cheng, J. P. *Chem. Rev.* **2017**, *117*, 8622–8648.
- (12) Hartwig, J. F. *J. Am. Chem. Soc.* **2016**, *138*, 2–24.
- (13) Kondrashov, M.; Provost, D.; Wendt, O. F. *Dalton Trans.* **2016**, *45*, 525–531.
- (14) Lane, B. S.; Brown, M. A.; Sames, D. *J. Am. Chem. Soc.* **2005**, *127*, 8050–8057.
- (15) Pivsa-Art, S.; Satoh, T.; Kawamura, Y.; Miura, M.; Nomura, M. *B. Chem. Soc. Jpn.* **1998**, *71*, 467–473.
- (16) García-Cuadrado, D.; De Mendoza, P.; Braga, A. A. C.; Maseras, F.; Echavarren, A. M. *J. Am. Chem. Soc.* **2007**, *129*, 6880–6886.
- (17) García-Cuadrado, D.; Braga, A. A. C.; Maseras, F.; Echavarren, A. M. *J. Am. Chem. Soc.* **2006**, *128*, 1066–1067.
- (18) Gorelsky, S. I.; Lapointe, D.; Fagnou, K. *J. Org. Chem.* **2012**, *77*, 658–668.

- (19) Lapointe, D.; Fagnou, K. *Chem. Lett.* **2010**, 39, 1118–1126.
- (20) Gorelsky, S. I.; Lapointe, D.; Fagnou, K. *J. Am. Chem. Soc.* **2008**, 130, 10848–10849.
- (21) Lafrance, M.; Gorelsky, S. I.; Fagnou, K. *J. Am. Chem. Soc.* **2007**, 129, 14570–14571.
- (22) Lafrance, M.; Fagnou, K. *J. Am. Chem. Soc.* **2006**, 128, 16496–16497.
- (23) Davies, D. L.; Macgregor, S. A.; McMullin, C. L. *Chem. Rev.* **2017**, 117, 8649–8709.
- (24) Boutadla, Y.; Davies, D. L.; Macgregor, S. A.; Poblador-Bahamonde, A. I. *Dalton Trans.* **2009**, 5820–5831.
- (25) Hennessy, E. J.; Buchwald, S. L. *J. Am. Chem. Soc.* **2003**, 125, 12084–12085.
- (26) Thompson, M. E.; Baxter, S. M.; Ray Bulls, A.; Burger, B. J.; Nolan, M. C.; Santarsiero, B. D.; Schaefer, W. P.; Bereaw, J. E. *J. Am. Chem. Soc.* **1987**, 109, 203–219.
- (27) Davies, D. L.; Donald, S. M. A.; Macgregor, S. A. *J. Am. Chem. Soc.* **2005**, 127, 13754–13755.
- (28) McGlacken, G. P.; Bateman, L. M. *Chem. Soc. Rev.* **2009**, 38, 2447–2464.
- (29) Love, B. E. *Eur. J. Med. Chem.* **2015**, 97, 377–387.
- (30) Zhang, L.; Zhang, Y. X.; Hu, Y.; Shi, X. B.; Jiang, Z. Q.; Wang, Z. K.; Liao, L. S. *ACS Appl. Mater. Interfaces* **2016**, 8, 16186–16191.
- (31) Nakanishi, K.; Fukatsu, D.; Takaishi, K.; Tsuji, T.; Uenaka, K.; Kuramochi, K.; Kawabata, T.; Tsubaki, K. *J. Am. Chem. Soc.* **2014**, 136, 7101–7109.
- (32) Shyam Sundar, M.; Bedekar, A. V. *Org. Lett.* **2015**, 17, 5808–5811.
- (33) Nakahara, K.; Mitsui, C.; Okamoto, T.; Yamagishi, M.; Matsui, H.; Ueno, T.; Tanaka, Y.; Yano, M.; Matsushita, T.; Soeda, J.; Hirose, Y.; Sato, H.; Yamano, A.; Takeya, J. *Chem. Comm.* **2014**, 50, 5342–5344.
- (34) Itoh, K.; Sibi, M. P. *Org. Biomol. Chem.* **2018**, 16, 5551–5565.
- (35) Martel, R. R.; Rochefort, J. G.; Klicius, J.; Dorson, T. A. *Can. J. Physiol. Pharmacol.* **1974**, 52, 669.
- (36) Ye, Y. Q.; Negishi, C.; Hongo, Y.; Koshino, H.; Onose, J. I.; Abe, N.; Takahashi, S. *Bioorg. Med. Chem.* **2014**, 22, 2442–2446.

- (37) Patpi, S. R.; Pulipati, L.; Yogeewari, P.; Sriram, D.; Jain, N.; Sridhar, B.; Murthy, R.; Anjana Devi, T.; Kalivendi, S. V.; Kantevari, S. *J. Med. Chem.* **2012**, *55*, 3911–3922.
- (38) Wossa, S. W.; Beekman, A. M.; Ma, P.; Kevo, O.; Barrow, R. A. *Asian J. Org. Chem.* **2013**, *2*, 565–567.
- (39) Oliveira, A. M. A. G.; Raposo, M. M. M.; Oliveira-Campos, A. M. F.; Machado, A. E. H.; Puapairoj, P.; Pedro, M.; Nascimento, M. S. J.; Portela, C.; Afonso, C.; Pinto, M. *Eur. J. Med. Chem.* **2006**, *41*, 367–372.
- (40) Kaniwa, K.; Ohtsuki, T.; Yamamoto, Y.; Ishibashi, M. *Tetrahedron Lett.* **2006**, *47*, 1505–1508.
- (41) Alami, M.; Provot, O. *Org. Biomol. Chem.* **2024**, *22*, 1323–1345.
- (42) Ames, D. E.; Opalko, A. *Synthesis (Stuttg)* **1983**, *3*, 234–235.
- (43) Campeau, L. C.; Thansandote, P.; Fagnou, K. *Org. Lett.* **2005**, *7*, 1857–1860.
- (44) Campeau, L. C.; Parisien, M.; Jean, A.; Fagnou, K. *J. Am. Chem. Soc.* **2006**, *128*, 581–590.
- (45) Mackey, K.; Jones, D. J.; Pardo, L. M.; McGlacken, G. P. *Eur. J. Org. Chem.* **2021**, *2021*, 495–498.
- (46) Amatore, C.; Pflüger, F. *Organometallics*, **1990**, *8*, 2276 – 2282.
- (47) Panda, N.; Mattan, I.; Nayak, D. K. *J. Org. Chem.* **2015**, *80*, 6590–6597.
- (48) Xu, H.; Fan, L.-L. *Chem. Pharm. Bull.* **2008**, *56*, 1496 – 1498.
- (49) Lockner, J. W.; Dixon, D. D.; Risgaard, R.; Baran, P. S. *Org. Lett.* **2011**, *13*, 5628–5631.
- (50) Wang, C.; Piel, I.; Glorius, F. *J. Am. Chem. Soc.* **2009**, *131*, 4194–4195.
- (51) Niu, L.; Yang, H.; Jiang, Y.; Fu, H. *Adv. Synth. Catal.* **2013**, *355*, 3625–3632.
- (52) Nervig, C. S.; Waller, P. J.; Kalyani, D. *Org. Lett.* **2012**, *14*, 4838–4841.
- (53) Ferguson, D. M.; Rudolph, S. R.; Kalyani, D. *ACS Catal.* **2014**, *4*, 2395–2401.
- (54) Wang, J.; Ferguson, D. M.; Kalyani, D. *Tetrahedron* **2013**, *69*, 5780–5790.
- (55) Xiao, B.; Gong, T. J.; Liu, Z. J.; Liu, J. H.; Luo, D. F.; Xu, J.; Liu, L. *J. Am. Chem. Soc.* **2011**, *133*, 9250–9253.

- (56) Li, J.; Xu, Q. N.; Wang, Z. B.; Li, Y.; Liu, L. *ACS Omega* **2018**, *3*, 12923–12929.
- (57) Clarkson, G. J.; Roesner, S. *J. Org. Chem.* **2023**, *88*, 684–689.
- (58) Liu, J.; Fitzgerald, A. E.; Mani, N. S. *J. Org. Chem.* **2008**, *73*, 2951–2954.
- (59) Zhao, H.; Yang, K.; Zheng, H.; Ding, R.; Yin, F.; Wang, N.; Li, Y.; Cheng, B.; Wang, H.; Zhai, H. *Org. Lett.* **2015**, *17*, 5744–5747.
- (60) Sumida, Y.; Harada, R.; Sumida, T.; Johmoto, K.; Uekusa, H.; Hosoya, T. *Org. Lett.* **2020**, *22*, 6687–6691.
- (61) Tobisu, M.; Kita, Y.; Ano, Y.; Chatani, N. *J. Am. Chem. Soc.* **2008**, *130*, 15982–15989.
- (62) Akermarck, B.; Ebersson, L.; Jonsson, E.; Pettersson, E. *J. Org. Chem.* **1975**, *40*, 1365.
- (63) Akinori Shiotani, B.; Itatani, H. *J. Chem. Soc., Perkin Trans. 1* **1976**, 1236.
- (64) Liégault, B.; Lee, D.; Huestis, M. P.; Stuart, D. R.; Fagnou, K. *J. Org. Chem.* **2008**, *73*, 5022–5028.
- (65) Hussain, M.; Hung, N. T.; Langer, P. *Tetrahedron Lett.* **2009**, *50*, 3929–3932.
- (66) Silarska, E.; Trzeciak, A. M.; Pernak, J.; Skrzypczak, A. *Appl. Catal. A: General* **2013**, *466*, 216–223.
- (67) Schroeter, F.; Soellner, J.; Strassner, T. *ACS Catal* **2017**, *7*, 3004–3009.
- (68) Huynh, H. V.; Han, Y.; Ho, J. H. H.; Tan, G. K. *Organometallics* **2006**, *25*, 3267–3274.
- (69) Precht, M. H. G.; Scholten, J. D.; Dupont, J. *Molecules* **2010**, *15*, 3441–3461.
- (70) Kohler, D. G.; Gockel, S. N.; Kennemur, J. L.; Waller, P. J.; Hull, K. L. *Nat. Chem.* **2018**, *10*, 333–340.
- (71) Thathagar, M. B.; Kooyman, P. J.; Boerleider, R.; Jansen, E.; Elsevier, C. J.; Rothenberg, G. *Adv. Synth. Catal.* **2005**, *347*, 1965–1968.
- (72) Reetz, M. T.; Westermann, E. *Angew. Chem. Int. Ed.* **2000**, *39*, 165 – 168.
- (73) Reetz, M. T.; Wanninger, K. *Tetrahedron Lett.* **1996**, *37*, 4499–4502.
- (74) Belier, M.; Fischer, H.; Kihlein, K.; Reisinger, C.-P.; Herrmann, W. A. *J. Organomet. Chem.* **1996**, *520*, 257–259.
- (75) Bellina, F.; Lessi, M.; Manzini, C. *Eur. J. Org. Chem.* **2013**, 5621–5630.

- (76) Ehlers, P.; Petrosyan, A.; Baumgard, J.; Jopp, S.; Steinfeld, N.; Ghochikyan, T. V.; Saghyan, A. S.; Fischer, C.; Langer, P. *ChemCatChem* **2013**, *5*, 2504–2511.
- (77) Gniewek, A.; Trzeciak, A. M.; Ziółkowski, J. J.; Kępiński, L.; Wrzyszczy, J.; Tylus, W. *J. Catal.* **2005**, *229*, 332–343.
- (78) Pryjomska-Ray, I.; Gniewek, A.; Trzeciak, A. M.; Ziółkowski, J. J.; Tylus, W. in *Top. Catal.*, **2006**, pp. 173–184.
- (79) Yang, S.; Hong, S. H. *Asian J. Org. Chem.* **2020**, *9*, 1846–1851.
- (80) De Vries, A. H. M.; Parlevliet, F. J.; Schmieder-van De Vondervoort, L.; Mommers, J. H. M.; Henderickx, H. J. W.; Walet, M. A. M.; De Vries, J. G. *Adv. Synth. Catal.* **2002**, *344*, 996–1002.
- (81) Ackermann, L. *Chem. Rev.* **2011**, *111*, 1315–1345.
- (82) Momotake, A.; Lindegger, N.; Niggli, E.; Barsotti, R. J.; Ellis-Davies, G. C. R. *Nat. Methods* **2006**, *3*, 35–40.
- (83) Zhang, W.; Wei, W.; Shi, J.; Chen, C.; Zhao, G.; Jiao, R.; Tan, R. *Bioorg. Med. Chem. Lett.* **2015**, *25*, 2698–2701.
- (84) Jeffery, T. *Tetrahedron* **1996**, *52*, 10113–10130.
- (85) Jeffery, T. *J. Chem. Soc., Chem. Commun* **1984**.
- (86) Yang, C. T.; Fu, Y.; Huang, Y. B.; Yi, J.; Guo, Q. X.; Liu, L. *Angew. Chem. Int. Ed.* **2009**, *48*, 7398–7401.
- (87) Liu, L.; Frohn, M.; Xi, N.; Dominguez, C.; Hungate, R.; Reider, P. J. *J. Org. Chem.* **2005**, *70*, 10135–10138.
- (88) Abdo, N. I.; El-Shehawy, A. A.; El-Barbary, A. A.; Lee, J. S. *Eur. J. Org. Chem.* **2012**, 5540–5551.
- (89) Xu, H. J.; Zhao, Y. Q.; Zhou, X. F. *J. Org. Chem.* **2011**, *76*, 8036–8041.
- (90) Trippé-Allard, G.; Lacroix, J. C. *Tetrahedron* **2013**, *69*, 861–866.
- (91) Sugihara, T.; Satoh, T.; Miura, M. *Tetrahedron Lett.* **2005**, *46*, 8269–8271.
- (92) Farina, V. *Adv. Synth. Catal.* **2004**, *346*, 1553–1582.
- (93) Wong, N. W. Y.; Forgione, P. *Org. Lett.* **2012**, *14*, 2738–2741.

- (94) Azzena, U.; Carraro, M.; Pisano, L.; Monticelli, S.; Bartolotta, R.; Pace, V. *ChemSusChem* **2019**, *12*, 40–70.
- (95) De Gonzalo, G.; Alcántara, A. R.; Domínguez de María, P. *ChemSusChem* **2019**, *12*, 2083–2097.
- (96) King, A. E.; Brunold, T. C.; Stahl, S. S. *J. Am. Chem. Soc.* **2009**, *131*, 5044–5045.
- (97) Vantourout, J. C.; Miras, H. N.; Isidro-Llobet, A.; Sproules, S.; Watson, A. J. B. *J. Am. Chem. Soc.* **2017**, *139*, 4769–4779.
- (98) Jalalian, N.; Ishikawa, E. E.; Silva, L. F.; Olofsson, B. *Org. Lett.* **2011**, *13*, 1552–1555.
- (99) Chan, D. M. T.; Monaco, K. L.; Wang, R.-P.; Winters, M. P. *Tetrahedron Lett.* **1998**, *39*, 2933–2936.
- (100) Evans, D. A.; Katz, J. L.; West, T. R. *Tetrahedron Lett.* **1998**, *39*, 2937–2940.
- (101) Bouquillon, S.; Du Moulinet D’hardemare, A.; Averbuch-Pouchot, M.-T.; Henin, F.; Muzart, J. *Polyhedron*, **1999**, *18*, 3511 – 3516.
- (102) Cabrera, P. J.; Lee, M.; Sanford, M. S. *J. Am. Chem. Soc.* **2018**, *140*, 5599–5606.
- (103) Laali, K. K.; Borodkin, G. I. *J. Chem. Soc., Perkin Trans.* **2002**, *2*, 953–957.
- (104) Eoin O Muimhneachain, PhD thesis, University College Cork, **2018**.
- (105) Campeau, L. C.; Parisien, M.; Leblanc, M.; Fagnou, K. *J. Am. Chem. Soc.* **2004**, *126*, 9186–9187.
- (106) Rishton, G. M. *Am. J. Cardiol.* **2008**, *101*, 43 – 49.
- (107) Lavrado, J.; Moreira, R.; Paulo, A. *Curr. Med.Chem.* **2010**, *17*, 2348–2370.
- (108) Thobokholt, E. N.; Larghi, E. L.; Bracca, A. B. J.; Kaufman, T. S. *RSC Adv* **2020**, *10*, 18978–19002.
- (109) Oliver-Bever, B. *Medicinal Plants in Tropical West Africa*, Cambridge University Press, Cambridge, **1986**.
- (110) Shanahan, R. M.; Hickey, A.; Reen, F. J.; O’Gara, F.; McGlacken, G. P. *Eur. J. Org. Chem.* **2018**, *2018*, 6140–6149.
- (111) James Forrest, B. *J. Chem. Soc.* **1960**, 581–588.

- (112) Ebisawa, M.; Ueno, M.; Oshima, Y.; Kondo, Y. *Tetrahedron Lett.* **2007**, *48*, 8918–8921.
- (113) Maetani, S.; Fukuyama, T.; Ryu, I. *Org. Lett.* **2013**, *15*, 2754–2757.
- (114) Bao, Y. S.; Bao, A.; Bao, Z.; Jia, M.; Baiyin, M. *Org. Biomol. Chem.* **2015**, *13*, 4179–4182.
- (115) Hong, F.; Chen, Y.; Lu, B.; Cheng, J. *Adv. Synth. Catal.* **2016**, *358*, 353–357.
- (116) Gao, H.; Xu, Q. L.; Yousufuddin, M.; Ess, D. H.; Kürti, L. *Angew. Chem. Int. Ed.* **2014**, *53*, 2701–2705.
- (117) Zhu, D.; Li, M.; Wu, Z.; Du, Y.; Luo, B.; Huang, P.; Wen, S. *Eur. J. Org. Chem.* **2019**, *2019*, 4566–4571.
- (118) Håheim, K. S.; Lund, B. A.; Sydnes, M. O. *Eur. J. Org. Chem.* **2023**, *26*, e202300137.



So many foreign worlds

So relatively -

So ready for us

The Creature Fear

Chapter 2

The Asymmetric Rh- Catalysed 1,4-Addition of *N*-H Indolyl Boronic Acids

5. Introduction

5.1. Introduction to C–C bond formation by Conjugate Addition

The ability to form carbon–carbon bonds efficiently and selectively is a key aspect of synthetic chemistry. The ability to do so in a regio- and enantioselective manner gives chemists the tools to create new targets and investigate novel chemical space. Many named reactions are excellent examples of this reaction type, such as the Diels-Alder,¹ Wittig^{2,3} and many variants of the Pd-catalysed cross-coupling reactions.⁴

One such reaction is the conjugate addition reaction. This reaction has been known for nearly 150 years and is afforded a full chapter in Clayden's *Organic Chemistry*.⁵ A conjugate addition is a type of reaction where a nucleophile adds to a particular C=C double bond in a conjugated molecule. This type of nucleophilic addition to a α,β -unsaturated system is also known as a Michael addition and consequently, these α,β -unsaturated compounds are known as Michael acceptors (Figure 7).





Figure 7 α,β -unsaturated molecules and their affinity for nucleophilic conjugate addition


The earliest example of this reaction type was in 1883 where Komnenos reported the addition of sodium diethyl malonate to ethylidene malonate to give a symmetrical conjugate addition product (Scheme 68).⁶



Scheme 68 First report of a 1,4-conjugate addition reaction in 1883


Three years after this initial report, Michael reported the conjugate addition of the same sodium diethyl malonate to an acrylic bromide which yielded a cyclopropyl product (Scheme

69a).⁷ Michael postulated that this product could only arise from a conjugate addition reaction to create an intermediate which could then cyclise. This hypothesis was confirmed when the coupling of sodium diethyl malonate with a linear enone was investigated and a conjugate addition product was formed (Scheme 69b).



Scheme 69 Seminal work by Michael involving the conjugate addition reaction

The first metal-catalysed variant of this reaction was published in 1941, when Kharasch used a catalytic quantity of copper to react a Grignard reagent with isophorone to give the conjugate addition product shown in Scheme 70.⁸




Scheme 70 The first report of a metal catalysed conjugate addition reaction

From this initial reaction, many variants of this transformation were published, mainly using Cu,⁹ Ni^{10–12} or Pd^{13,14} as the metal catalyst and Mg¹⁵ or Li¹⁶ organometallic nucleophile. The most common metals used to facilitate this transformation are, Co, Ni, Cu, Zn, Rh and Pd. All these metals have been employed successfully. However, when considering efficiency, selectivity, substrate scope, generality and catalyst availability, rhodium is the best performing metal. This thesis will include an introduction to rhodium-catalysed 1,4-additions.


5.2. Rhodium-Catalysed Conjugate Additions

The first example of a rhodium-catalysed conjugate addition was described by Ito in 1992 where α -cyano carboxylates could be asymmetrically added to vinyl ketones (Scheme 71).¹⁷ It was found that the cyano group of the substrate was essential to the success of the transformation as it ligated the chiral rhodium catalyst. A good substrate scope was displayed, with high yields and enantioselectivities. The reaction proceeded under mild temperature and in a short time of 4 hours.



Scheme 71 The first example of a Rh-catalysed conjugate addition reaction

The first example of the rhodium-catalysed 1,4-addition of a boronic acid to an enone was reported in 1997 by Hayashi and Miyaura (Scheme 72).¹⁸ This work improved on previous protocols which employed Pd-catalysis with organoboronic acids in the presence of SbCl₃. Using Rh(acac)(CO)₂/dppb as a catalyst system, phenyl boronic acids could be successfully added to linear enones in excellent yields, setting the scene for this powerful transformation.




Scheme 72 The first example of a Rh-catalysed 1,4-addition involving aryl boronic acids

5.2.1. The Development of Asymmetric Conjugate Additions

The success of this transformation was founded on the use of 1,4-bis(diphenylphosphino)butane (dppb) as a ligand.¹⁸ Other ligands were screened, such as monodentate AsPh₃ and PPh₃, and bidentate phosphines such as dppp and dppe, which were all found to be less effective as ligands in the reaction. With the latter, the reaction

inefficiency was found to correlate to the size of the bite angle in the P-Rh-P complex. Despite the success observed with modifying the phenyl substituents, the reaction would not proceed when cyclohexenone was employed as the Michael-acceptor. However, in the following year, this hurdle was overcome when Hayashi and Miyaura utilised an alternative catalyst to access cyclic Michael-acceptors.¹⁹ The key finding was to switch the Rh source to $[\text{Rh}(\text{acac})(\text{C}_2\text{H}_4)_2]$ and to investigate the use of alternative phosphine ligands for the transformation. Through ligand screening, (*S*)-BINAP proved to be the most efficient ligand for the reaction. By altering the reaction solvent, temperature and time, in conjunction with the use of a new catalyst system, Hayashi could perform the first asymmetric 1,4-addition in quantitative yields and excellent enantioselectivities to afford the desired product (Scheme 73).




Scheme 73 The asymmetric 1,4-addition of aryl boronic acids to cyclic enones


This methodology was suitable for a range of phenylboronic acids as well as cyclic and linear Michael-acceptors. The immediate expansion of this work was summarised by Hayashi in a report highlighting recent improvements.²⁰ Developments since then have included refining of the catalyst source, ligand type, reaction conditions and substrate tolerance. An excellent review on advances since Hayashi and Miyaura's seminal work was published by Fagnou and Lautens in 2003²¹ which illustrates the many notable examples of how quickly the field was expanded by the chemistry community. The robustness of the chemistry allowed for rapid industrial uptake to synthesise enantioenriched products and manipulating the catalyst system allowed for much milder conditions to be employed, including reduced temperature and reaction time.²¹

A general catalytic cycle for this reaction is outlined below (Scheme 74).²² The cycle begins with transmetalation between the aryl boronic acid and rhodium catalyst. This is then followed by the insertion of an unsaturated compound into the aryl–rhodium bond which subsequently undergoes hydrolysis giving a hydroarylation product and a hydroxorhodium species. In the elucidation of this catalytic cycle it became apparent that there is a more

direct route to product formation. The regeneration of the acac-H from the Ar-B(OH)_2 is a slow step in the cycle. However, if you start with a hydroxy rhodium precatalyst, the regeneration of the Rh-Ar species is much more efficient. This was demonstrated by Hayashi where milder conditions were employed to retain excellent enantioselectivities and yields (Scheme 75).²²



Scheme 74 General catalytic cycle for the Rh-catalysed 1,4-addition of aryl boronic acids to enones




Scheme 75 The use of a Rh-hydroxy precatalyst to create a more efficient catalytic cycle

5.2.2. Ligand Development for Asymmetric Conjugate Additions


The next advancement in the field of rhodium-catalysed 1,4-addition was in 2003 when Hayashi and Yoshida pioneered the use of chiral dienes as ligands for rhodium catalysis.²³ These dienes have a chiral environment which enables asymmetric transformations through the sterics existing between the phenyl (or benzyl) group and the hydrogen atom on the alkene(s) of the ligand. In the traditional BINAP-type ligands, the chirality is controlled by the

conformation taken once both phosphines have ligated the metal. In the case of chiral dienes, the metal is ligated in a rigid conformation and thus, the spacial discrimination is controlled by altering the size of the olefin substituent (Scheme 76).




Scheme 76 The chiral conformation of phosphine and diene catalytic systems

This new class of ligand was tested using literature standard Rh-catalysed 1,4-addition reactions and excellent yields and enantioselectivities (up to 99% e.e.) were observed.²³ One immediate advantage of having a new ligand class was that reactions which previously proceeded poorly with phosphine ligands could be trialled under new catalytic pretences. One example which highlights this advantage is in the case of utilising organostannane reagents.²³ The low catalytic activity of the phosphine complex can be overcome in this case by using a chiral diene ligand and the desired 1,4-addition product can be achieved in two-steps in 80% yield and 95% e.e. (Scheme 77).



Scheme 77 The use of chiral diene ligands to allow the use of organostannane reagents


Another example of the benefit of chiral diene catalysis is shown in the enantioenrichment of organosilicon compounds. With (*R*)-BINAP, this reaction proceeds with good yields and moderate enantioselectivities. However, when a chiral diene is employed in the case of (*R,R*)-Ph-bod* or (*R,R*)-Bn-bod*, the target 1,4-addition product is achieved in excellent yield, and an e.e. up to 99% (Scheme 78).²⁴ This dramatic improvement in enantioenrichment is also accompanied by the additional benefits of mild reaction conditions.



Scheme 78 Comparative yields and enantioenrichment of organosilicon products with chiral ligands


Hayashi later reported that these diene ligands coordinate to transition-metals more weakly than the comparative phosphine ligands.²⁵ In an attempt to unify the two ligand classes, a phosphine-olefin hybrid ligand was designed (Scheme 79). This new ligand displayed an

efficiency comparable with the previous chiral dienes designed. Given the comparative results for this ligand against simpler dienes and phosphines, the arduous synthesis outweighs the potential benefit of using this compound in a catalytic system.




Scheme 79 The route to access a hybrid phosphine-olefin class of ligand

In the years following Hayashi's publication of a chiral diene ligand, many reports from other groups emerged showcasing other types of chiral diene ligand suitable for this transformation. One such report was by Carreira where the chiral dienes of type I (Scheme 80) were synthesised.²⁶ An advantage of this new ligand is that it displays activity to a wider range of Michael-acceptors than previously shown by Hayashi. This list included cyclic and acyclic enones, lactones, esters, coumarins and amides, while these substrates showcased varying yields but excellent enantioselectivities (Scheme 80).



Scheme 80 An alternative chiral diene ligand with broad substrate applicability

In 2011 a new class of ligands, mostly derived from Ellman's auxiliary, found widespread use in asymmetric catalysis. The majority of this initial work was by Lin and co-workers which was rooted in Sml_2 -mediated asymmetric synthesis.^{27–29} On the back of the rise in sulphur-based chiral ligands for asymmetric catalysis, Xu and co-workers aimed to fuse the success of chiral dienes in rhodium-catalysis with the popularity of chiral sulphur ligands. In 2011, Xu reported the first instance of a hybrid sulphur-olefin ligand which was employed to facilitate rhodium-catalysed 1,4-additions with cyclic α,β -unsaturated carbonyl compounds.³⁰ Excellent yields and enantioselectivities were observed, up to 99% and 98% e.e. respectively. The modularity afforded with this simple chiral building block readily enabled ligand derivatisation. In a rapid release of publications, many variations of these sulphur-olefin ligands were reported to facilitate rhodium-catalysed asymmetric 1,2- and 1,4-addition reactions (Scheme 81).



Scheme 81 The range of sulphur-olefin ligands published between 2011-2013

5.3. Alternative Organometallic Reagents

A remaining challenge for rhodium-catalysed conjugate additions is the quantity of boronic acid required for efficient conversion, particularly when using heteroaromatic substrates. This is on account of competitive protodeboronation pathways. Boronate esters such as ethylene glycol, pinacol and 2-methyl-2,4-pentanediol derivatives are well-known entities used as viable alternatives to boronic acids in palladium cross-couplings. However, they are lesser used reagents for 1,4-additions in comparison to their boronic acid counterparts. However, a number of more suitable arylboronates can be used in 1,4-additions (Figure 8).





Figure 8 Examples of published aryl boronate esters


The lithium trimethoxyboronate species shown in Figure 8 is the first example of an arylboronate being employed in rhodium-catalysed 1,4-additions.³¹ Hayashi describes the *in situ* formation of the boronate ester by addition of *n*BuLi to the appropriate aryl bromide followed by subsequent treatment with trimethoxyborane to access the desired species

(Scheme 82). However, as expected, these boron species are sensitive reagents and a specific quantity of water was required to facilitate the conjugate addition while concurrently not accelerating the hydrolysis of the carbon–boron bond.



Scheme 82 The first use of lithium trimethoxyboronates in Rh-catalysed 1,4-addition reactions


A report by Whitehead and co-workers in 2006 shows how aryl bromides (or boronic acids) can be simply turned into their corresponding trihydroxyborate sodium salts by treatment with sodium hydroxide solution in toluene or hexane.³² The resulting salts were effectively deployed in Pd-catalysed cross-coupling reactions, allowing easy access to boronate reagents (Scheme 83). These trihydroxyborates have, to the best of our knowledge, not been used in Rh-catalysed conjugate additions.



Scheme 83 The formation of sodium aryltrihydroxyborates for cross-couplings


Other important arylboronate species are potassium organotrifluoroborates, which are currently the boronate reagent of choice for a variety of organometallic processes.³³ These species boast stability towards reagents that can be troublesome for other boron reagents. They are air and water stable, as first described by Thierig and Umland in 1967.³⁴ In the case of rhodium-catalysed 1,4-additions, these species were first introduced as suitable reagents in back-to-back publications by Genêt and co-workers.^{35,36} The relative rate of reaction for

BF_3K salts is faster than their boronic acid counterparts, which is thought to be due to a faster transmetalation step in the catalytic cycle. Genêt showcased how, when using the appropriate rhodium precatalyst, full conversion to the desired product could be obtained in 2 hours using this boron species, and excellent enantioselectivities were still observed (Scheme 84).



Scheme 84 The use of potassium organotrifluoroborates in Rh-catalysed 1,4-addition reactions

Finally, Miyauchi and co-workers have reported access to potassium and lithium cyclic triolboronate salts from various boronic acid starting materials.³⁷ Using the triol depicted in Scheme 85, alongside potassium or lithium bases, the desired cyclic triolboronates can be readily prepared in excellent yields. The authors also show the application of these triolboronate salt species in Pd-catalysed cross-couplings. As with the sodium aryltrihydroxyborates, these species have yet to be exploited in Rh-catalysis for conjugate additions.




Scheme 85 The synthesis of potassium and lithium cyclic triolboronates

It is worth noting that this list of alternative boron reagents is not exhaustive. Many varieties of arylboronates exist as viable counterparts to traditional boronic acid coupling partners.


5.4. Substrate Scope of the Rh-Catalysed Conjugate Addition

So far within this introduction to the Rh-catalysed 1,4-addition reaction, the Michael-acceptors described have been variations on cyclic and acyclic enones. It would be remiss not to mention the array of Michael-acceptor type substrates which can be employed, such as: Alkenylphosphonates,³⁸ nitroalkenes,³⁹ 5,6-dihydro-2(1*H*)-pyridinones,⁴⁰ coumarins,⁴¹ substituted maleimides,⁴² as well as many other α,β -unsaturated compounds (Scheme 86).


Alkenylphosphonate Addition





Nitroalkene Addition




Dihydropyridinone Addition



Coumarin Addition*Maleimide Addition***Scheme 86** Select examples of Michael-acceptor substrates employed in the 1,4-addition reaction


Of the many examples of Michael acceptors subjected to Rh-catalysed conjugate additions, this Introduction will highlight some recent, and more exotic, examples of the variety of substrates available for this transformation.

Marek and co-workers reported an unusual Michael-acceptor type substrate in 2018.⁴³ Using small nonfunctionalized cyclopropenes, a variety of asymmetrically arylated cyclopropanes could be efficiently accessed *via* Rh-catalysis. Although a large range of phenyl boronic acids were trialled under the reaction conditions (as shown in Scheme 87). The cyclopropene substitution could also be efficiently altered from small to bulky substituents as well as tolerating bicyclic systems. It is worth highlighting that the heteroaromatic boronic acids of thiophene, furan or pyridine were not successfully employed in their reaction scope.




Scheme 87 The Rh-catalysed conjugate addition of arylboronic acids to cyclopropene substrates

In 2021, Fletcher and co-workers reported a rhodium-catalysed approach to access complex enantioenriched cyclobutanes.⁴⁴ This comprehensive publication looks at the different reaction pathways available to this unique substrate. Once the cyclobutene is metalated with the rhodium catalyst, the reaction conditions and substitution pattern of the substrate can determine the fate of the product. A hydroarylation, 1,5-addition, reductive Heck or remote substitution *via* chain walking can all take place, giving rise to a myriad of products (Scheme 88). While this chemistry does not fall under the umbrella of conjugate addition reactions, it showcases the work still ongoing in the field of asymmetric rhodium catalysis and the plethora of Michael acceptor-type substrates to be exploited.



Scheme 88 The various reaction pathways of metalated cyclobutenes

A recent, relevant example of Rh-catalysed 1,4-addition is the enantioselective synthesis of 3-piperidines from pyridine.⁴⁵ By reducing pyridine to the appropriate phenyl carbamate dihydropyridine, a suitable Michael-acceptor type substrate was unmasked to yield difficult-to-access enantioenriched 3-piperidines (Scheme 89). This work again highlights the array of substrates susceptible for conjugate addition. The dihydropyridine was synthesised by alkylating the pyridine nitrogen followed by reduction through a source of hydride. It was found that the alkylating group was fundamental to the success of this transformation and the phenyl carbamate-protected dihydropyridine was a substrate which could be easily isolated as a crystalline solid. The prevalence of chiral piperidines in APIs was a driving force for the development of this protocol and the authors showcase a broad substrate scope for the asymmetric conjugate additions to dihydropyridines.




Scheme 89 The synthesis of enantioenriched 3-piperidien-2-one via asymmetric 1,4-addition

5.4.1. Heteroaryl Substrate Scope


As much as the Michael acceptor component of this reaction has varied throughout the years, the organometallic species has remained, by and large, phenyl boronic acid or derivatives thereof. Using a heteroaryl boron derivative in this chemistry is much less common. Few examples of these heteroaromatic boronic acids are used in reactions, namely: Furan, thiophene, protected pyrroles and recently, pyridine.⁴⁶ A large reason for the lack of success with heteroboron derivatives is due to the lability of the heteroarylboronic acid bond, and the associated rapid protodeboronation. This is especially problematic considering the prerequisite for water in many of the existing catalytic systems. Additionally, low reactivity can be observed with certain heteroaromatics due to their ability to poison metal catalysts. As mentioned, there are some examples of select heteroaryl groups being used in this chemistry to varying degrees of success. The substitution of the heteroaromatic group and the nature of the boron reagent are paramount when devising the use heterocycles in asymmetric Rh-catalysed conjugate additions.

In 2003, Hayashi reported the 1,4-addition of 3-thiopheneboronic acids to α,β -unsaturated compounds. A range of cyclic and acyclic enones were shown to undergo efficient asymmetric conjugate addition to give the heteroaromatic products in good yield and excellent enantioselectivity (Scheme 90).⁴⁷



Scheme 90 The coupling of 3-thiopheneboronic acids with α,β -unsaturated compounds


Examples like this coupling, where heteroaryl residues are transferred as a boronic acid are rare within this reaction type. A recent example which highlights the use of heteroaromatic boronic acids in conjugate additions was published by Chang and co-workers.⁴⁸ Evidently, this reaction is not a rhodium-catalysed transformation but instead, is a selected example of an magnesium-catalysed reaction which can also form enantioenriched conjugate addition products. Select substrate examples are depicted in Scheme 91. Like Hayashi's previous work, success was observed with the thiophene boronic acids. It is worth noting however, that the furan boronic acid and benzofuran boronic acid both gave a significant reduction in enantioenrichment.



Scheme 91 A chiral diol catalysed enantioselective conjugate addition


However, as mentioned previously, the few examples employing heteroaromatic substrates in rhodium-catalysed conjugate additions primarily require some form of a boronate ester.

Miyaura showcased how heteroaromatic triolborates can be used in Rh-catalysed conjugate additions.⁴⁹ A range of thiophene and pyridine triolborates underwent efficient asymmetric conjugate addition with various Michael-acceptors. However, some of these heteroaromatic substrates displayed poor yield and/or enantioenrichment (Scheme 92). It was concluded that the electronic character of the C–B bond determined the level of reactivity of the substrate. The lower nucleophilicity of unsubstituted pyridines and thiophenes lead to no product being formed and it was hypothesised that the competitive hydrolytic C–B bond cleavage outcompeted the conjugate addition.




Scheme 92 The use of heteroaromatic cyclic triolborates in conjugate additions

Boysen and co-workers have published a comprehensive study on the use of heteroarylboronates in rhodium-catalysed conjugate additions.⁴⁶ This work culminates what was previously reported in the literature, whereby the nucleophilic character of the C–B position determines the reaction success. Several heteroaryl substrates were trialled in their MIDA or pinacol boronate forms. Different pyridines, furans, thiophenes and pyrroles were investigated but it is worth noting that in the case of the pyrrole substrates, the N–H had to be protected in the form of a TIPS, Boc or methyl protecting group. The Boysen group concluded that the success of the reaction largely depends on the electronic nature of the boron species and thus, on the borylation position on the heteroaromatic ring. To efficiently couple these heteroaromatic residues in an asymmetric fashion required intense optimisation, particularly regarding ligand design. However, many substrates proved to be problematic. Only promising substrates were trialled in the asymmetric variant. Some successful examples of these heteroarylboronates are depicted in Scheme 93.




Scheme 93 The use of MIDA or pinacol boronates in Rh-catalysed conjugate additions

A final, and recent, example concerning heteroaryl conjugate addition reactions was published by Dou and co-workers in 2022.⁵⁰ This work reports the rhodium-catalysed asymmetric conjugate pyridylation of α,β -unsaturated carbonyl compounds with pyridylboronic acids. This work was enabled by employing a bifunctional chiral amide-diene ligand. As well as acting as a chiral ligand for the reaction, the authors suggest that the ligand dramatically accelerated the rate of reaction *via* H-bonding, allowing the conjugate addition to outcompete the protodeboronation. The reaction was found to only proceed efficiently when carried out in aqueous ethanol, supporting this H-bonding hypothesis. A large range of Michael-acceptor substrates were showcased with various pyridylboronic acids. A select few examples are shown in Scheme 94. The H-bonding effect of the chiral amide-diene ligand was explored by the authors and when the amide proton was changed to a methyl group, a large reduction in reaction rate was observed (Scheme 95).



Scheme 94 The asymmetric conjugate addition of pyridylboronic acids



Scheme 95 The potential H-bonding effect of the chiral amide-diene ligand


5.5. The Importance of Indole as a Heteroaromatic Scaffold

Despite the research in this space, it is clear that there is no general means for accessing heteroaryl conjugate addition products. Particularly for systems which are electron-deficient at boron. Using a heterocyclic boronic acid instead of a modified boronate ester is increasingly difficult for heteroaryl residues. Additionally, applying heteroaromatic groups with a free N-H bond is unreported. In fact, there is, to the best of our knowledge, only one example of indolyl boronic acids being employed in this transformation and it requires the

N-H bond to be suitably protected (N-Me).⁵¹ The lack of reactivity observed is presumably a consequence of indoles propensity to undergo protodeboronation⁵² and potentially interact with metal catalysts.⁴⁹ As a result, there has been no report of indolylboronic acids undergoing rhodium-catalysed conjugate addition reactions. This represents a significant gap in the scientific literature.

Indole represents one of the most abundant and important heterocycles in nature. For over a hundred years there has been a large scientific effort to explore the derivatisation of indole ring systems owing to their status as ‘privileged biological structures’. The indole pharmacophore is critical to the function of a profusion of biologically active entities, ranging from large and complex natural products to simpler signalling molecules, like serotonin. Indole is central to the structure of many blockbuster APIs for the treatment of cancer, migraine, hypertension and other human diseases. In fact, it was reported that the indole-containing drugs sumatriptan, tadalafil, rizatriptan and fluvastatin accounted for total sales of \$3.2 billion in 2010. An example of some of the many indole containing compounds is illustrated in Scheme 96 including common API’s and signalling molecules.⁵³



Derivatisation of the indole structure is commonly observed on the heterocyclic ring, particularly at the C3-position, owing to the inherent reactivity of that position towards electrophilic aromatic substitution.⁵⁴ The C2-position of the heterocycle is also commonly observed to be activated with appropriate transition-metal catalysts and the N-H bond itself is often exploited in alkylation or reductive amination protocols. Substitution processes on the phenyl backbone of indole is less commonly observed.⁵⁵



Scheme 96 Indole containing APIs and natural occurring compounds

5.6. The use of Micellar Catalysis for Rh-Catalysed Conjugate Addition


As outlined previously, the utilisation of heteroaromatic coupling partners in 1,4-addition is limited by several factors. In some cases, their poor solubility in organic solvent and the additional problem of protodeboronation accelerated by base and water can create a roadblock when designing a reaction scheme. Micellar catalysis has, in recent years, come to the fore as viable alternative to organic solvent in chemical reactions, particularly through the work of Lipshutz.^{56,57} The use of micellar catalysis has been successfully employed in the arena of Rh-catalysis, particularly in relation to asymmetric 1,4-additions.^{58,59} This allows the benefit of aqueous solubility to be combined with the efficiency of an organic solvent for these transformations (Scheme 97). Micelles have associated potential benefits including; improving the green metrics of a reaction, allowing catalyst (or ligand) recyclability, milder reaction conditions and new reaction pathways as a consequence of the high concentrations associated with the use of micelles. Rhodium catalysis has, in particular, benefited from the use of micellar catalysis in recent years.




Scheme 97 A summary of micelles and various surfactant⁶⁰

In a report by Lipshutz, the benefit of aqueous micellar chemistry is highlighted by improved yields and enantioselectivities relative to those in organic solvent (Scheme 98).⁵⁸ Lipshutz and co-workers designed a micelle-catalyst system where the polyethyleneglycol ubiquinol succinate (PQS) surfactant was bound to the chiral ligand and could be premixed with a

suitable rhodium catalyst to create a chiral surfactant catalyst. The success of this reaction medium was showcased through employing different ring sizes of the Michael-acceptor and by alternating the arylboronic acid. In all cases, improved and more consistent yields and enantioselectivities were observed using aqueous micellar catalysis. It should be noted however, that the initial results in organic solvent were still excellent, for the most part. The synthesis of this simple surfactant ligand and catalyst system is shown in Scheme 99.





Scheme 98 Lipshutz's comparison of the solvent effect on Rh-catalysed asymmetric 1,4-additions




Scheme 99 The synthesis of PQS-BINAP-Rh for asymmetric micellar catalysis

Similar work was carried out by Fernandez and co-workers,⁵⁹ where rather than pre-forming their chiral surfactant, they used a standard catalyst in a surfactant solvent for the reaction. A range of Michael-acceptors with phenylboronic acids was trialled in suitable surfactants to yield desired products in excellent yields and enantioselectivities (Scheme 100). Furthermore, using these developed reaction conditions, the corresponding 1,2-addition could also be performed in aqueous media. The structures of the PTS and SDS surfactants used are represented in Figure 9.

1,4-addition



1,2-addition



Scheme 100 The use of surfactants in Rh-catalysed conjugate addition reactions




Figure 9 Structures of common surfactants for micellar catalysis

The use of micelles as a reaction medium for Rh-catalysed 1,4-additions sets the stage for their application to heteroaryl boronic acids.

6. Results & Discussion

6.1. Objectives

Indole represents one of the most abundant and important heterocycles in nature. A straightforward approach to building molecular complexity on the indole backbone would be to employ indolyl boronic acids in asymmetric 1,4-addition reactions. As described in the Introduction, the use of heteroaryl boronic acids is under-reported in the literature as a consequence of their propensity to undergo protodeboronation, unwanted interaction with metal catalysts and engage in alternative reactive pathways. This section looks at utilising indolyl boronic acids in the asymmetric 1,4-addition reaction to yield enantioenriched, novel indole derived scaffolds. Ideally, this project would allow for a protecting-group-free strategy in aqueous media. The proof-of-principle reactions in this Chapter were carried out by another member of the McGlacken Group, Dr Katrina Mackey.


6.2. Background Chemistry

As this work was started by another member of the McGlacken group, some of the initial attempts to couple indoles with Michael-acceptors will be described to provide context for this thesis. This project was in collaboration with Eli Lilly, Indianapolis who required a route to access enantioenriched conjugate addition products from indole precursors. The initial reaction concept looked at employing an indole bromide with a suitable enone under transition metal catalysis to yield the conjugate addition product. The use of an aryl bromide could circumvent the foreseen issues with heteroaryl boronic acids. Many reactions were attempted using aryl halides with various palladium and rhodium catalysed protocols. However, any attempt to couple an indole halide with a enone failed to afford the desired product in a decent yield.


6.3. Initial Reaction Screening – Dr Katrina Mackey

On the premise that there was no obvious path to proceed with using indolyl halides, the idea of utilising Rh-catalysis and indole boronic acids for an asymmetric conjugate addition was conceptualised. As described in the Introduction of this Chapter, the precedent for using heteroaromatic boronic acids in this chemistry is limited, and the use of indolyl boronic acids is unreported. The state-of-the-art for this reaction would use mild reaction conditions, a chiral ligand and a simple Rh catalyst, as seen in seminal work by Hayashi and Miyauchi

(Scheme 101).¹⁹ More recent work by Fernandez and co-workers shows the power of using surfactants in unison with this chemistry, where at room temperature and in aqueous media, conjugate additions can be carried out in quantitative yields and in an e.e. up to 99% using a chiral sulphur-olefin ligand (Scheme 102).⁶¹




Scheme 101 The first Rh-catalysed asymmetric addition using phenyl boronic acids




Scheme 102 Modern advances in Rh-catalysed asymmetric additions

An initial reaction was trialled using 5-indolyl boronic acid in conjunction with (*R*)-BINAP, a standard rhodium catalyst and polyoxyethanyl- α -tocopheryl sebacate (PTS), which was the best performing surfactant for Fernandez and co-workers (Scheme 103).⁵⁹ The desired product was formed, albeit in low conversion of 31% and moderate enantiomeric ratio (e.r.) of 63:37.




Scheme 103 Initial reaction conditions for the Rh-catalysed conjugate addition of indolyl boronic acids

From this, the sulphur-olefin ligand **L1** employed by Fernandez was examined.⁵⁹ The ligand could be simply synthesised *via* reductive amination between cinnamaldehyde and Ellman's auxiliary.⁵⁹ The first step utilises titanium ethoxide as an activating agent⁶² to form the imine intermediate which is subsequently reduced by sodium borohydride to furnish the desired amine product (Scheme 104). Both the racemic and enantiopure variants of the ligand were synthesised. The racemic reaction proceeded smoothly and provided access to a racemic product for HPLC method development (Scheme 105) (see Experimental for more information).




Scheme 104 The synthesis of chiral sulphur-olefin ligand by reductive amination




Scheme 105 The racemic Rh-catalysed reaction of 5-indolyl boronic acid with cyclohexenone

The corresponding asymmetric variant with the (*S*)-enantiomer ligand **L1** was then employed in the reaction. Under these initial reaction conditions, a yield of 70% was achieved with an enantiomeric ratio of 95:5.




Scheme 106 The asymmetric Rh-catalysed reaction of 5-indolyl boronic acid with cyclohexenone

The parallel reaction was also trialled initially in water rather than in a micellar solution and a comparable yield and enantioselectivity was obtained (Scheme 107). However, these conditions gave a more complex crude spectrum with additional side-products and was not as optimal as the corresponding version carried out in micelles.



Scheme 107 The comparable asymmetric reaction in water as a reaction solvent

As outlined in the Introduction, the macro structure of micelles can be altered by the addition of small amounts of organic solvent.^{63,64} Methanol, acetone and other organic solvents are commonly used to alter micelle size, offering alternative reactivity, much like changing reaction concentration. Table 10 depicts the effect that adding 10% MeOH to either PTS or TPGS-750-M has on the reactions efficiency and enantiocontrol. Micelle TPGS-750-M is considered a designer surfactant. It is a second generation surfactant, developed from the base structure of PTS. In PTS, the conversion is lowered but a slightly higher enantioenrichment is observed (Table 10, Entry 1). With methanol, TPGS provides a higher conversion than the PTS, but a slightly poorer enantiomeric ratio observed (Table 10, Entry 2). Interestingly, 10% MeCN retained the enantioenrichment of 96:4 while boosting the reaction conversion to 91% (Table 10, Entry 3).




Surfactant	Additive	Conversion ^a	<i>e.r.</i> ^b
PTS	MeOH	60%	96:4
TPGS-750-M	MeOH	73%	95:5
PTS	MeCN	91%	96:4

^a Conversion is based off the relative ratio of starting material to product
^b Enantiomeric ratio is determined by chiral HPLC on an OD-3 column

Table 10 The effect of organic solvent additives

Finally, Dr Mackey showcased the fundamental importance of the sulphur-olefin ligand for reaction efficiency. In the absence of the ligand, the reaction proceeded to only 14% conversion even after 48 hours (Scheme 108).




Scheme 108 Investigation into conjugate additions in the absence of ligand

6.4. Reaction Optimisation

The reaction of cyclohexenone with 5-indolyl boronic acid was chosen as the model reaction to optimise this reaction type using similar conditions as those depicted in Table 10. As described in the Introduction, micelle solutions are surfactants which come together to form ‘nanoreactor spheres’ with a hydrophobic centre and hydrophilic shell.⁶⁰ It is inside these hydrophobic centres that the organic chemistry can take place. These nanoreactors create highly concentrated environments and thus, the high concentrations can sometimes obviate the requirement for prolonged reaction times or high temperatures.^{60,65} Consequently, investigating the concentration of the micellar solution employed is incredibly important. The PTS solution is a 15 wt% solution in H₂O and a volume of 0.7 mL of this solution in 0.3

mmol of cyclohexenone results in a concentration of 0.4 M for the reaction. With 10% of acetonitrile (MeCN) as an additive, the reaction progressed to 78% at 0.4 M, 91% at 0.8 M and was lowered to 50% at 0.2 M (Table 11, Entries 1-3). Using the concentration of 0.8 M, the catalyst and ligand loadings were lowered to 2.5 mol%. However, the yield of the desired product was reduced (Table 11 Entry 4). Despite the more concentrated system giving higher conversion, the crude material consisted of multiple side-products. The concentration of 0.4 M gave a much cleaner reaction profile and so, 0.4 M remained the preferred reaction concentration. The catalytic loading was also examined at 0.4 M. Initially, the catalyst to ligand ratio was run at 1:1 (5 mol%). When a 1:2 catalyst to ligand ratio (2.5:5 mol%) was employed, an improved conversion to 86% was observed (Table 11 Entry 5).




Entry	$[Rh(C_2H_4)_2Cl]_2$ (mol%)	L1 (mol%)	Concentration	Conversion^a
1	5	5	0.4 M	78%
2	5	5	0.8 M	91%
3	5	5	0.2 M	50%
4	2.5	2.5	0.8 M	67%
5	2.5	5	0.4 M	86%

^a Conversion was determined by ¹H NMR spectroscopy using the relative ratio of product to cyclohexenone signals

Table 11 The screening of micelle concentration in the reaction

A small solvent and additive screening was also carried out in the initial investigations (Table 12). The use of water, PTS or TPGS as the reaction solvent all gave excellent levels of enantioenrichment. Similarly, the use of NaCl, MeCN or MeOH as solvent additives allowed high levels of enantiocontrol to be achieved in the transformation. However, optimal results were observed when PTS was combined with NaCl (Table 12, Entry 2) or 5% of MeCN (Table 12, Entry 5). The use of NaCl as an additive provided a cleaner crude NMR spectrum of the

reaction in comparison to the reaction using MeCN as an additive. Consequently, PTS and NaCl were chosen as the optimal reaction media and additive for the conjugate addition.



Entry	Solvent	Additive	Conversion ^a	e.r. ^b
1	PTS	-	75%	97:3
2	PTS	NaCl (3.0 M)	90%	97:3
3	TPGS	MeOH (10%)	73%	95:5
4	H ₂ O	-	65%	96:4
5	PTS	MeCN (5%)	90%	97:3
6	H ₂ O	NaCl (3.0 M)	76%	90:10


^a Conversion was determined by ¹H NMR spectroscopy using the ratio of product to cyclohexenone

^b Enantiomeric ratio was determined by chiral HPLC

Table 12 Investigation into the solvent and additive effect on the reaction

6.4.1. General Reaction Parameters

We then investigated the effect of time and temperature on the reaction progress. The model reaction was sampled at various timepoints to view the rate of product formation as well as the corresponding enantiomeric ratio (e.r.). The e.r. of the product remained consistent at 97:3 throughout all timepoints and temperatures trialled. After 1 hour, the product had formed in 55% yield by ¹H NMR (Table 13, Entry 1). After 8 hours the yield had increased to 72% (Table 13, Entry 2). After 16 hours only a slight increase to 78% was observed (Table 13, Entry 3). At the timepoint of 18 hours the product was formed in 83% (Table 13, Entry 4) and the reaction reached completion after 24 hours where a 90% yield of the desired product was observed (Table 13, Entry 5). Finally, it was shown that the increase of temperature from room temperature to 40 °C allowed the yield to be increased to 95% while retaining the excellent levels of enantioselectivity (Table 13, Entry 6).



<i>Entry</i>	<i>Time</i> (hr)	<i>Temperature</i> (°C)	<i>Yield</i> ^a	<i>e.r.</i> ^b
1	1	20	55%	97:3
2	8	20	72%	97:3
3	16	20	78%	97:3
4	18	20	83%	97:3
5	24	20	90%	97:3
6	24	40	95%	97:3


^a Yield was determined by ¹H NMR spectroscopy using 1,3,5-trimethoxybenzene as internal standard

^b Enantiomeric ratio was determined by chiral HPLC

Table 13 Screening of time and temperature for the Rh-catalysed conjugate addition of 5-indolyl boronic acid and cyclohexenone

6.4.2. Base Screening

We then decided to investigate the effect that the base had on the reaction (Table 14). Sodium hydroxide allowed the product to be formed in a good yield of 86%, albeit with a reduced enantiomeric ratio of 95:5 (Table 14, Entry 1). Use of triethylamine gave an excellent yield and enantiomeric ratio of 91% and 96:4 respectively (Table 14, Entry 2). Potassium bifluoride exhibited excellent enantioenrichment of the desired product (98:2 e.r.) but with a reduction in yield (33%) (Table 14, Entry 3). The greatest level of enantioselectivity was observed by the use of potassium fluoride (99:1 e.r.) (Table 14, Entry 4). Despite this high level of enantioenrichment, only a moderate yield of 70% was achieved. Tripotassium phosphate provided the product in an excellent yield of 90% with an enantiomeric ratio of 97:3 (Table 14, Entry 5). Thus, KOH remained the optimal base for this transformation, affording high yields and enantioenrichment of the conjugate addition product **2** (Table 14, Entry 6).



Entry	Base (aq. 2.5 M)	Yield ^a	e.r. ^b
1	NaOH	86%	95:5
2	NEt ₃	91%	96:4
3	KHF ₂	33%	98:2
4	KF	70%	99:1
5	K ₃ PO ₄	90%	97:3
6	KOH	95%	97:3


^a Yield was determined by ¹H NMR spectroscopy using 1,3,5-trimethoxybenzene as internal standard
^b Enantiomeric ratio was determined by chiral HPLC

Table 14 The base screening of the Rh-catalysed asymmetric conjugate addition of 5-indolyl boronic acid and cyclohexenone

6.4.3. Investigating the Use of KF

Employing KF as a base in our system led to high levels of enantioenrichment and so, we decided to further explore reaction parameters which could retain the e.r. of 99:1 while increasing the yield of the product. Alternatively, it was hoped that the enantiocontrol could be improved by varying the reaction conditions and increase our level of enantiocontrol. Initially, the equivalents of KF were lowered to try slow the reaction progress and give an increased e.r. However, halving the loading of the base resulted in a drastic drop-off in yield (26%) with no change in the enantioselectivity (Table 15, Entry 1). To try increase the reaction yield, the loading of rhodium catalyst was increased to 5 mol% but interestingly, this also resulted in reduced yield (Table 15, Entry 3). Similarly, when the KF loading was increased to 2 equivalents a yield of 44% was observed after 24 hours (Table 15, Entry 4). Given the success the use of KOH had in achieving high yields of product, it was thought that adding an equimolar amount of KOH and KF may have a synergistic effect on the reaction. However, when this was trialled, the excellent enantiomeric ratio of 99:1 was retained but only a moderate yield of 53% was obtained (Table 15, Entry 5). Finally, as the yield of the reaction could not be increased from 70%, alternative efforts were made to increase the e. r. Firstly,

the reaction temperature was lowered to 0 °C. This expectingly lowered the yield to 33% but, the e.r. remained at 99:1. Lastly, the reaction progress was monitored to see if the initial enantioenrichment was higher early in the reaction compared to later. The reaction was stopped after 1 hour and surprisingly, a good yield of 66% was achieved, albeit with the e.r. of 99:1, unchanged from previous attempts. It was concluded that the yield and e.r. of the product could not be easily improved upon when KF was employed and thus, KOH remained the base of choice for this reaction.



Entry	KF (equiv.)	Deviation	Temp (°C)	Time (h)	Yield ^a	e.r. ^b
1	0.5	-	40	24	26%	99:1
2	1	-	40	24	70%	99:1
3	1	[Rh] – 5 mol%	40	24	45%	99:1
4	2	-	40	24	44%	99:1
5	1	KOH – 1 equiv.	40	24	53%	99:1
6	1	-	0	24	33%	99:1
7	1	-	40	1	66%	99:1

^a Yield was determined by ¹H NMR spectroscopy using 1,3,5-trimethoxybenzene as internal standard

^b Enantiomeric ratio was determined by chiral HPLC

Table 15 The screening of potassium fluoride and alternate reaction conditions in the model reaction

6.5. Investigation into the Chiral Ligand

With conditions optimised for time, temperature, solvent and base, we decided to investigate the final reaction variable; the chiral ligand. As outlined in the introduction, there is a large variety of chiral ligands routinely employed in the field of asymmetric rhodium catalysis. Thus far, we had only examined BINAP and the sulphur-olefin ligand **L1**. In an effort to see if the level of enantioenrichment could be raised with **L1** from an e.r. of 97:3, we

envisaged screening a range of chiral ligands. This list included chiral mono- and bi-phosphines, dienes and derivatised sulphur-olefin based ligands. Many of these ligands were commercially available, but it was required to individually synthesise the sulphur-olefin ligands. With the sulphur-olefin ligand (**L1**) we had utilised thus far, we noticed that the majority of the published protocols use the unoptimised ligand **L1** (Figure 10).^{66–68} In a few instances, some functionalisation on the aryl ring of the cinnamaldehyde precursor was reported.^{67,69} In one instance, the olefin bond was substituted with a methyl group.⁷⁰ In no instance had the sulphur chiral auxiliary been altered from a *t*-butyl group (Figure 10). Understandably, modulation of the aryl ring is the most commonly observed derivatisation, as many functionalised cinnamaldehydes are readily available. However, we were surprised to see how few reports included derivatisation on the olefin or sulphur functionalities, as it is understood that these are the moieties which chelate directly to the metal centre.^{67–69} Overall, we hoped to functionalise this sulphur-olefin core to afford novel chiral ligands and potentially increase the enantioselectivity observed in our model reaction.





Figure 10 The literature precedent for this sulphur-olefin ligand functionalisation

6.5.1. The Synthesis of Cinnamaldehyde Based Ligands

To synthesise a range of these ligands, various cinnamaldehyde precursors were subjected to a standard reductive amination protocol (Scheme 109). The aldehyde, sulfinamide and titanium ethoxide were added to a flask containing anhydrous THF under an inert atmosphere and heated for 4 hours at reflux. The mixture was subsequently cooled and 2 – 4 equivalents of sodium borohydride was added to reduce the imine formed. The *p*-Me ligand **L3** was synthesised in a moderate yield of 40%. The corresponding *p*-OMe (**L4**), *p*-NMe₂ (**L5**) and *p*-F (**L6**) derivatives were furnished in moderate to good yields. The α -methyl ligand **L7** was obtained in a moderate yield of 41%. Extending the chain length of the functional

group on the olefin to a five carbon chain allowed the sulfinamide **L8** to be obtained, albeit in a poor yield of 26%. The olefin could be tethered to the aryl ring as in the case of ligand **L9**, which was afforded in a good yield of 64%. The other position on the olefin was also functionalised as seen with the β -phenyl ligand **L10**, which was synthesised in 54% yield. The imine **L11** was obtained in an excellent yield of 87%. Finally, the chiral sulphur group could be installed as a *p*-tolyl group to give the corresponding sulfinamide **L12** in 26% isolated yield. These isolated yields are not optimised as it was initially only desired to obtain enough material to screen the chiral ligand in the model conjugate addition reaction.



Scheme 109 The range of sulphur-olefin ligands synthesised

6.5.2. Alternative Classes of Chiral Ligands

The range of chiral ligands was then expanded to include a chiral diene and chiral phosphine ligands (Figure 11). It was hoped that this range of ligands would cover a large area of chemical space (BINAP-type ligands, chiral bi-phosphines, mono-phosphines and a chiral diene ligand).





Figure 11 Alternative ligands obtained to trial in the model reaction

6.5.3. Unsuccessful Syntheses of Alternative Chiral Ligands


Through the course of these investigations, alternative sulphur-olefin type ligands were also considered for this transformation. As described in the Introduction, a large number of these ligand classes are reported in the literature and have proven successful with rhodium catalysed reactions. One such ligand is **L20** where the key olefin moiety is in an alternative position in comparison to **L1**.^{71,72} To access this ligand, the 3-phenylpropanal aldehyde precursor was treated with formaldehyde in CH_2Cl_2 with pyrrolidine in water to yield the conjugated product (Scheme 110). This conjugated compound could then undergo the same reductive amination protocol as with the cinnamaldehyde-based ligands to yield a chiral ligand (Scheme 110). However, the first step concerning the insertion of the double bond on the aldehyde precursor was a poor performing reaction with a very low yield of isolated

product obtained. Alternative conditions were also trialled for this transformation using methanol and propionic acid but similarly, poor conversion to the desired product was observed. Additionally, when the reductive amination protocol was applied to the conjugated intermediate, only trace amounts of product were observed and sufficiently pure material could not be isolated to trial this ligand in the asymmetric 1,4-addition.




Scheme 110 The unsuccessful synthesis of an alternative sulphur-olefin ligand

Another class of sulphur-olefin ligand was reported in the form of the aziridine **L21** (Scheme 111).⁷³ In order to access this structure, a sulfinylimine and *S*-allyl tetrahydrothiophenium bromide were required to react under basic conditions. Both the sulphur salt and the sulfinylimine could be prepared successfully. However, the aziridine formation using lithium *t*-butoxide only generated the desired compound in trace amounts (Scheme 111). The use of alternative bases such as caesium carbonate did not improve conversion to product.



Scheme 111 Unsuccessful formation of a chiral aziridine ligand

Finally, we attempted to access a naphthyl variant of the model cinnamaldehyde ligand. The pathway to this ligand started with a palladium-catalysed Suzuki-Miyaura reaction with allyl bromide and naphthyl boronic acid to yield the allyl compound. This intermediate could then be oxidised to afford the conjugated aldehyde which could subsequently undergo reductive amination with Ellman's auxiliary. The Suzuki-Miyaura reaction was performed successfully after some moderate optimisation, to provide the allyl intermediate in low yield (15%). However, the oxidation with DDQ only afforded trace amounts of the desired aldehyde and so, the synthesis was not progressed further. Similarly, for the bis-*ortho* methyl derivative, the Suzuki-Miyaura cross-coupling could be performed successfully in moderate yield (28%). However, the oxidation, once again, failed to produce any of the desired aldehyde. A palladium catalysed variant of the DDQ oxidation was also attempted for the bis-*ortho* methyl derivative but no product was obtained under either reaction conditions (Scheme 112).





















Scheme 112 The unsuccessful oxidation of cinnamaldehyde precursors for ligand synthesis

6.5.4. Chiral Ligand Screening

With the range of ligands to hand, we trialled each ligand in the model reaction of 5-indolyl boronic acid with cyclohexenone (Table 16). This investigation was performed with the currently optimised conditions of KOH, NaCl and PTS for 24 hours at 40°C with $[\text{Rh}(\text{C}_2\text{H}_4)_2\text{Cl}]_2$ as the rhodium catalyst. As a whole, the BINAP-type ligands performed poorly, giving moderate yields and poor enantioenrichment. In the case of $\text{H}_8\text{-BINAP}$, a nearly racemic product was obtained and in very low yield. The other phosphine ligands proved similarly futile where QuinoxP* and Me-BPE gave poor conversion to the product and very low enantiomeric ratio. Low yields and no enantioselectivity was observed using the monophosphine ligand (**L18**) employed in the reaction. The cinnamaldehyde based ligands investigated were functionalised on both the α and β positions of the alkene, the aromatic ring and the chiral sulfinamide itself. It was observed that any functionalisation α to the amide nitrogen on the olefin resulted in a drop in yield and lower enantioenrichment of the

product. Functionalising this position with a methyl group allowed good enantiocontrol to be retained (90:10) but gave a poorer yield (62%). Increasing this chain length to five carbons resulted in only 9% yield of the desired product with a corresponding e.r. of 55:45. When this position was tethered to the aryl ring, in the case of **L9**, the reaction failed to furnish any product. The β position of the alkene showed some tolerance to functionalisation. A phenyl group was successfully attached to the olefin at this position (**L10**) which provided a moderate yield of product (34%) but with a high level of enantioenrichment (95:5). It was found that derivatising the aryl ring of the precursor provided more comparable results to our standard ligand. The *para*-position was functionalised with Me, OMe, NMe₂ and F groups. Unfortunately, due to commercial availability or reaction and purification issues, a more comprehensive electronic and steric investigation to this aryl ring could not be conducted. The *p*-Me ligand (**L3**) provided a comparable e.r. to our initial unsubstituted ligand (96:4) albeit with a drop in the yield to 72%. The *p*-OMe derivative (**L4**) enabled high yields of the desired product (94%) but with a lower level of enantioenrichment (93:7). The *p*-NMe₂ ligand (**L5**) provided results similar to the *p*-Me ligand exhibiting good yield of 74% and excellent enantioselectivities (97:3). Employing the imine ligand **L11** afforded moderate yield and poor enantioenrichment of the conjugate addition product (39% and 60:40). Altering the chiral auxiliary functional group from a *t*-butyl to a *p*-tolyl moiety in the case of **L12** resulted in both a poorer yield (54%) and e.r. of the desired product (84:16). Finally, employing a commercially available chiral diene (**19**) in the reaction afforded the product in moderate yield (51%) and moderate enantioenrichment (72:28). Thus, the initial, unsubstituted ligand we began with proved to be the best ligand for this transformation.

<i>Ligand</i>		<i>Yield</i> ^a	<i>e.r.</i> ^b	<i>Ligand</i>		<i>Yield</i>	<i>e.r.</i>
	L1	90%	97:3		L11	39%	60:40
	L3	72%	96:4		L12	56%	84:16
	L4	94%	93:7		L13	31%	63:37
	L5	73%	97:3		L14	22%	62:38
	L6	67%	90:10		L15	8%	50:50
	L7	62%	90:10		L16	19%	59:41
	L8	9%	55:45		L17	18%	51:49
	L9	0%	-		L18	17%	56:44
	L10	34%	95:5		L19	51%	72:28

^a Yield was determined *via* ¹H NMR spectroscopy using 1,3,5-trimethoxybenzene as an internal standard


^b Enantiomeric ratio was determined by chiral HPLC

Table 16 The ligand screen of the Rh-catalysed conjugate addition reaction

6.6. Pre-Generation of the Catalytic Species

Before applying these conditions to a range of suitable substrates, we wanted to comprehensively investigate reaction conditions which may improve the high level of enantiocontrol observed to date (Scheme 113). Numerous literature protocols call for the pre-generation of an active catalytic species with this type of reaction.^{61,74} Firstly, we

investigated potential effects of premixing the rhodium catalyst with the ligand. Thus, 2.5 mol% $[\text{Rh}(\text{C}_2\text{H}_4)_2\text{Cl}]_2$ was added to the PTS solution with 5 mol% of **L1**. These species were mixed for 15 minutes before adding the remaining reaction components. The reaction then proceeded under usual conditions. This protocol resulted in a reduced yield of the product (57%) while high levels of enantioenrichment were retained (96:4). Following this, it was decided to allow all reaction components to pre-mix, except for the cyclohexenone substrate. By following a literature precedent for this procedure, everything was added to the reaction flask and mixed for 30 minutes before the Michael-acceptor was added to the reaction mixture. This procedure provided the same level of enantiomeric ratio (97:3) but with a slightly reduced yield relative to our optimal conditions (89%). Thus, we were confident that the most robust protocol was the original method devised.



Scheme 113 The investigation into the pre-generation of active catalytic species for the reaction



6.7. Substrate Scope

With these investigations complete, we turned our attention to applying this protocol to a range of indolyl-boronic acids and suitable Michael-acceptors. We started this investigation by employing different cyclic enones with our model 5-indolyl boronic acid. The five-membered ring product **22** could be generated in a good yield of 81% and an excellent enantiomeric ratio of 98.5:1.5. The corresponding cycloheptyl substrate **23** was formed in a moderate yield of 51% but with a high level of enantiocontrol (94:6 e.r.). A lactone moiety was also tolerated at the 5-position, affording the product **24** in a good yield and
















enantiomeric ratio (61%, 95:5 e.r.). We next turned our attention to accessing the 4- and 6-substituted products. It was anticipated that the electron deficient nature of these positions would result in a more difficult coupling than the model 5-position.⁷⁵ The nucleophilic character of the carbon attached to the boron is known to be important in many cases of Rh-catalysed conjugate additions.⁴⁶ Pleasingly however, our methodology afforded the desired products in good to excellent yields, with excellent enantioenrichment. Once again, several ring sizes were tolerated. The product with a six-membered ring at the 6-position (**25**) was obtained in good yield and with a good level of enantioenrichment (74%, 97:3 e.r.). The corresponding cyclopentyl product **26** gave a similar yield with a much higher enantioenrichment (72%, 97.5:2.5 e.r.). The cycloheptyl product **27** was furnished in the highest yield to date (94%) with an excellent enantiomeric ratio of 96:4. Determination of stereochemical orientation was achieved through resolution of crystal structures for products **26** and **27** products. The 6-position was also successfully functionalized with a lactone moiety in moderate yield and enantioenrichment to afford **28** (74%, 92:8 e.r.). Similar results were achieved using the 4-indolyl boronic acid starting materials. The cyclohexanone residue was successfully installed at the 4-position to yield **29** in 73% yield and an enantiomeric ratio of 97.5:2.5. A high yield of 87% was afforded for the corresponding cyclopentenone substrate (**30**) with a good enantiomeric ratio of 96.5:3.5. Finally, a cycloheptanone ring was successfully installed at the 4-position (**31**) in a moderate yield of 41%, but with excellent levels of enantioenrichment (97:3 e.r.). A single crystal structure of **31** was also obtained to determine the absolute stereochemistry of the chiral centre created.

Finally, we investigated the 7-position of the indole structure, which is the closest position to the nitrogen of the heteroaromatic ring. The reaction proceeded well and the desired 7-substituted indole **32** was isolated in a moderate 55% yield. However, this product was formed with excellent levels of enantioselectivity (98.5:1.5 e.r.). It was noted that when the cyclohexenone ring was employed with this boronic acid, an undesired product formed. This will be discussed later in Section 'Novel Polycyclic Product Formation'.

We then turned our attention to acyclic enone variants. Despite the success with cyclic enones, early attempts to apply our optimized conditions to acyclic variants gave poorer yields. Moreover, all substrates trialled (**33–36**) produced racemic products.



86%, 97:3 e.r.

**22**, 81%, 98.5:1.5 e.r.**23**, 51%, 94:6 e.r.**24**, 61%, 95:5 e.r.**25**, 74%, 97:3 e.r.**26**, 72%, 97.5:2.5 e.r.**27**, 94%, 96:4 e.r.**28**, 74%, 92:8 e.r.**29**, 73%, 97.5:2.5 e.r.**30**, 87%, 96.5:3.5 e.r.**31**, 41%, 97:3 e.r.**32**, 55%, 98.5:1.5 e.r.**33**, 23%^a**34**, 20%^a**35**, 81%**36**, 42%

All linear enones afforded racemic products

^a Yield was determined by ¹H NMR spectroscopy using 1,3,5-trimethoxybenzene as internal standard

6.7.1. Single Crystal Structures



Figure 12 Single crystal structure obtained for the cycloheptyl substrate **31**




Figure 13 Single crystal structure obtained for the cycloheptyl structure **27**





Figure 14 Single crystal structure obtained for the cyclopentyl substrate **26**

6.7.2. Optimisation of Acyclic Enone Substrates

To fully expand the protocol to acyclic enones, further optimisation was required (Table 17, Entry 1). The linear enone **37** was chosen as the model substrate to optimise the reaction parameters (Table 17). Initially, we tried changing the solvent from aqueous micelles to 1,4-dioxane, which allowed a moderate e.r. of 60:40 to be achieved, albeit with a reduction in yield to 60% (Table 17, Entry 2). We then attempted to use a mixture of PTS and dioxane as the reaction solvent but with this, a poor yield of 25% with an e.r. of 55:45 was observed (Table 17, Entry 3). We then trialled BINAP (Table 17, Entry 4) and the chiral diene **19** (Table 17, Entry 5) as chiral ligands in this reaction. Similar levels of enantiomeric excess were observed for BINAP (62:38 e.r.) and the diene ligand (65:35 e.r.). However, the diene enabled a much higher yield of product to be formed (81%). With the best enantioenrichment observed through the use of dioxane as the reaction solvent, we continued to employ organic solvent in place of aqueous media for the remainder of our screening. When the diene was employed in dioxane, full conversion to the desired product was observed and the enantioenrichment was increased to 80:20 e.r. (Table 17, Entry 6). As described previously, a drawback with the use of chiral diene ligands is that they are generally not commercially available. The syntheses of such ligands are often multi-step and arduous, meaning it is difficult to build up a library of ligands to screen for a particular reaction. Given that we could not functionalise this chiral diene ligand, the remaining variable to explore was the rhodium catalyst used in the reaction. Two other rhodium catalysts were employed alongside the chiral diene ligand in dioxane but poor conversion and enantioselectivities was obtained in both cases (Table 17, Entry 7 and 8).



Entry	Catalyst (2.5 mol%)	Ligand (5 mol%)	Solvent	Conversion ^a	e.r. ^b
1	[Rh(C ₂ H ₄) ₂ Cl] ₂		PTS	81%	50:50
2	[Rh(C ₂ H ₄) ₂ Cl] ₂		Dioxane	60%	60:40
3	[Rh(C ₂ H ₄) ₂ Cl] ₂		PTS/Dioxane	25%	55:45
4	[Rh(C ₂ H ₄) ₂ Cl] ₂		PTS	15%	62:38
5	[Rh(C ₂ H ₄) ₂ Cl] ₂		PTS	81%	65:35
6	[Rh(C ₂ H ₄) ₂ Cl] ₂		Dioxane	100%	80:20
7	[Rh(coe) ₂ Cl] ₂		Dioxane	35%	59:41
8	Rh(nbd) ₂ BF ₄		Dioxane	12%	62:38


^a Conversion was determined *via* ¹H NMR spectroscopy using the relative ratio of enone to product signals

^b Enantiomeric ratio was determined by chiral HPLC

Table 17 The optimisation of linear enones in the asymmetric conjugate addition

Given the influence that the choice of inorganic base had in our initial reaction screening, we decided to explore if screening bases with the chiral diene could increase the enantiomeric ratio of the acyclic products (Table 18). Potassium fluoride was previously found to provide excellent levels of enantiocontrol in the case of cyclic enones. However, the use of KF with acyclic enones gave poorer conversion to product as well as a lower enantiomeric ratio (Table

18, Entry 2). The enantiomeric ratio was found to remain constant when KHF_2 and NEt_3 were employed. In both cases however, a large reduction in product yield was observed (Table 18, Entry 3 and 4). The use of K_3PO_4 allowed excellent conversion to the desired product but as with KOH , the enantiomeric ratio remained at 80:20 (Table 18, Entry 5).




Entry	Base (aq. 2.5 M)	Conversion ^a	e.r. ^b
1	KOH	100%	80:20
2	KF	25%	69:31
3	KHF ₂	5%	80:20
4	NEt ₃	34%	80:20
5	K ₃ PO ₄	100%	80:20

^a Conversion was determined *via* ¹H NMR spectroscopy using the relative ratio of enone to product peaks
^b Enantiomeric ratio was determined by chiral HPLC

Table 18 The screening of inorganic bases for the conjugate addition of linear enones

The lack of modularity afforded by the chiral diene ligand meant structural alterations to improve enantioenrichment were not possible. However, we noted that the use of BINAP in the protocol did produce modest levels of enantioselectivity (Table 17, Entry 4). A large advantage associated with chiral phosphine ligands is the diversity of ligands commercially available. A plethora of functionalised chiral phosphines are readily available and so, using this modest 15% yield and 62:38 e.r. as a starting point, we decided to screen a range of chiral phosphine ligands. These reactions were carried out in dioxane as we had established that this solvent enabled the highest conversion to product, alongside the greatest levels of enantioenrichment. The use of QuinoxP* gave an immediate improvement over the chiral diene ligand, and the product was furnished in 81% yield and with an e.r. of 86:14 (Table 19, Entry 1). SegPhos proved to be comparable to QuinoxP* affording the product in 79% and in an e.r. of 87:13 (Table 19, Entry 2). The use of Tol-BINAP provided the product in the highest e.r. observed thus far (91:9 e.r.) and in a very good yield of 87% (Table 19, Entry 3). With this

result, we hypothesised that increasing the electron-density on the phosphorous would correspond with increased levels of enantioselectivity and product yield. Thus, the electron-rich phosphine DTMB-SegPhos was trialled in the reaction. This ligand afforded excellent levels of enantiocontrol giving an e.r. of 98:2 but with a moderate yield of 51% (Table 19, Entry 4). Given the excellent e.r. achieved with DTMB-SegPhos, an attempt was made to increase the product yield by increasing the reaction temperature to 70 °C (Table 19, Entry 5). However, the yield decreased to 29% while retaining the e.r. of 98:2. Another electron-rich phosphine, DM-SegPhos, was employed in the reaction and a good yield of 81% and an excellent e.r. of 95:5 was achieved (Table 19, Entry 6). The ligand DM-BINAP was then trialled under the reaction conditions where an excellent yield and enantiomeric ratio were achieved in 98% and 95:5 respectively (Table 19, Entry 7). Finally, H₈-BINAP was employed in the system. Using this ligand, a high yield of 90% was obtained with excellent enantioselectivity (97:3 e.r.) (Table 19, Entry 8). With the use of H₈-BINAP, we now had optimised conditions to access linear enones in this asymmetric conjugate addition reaction.




Entry	Ligand (5 mol%)	Ligand	Temperature (°C)	Conversion ^a	e.r. ^b
1		QuinoxP*	40	81%	86:14
2		SegPhos	40	79%	87:13
3		Tol-BINAP	40	87%	91:9
4		DTMB-SegPhos	40	51%	98:2
5		DTMB-SegPhos	70	29%	98:2
6		DM-SegPhos	40	83%	95:5
7		DM-BINAP	40	98%	95:5
8		H8-BINAP	40	[90%]	97:3

^a Conversion was determined *via* ¹H NMR spectroscopy using the relative ratio of enone to product peaks
^b Enantiomeric ratio was determined by chiral HPLC
 Square brackets indicate that the yield is isolated

Table 19 The screening of phosphine ligands for the asymmetric conjugate addition of acyclic enones

6.7.3. Substrate Scope of Acyclic Enones

Using our optimised conditions with H₈-BINAP, we selected some substrates to undergo asymmetric conjugate additions with 5-indolyl boronic acid (Scheme 114). The model substrate yielded the desired product **38** in 90% yield and in an enantiomeric ratio of 96:4. The long-chained product **39** could be generated in a good yield of 80% and with excellent levels of enantioenrichment (96:4 e.r.). A simple, branched enone was successfully subjected to the protocol and gave the product **40** in excellent yield (93%) but unfortunately was not separable on our chiral HPLC and so, the level of enantioselectivity is currently undetermined. Finally, the methyl cinnamate substrate was successfully employed in the reaction providing the ester product **41** in a good yield of 82% and an enantiomeric ratio of 89:11.



^a HPLC method still under development

Scheme 114 Substrate scope of linear enones with 5-indolyl boronic acid

6.8. Novel Polycyclic Product Formation

Previously, when indole-7-boronic acid was reacted with cyclohexanone, the expected product was not formed. When the NMR was analysed, the NH proton peak which was so evident in previous products, was not observed. Usually, this proton is evident downfield of 8 ppm but in this case, a new ¹H signal was observed around 2.5 ppm (Figure 15). Additionally, the relevant quaternary carbonyl peak was absent from the ¹³C NMR spectrum.





Figure 15 ^1H NMR spectrum of the isolated product from the conjugate addition reaction of 7-indolyl boronic acid and cyclohexenone

We hypothesised that the conjugate addition happens initially to form the desired product. Then under basic conditions, the indole nitrogen attacks the cyclohexyl carbonyl carbon to form a ring-closed product bearing a tertiary alcohol (Scheme 115). Isolation by column chromatography afforded the product in 65% yield. In fact, when the product was subjected to the chiral HPLC, an enantiomeric ratio of 97:3 was obtained.




Scheme 115 Suspected mechanism of product formation for the unexpected cyclised product

The tetracyclic indole based framework formed could be a very efficient means of accessing natural product analogues. Tetracyclic indoles are routinely observed as the core skeleton for a myriad of natural products.⁷⁶ Protocols to access polycyclic building blocks in a step-efficient manner would be highly coveted in the field of totally synthesis and drug discovery.⁷⁶ Consequently, this reaction may prove very useful.

Overall, a unique tetracyclic, indole-based framework was synthesised in good yield and with an excellent level of enantiocontrol. We believe that the asymmetric rhodium catalysed conjugate addition sets the stereochemistry of the β -position and subsequently, the indole nitrogen atom can only attack from one face.

6.9. Application to the 1,2-Addition

With the success observed in the application of indolyl boronic acids in asymmetric rhodium catalysed 1,4-additions, we decided to probe their utility in the corresponding 1,2-addition. Conditions similar to ours were previously published⁷⁷ in these asymmetric 1,2-additions. With the same chiral ligand (**L1**), we were able to successfully employ 5-indolyl boronic acid in a 1,2-addition reaction with benzil (**42**) to yield the desired product **43** in 95% yield and an high level of enantioselectivity of 95:5 e.r. (Scheme 116).




Scheme 116 The asymmetric 1,2-addition of benzil with 5-indolyl boronic acid

6.10. Cost Improvement Protocols

Despite the success achieved thus far with the methodology, some drawbacks still persisted. In particular, the cost of the reaction components. Micellar solutions have a large variety of structural variability and complexity. As a consequence, the cost of these solutions vary greatly. The PTS micelles employed by us thus far, are more expensive than alternative micelles, routinely used in rhodium catalysis.

6.10.1. Investigation of SDS

One particular micellar solvent commonly used is sodium dodecyl sulphate or SDS. SDS is relatively cheap (500 mL/€89) due to its global requirement in biological laboratories and so, we performed our optimised reaction in SDS. Unfortunately, a much lower conversion to the desired product was observed in SDS, albeit with a very good enantiomeric ratio (95:5 e.r.) (Scheme 117).




Scheme 117 The use of SDS as a reaction solvent as a cheap micellar solution

6.10.2. Recyclability Studies using Micelles

As an alternative means of reducing cost of materials, we decided to investigate an advantage of micelles; their recyclability. Work by Lipshutz and co-workers has thoroughly depicted the usefulness of micelles as reaction solvents, and one of these benefits is that they are potentially recyclable.⁷⁴ Lipshutz has reported on rhodium-catalysed conjugate

additions in micellar solutions.^{64,65,74} Once complete, the reaction mixture could be diluted with organic solvent and the product extracted. The catalyst and ligand remain in the aqueous micellar solution for another transformation. We wished to demonstrate this property and so firstly, we performed our standard reaction. After 24 hours, the reaction mixture was diluted with ethyl acetate and stirred for 5 minutes. The organic layer was then extracted and more indolyl boronic acid and cyclohexenone was added to the aqueous micellar layer. The reaction was then re-run for another 24 hours. The same high level of product conversion was observed after the second run. However, there was a small reduction in the enantiomeric ratio observed (Scheme 118). These results do exhibit the recyclability of micelles and particularly highlight how this method could be used to reduce the waste from the reaction, improve the cost of the reaction and improve the reaction's green metrics.




Scheme 118 The recyclability of the PTS micellar solution in our reaction

6.11. Mechanistic Considerations *via* Deuterium Labelling

Fletcher and co-workers recently reported on the asymmetric rhodium-catalysed conjugate additions of piperidines.⁴⁵ In this investigation, the authors report how the substrates employed in the reaction can undergo one of two mechanisms. The mechanisms can be differentiated by the site of deuterium incorporation on the product. The most common pathway for these reactions to proceed involves deuteration at the α site to the carbonyl. In Fletcher's case, some substrates incorporated deuterium on the aryl ring of the boronic acid component in a mechanism involving a 1,4-Rh shift. In light of this, we employed both the linear and cyclic enones in deuterium labelling studies with the model 5-indolyl boronic acid. In both cases, deuteration occurred solely at the α -position of the carbonyl ring (Scheme 119). The absence of deuteration on the aryl ring of indole indicates that the mechanism

does not involve a 1,4-Rh shift step (as observed by Fletcher).⁴⁵ We envisage a mechanism akin to that described in Figure 16.



Scheme 119 Deuterium labelling studies for both substrate classes




Figure 16 The proposed mechanism of the Rh-catalysed conjugate addition of indolyl boronic acids

6.12. Unsuccessful Substrates

Some substrates were not applicable to our reaction conditions. As outlined in the Introduction to this Chapter, there was a myriad of Michael-acceptor type substrates available to trial in our reaction protocol. The substrates depicted in Figure 17 were tested under our optimised reaction conditions but were unsuccessful. Either a complex reaction mixture was observed by ^1H NMR or no product could be isolated from the reaction mixture. However, we envisage that specific optimisation for each substrate class would enable efficient conversion to the desired product.




Figure 17 Unsuccessful substrates

6.13. Conclusions & Future Work

The asymmetric rhodium catalysed 1,4-addition of indolyl boronic acids was demonstrated. Using this methodology, a range of cyclic and acyclic enones were successfully installed on the indole carbocyclic backbone with a high level of enantiocontrol. In the case of cyclic substrates, this chemistry was performed in aqueous media, at mild temperature to give good to excellent yields of enantioenriched products. Several single crystal structures were obtained during the course of this work to determine the absolute stereochemistry of the chiral centre. The protocol was optimised to include acyclic enones, which proceeded in good yield and with excellent enantiomeric ratios. This chemistry was expanded to allow indolyl boronic acids undergo 1,2-addition with excellent levels of enantioenrichment. A novel tetracyclic indole scaffold was synthesised *via* an asymmetric conjugate addition and a subsequent intramolecular cyclisation. The polycyclic product, formed through this one-pot, two-step process, was afforded in good yield and with an excellent level of enantiocontrol (65%, 97:3 e.r.). This result could allow for a range of tetracyclic indole frameworks to be accessed through this methodology, enabling efficient means to natural product analogues. The micelle media was recycled and the products could be formed with minimal reduction

of yield and e.r. Finally, mechanistic insight was achieved *via* deuterium labelling. In the case of both substrate classes (cyclic and acyclic enones), the deuterium studies suggested that this protocol follows a documented mechanistic cycle for the conjugate addition reaction of 5-indolyl boronic acids.

Future work for this project could explore the application of these substrates in the 1,2-addition. Furthermore, the failed Michael-acceptor type substrates could be individually optimised to allow a larger breadth of substrate tolerance in the asymmetric functionalisation of the indole carbocyclic backbone. Finally, the tetracyclic indole formed through the use of cyclohexenone and 7-indolyl boronic acid could be expanded upon. Different ring sizes, substitution patterns and bases employed in the system could allow an expansion of these natural product scaffold analogues with high levels of enantioenrichment.

7. Experimental

7.1. General Information

Solvents and reagents were used as obtained from commercial sources and without purification.

Column chromatography was carried out using 60 Å (35-70 µm) silica. TLC was carried out on precoated silica gel plates (Merck 60 PF254). The developed plates were visualised under UV light.

Melting points were obtained on a uni-melt Thomas Hoover Capillary melting point apparatus.

NMR spectra were run in CDCl₃ or (CD₃)₂SO using TMS as the internal standard at 25 °C unless otherwise specified. ¹H NMR (600 spectra) ¹H NMR (500 MHz) spectra, ¹H NMR (400 MHz) spectra and ¹H NMR (300 MHz) spectra were recorded on Bruker Avance 600, Bruker Avance 500, Bruker Avance 400 and Bruker Avance 300 NMR spectrometers respectively. ¹³C (150 MHz) spectra, ¹³C (125 MHz) spectra, ¹³C (100 MHz) spectra and ¹³C (75.5 MHz) spectra were recorded on Bruker Avance 600, Bruker Avance 500, Bruker Avance 400 and Bruker Avance 300 NMR spectrometers respectively in proton decoupled mode. Chemical shifts δ_H and δ_C are expressed as parts per million (ppm), positive shift being downfield from TMS; coupling constants (*J*) are expressed in hertz (Hz). Splitting patterns in ¹H NMR spectra are designated as s (singlet), br s (broad singlet), d (doublet), dd (doublet of doublets), dt (doublet of triplets), t (triplet), q (quartet) and m (multiplet). For ¹³C NMR spectra, the number of attached protons for each signal was determined using the DEPT pulse sequence run in the DEPT-90 and DEPT-135 modes.


Nominal mass spectra were recorded on a Waters Quattro Micro triple quadrupole spectrometer (QAA1202) in ESI mode using 50% acetonitrile–water containing 0.1% formic acid as eluent. High resolution mass spectra (HRMS) were recorded on a Waters LCT Premier Time of Flight spectrometer (KD160) or a Waters Vion IMS mass spectrometer (SAA055 K) in ESI mode using 50% acetonitrile–water containing 0.1% formic acid as eluent. Samples (max. 1 mg) were dissolved in acetonitrile, methanol, water or 10% DMSO/acetonitrile.

The Microanalysis Laboratory, National University of Ireland, Cork, performed elemental analysis using a Perkin-Elmer 240 and Exeter Analytical CE440 elemental analysers.


High performance liquid chromatography was performed using an Agilent 1200 Series HPLC system and a CHIRACEL® OD-3 column, 250 mm × 4.6 mm × 3.0 µm, purchased from Parc d'Innovation. Alternatively in cases where better separation was required, a Phenomenex® Amylose-2 column, 250 mm x 4.6 mm x 3.0 µm was used. Representative samples were prepared for HPLC analysis in hexane;IPA, to a concentration of ca 2 mg/mL. Samples were filtered using PTFE filters (13 mm diameter, 0.2 µm pore size) before analysis.

Example of a HPLC chromatogram obtained:


Compound **31** (see below for crystal data)



7.2. General Procedure for the Synthesis of Cinnamaldehyde-Based Ligands




A solution of cinnamaldehyde (1.5 equiv.), (*S*)-tert-butanesulfinamide (1 equiv.) and $\text{Ti}(\text{OEt})_4$ (2 equiv.) in 30 mL anhydrous THF was heated to reflux for 4 hours. Then the reaction was cooled to room temperature and NaBH_4 (5 equiv.) was added. The mixture was stirred at room temperature for additional 2 hours. When the reaction was complete, methanol was added dropwise until the reaction mixture stopped bubbling. The mixture was poured to 30 mL of brine, stirred and filtered. The filtrate was extracted with ethyl acetate, dried over anhydrous Na_2SO_4 , and concentrated *in vacuo*. Purification by silica gel column chromatography was subsequently performed using DCM:hexanes as an eluent to yield the title products.

(*S,E*)-*N*-cinnamyl-2-methylpropane-2-sulfinamide (L1)

Synthesised according to the General Procedure using cinnamaldehyde (397 mg, 3 mmol, 1.5 equiv.) and (*S*)-tert-butanesulfinamide (241 mg, 2 mmol, 1 equiv.). The reaction mixture was poured to 30 mL of brine, stirred and filtered. The filtrate was extracted with ethyl acetate, dried over anhydrous Na_2SO_4 , and concentrated *in vacuo*. The resulting residue was purified by silica gel column chromatography using DCM:Ethyl acetate (9:1) as eluent to yield the title product as a yellow solid (213 mg, 45%). Characterisation data is consistent with the literature.⁷⁸


^1H NMR (300 MHz, CDCl_3) δ_{H} : 7.41 – 7.35 (m, 2H), 7.34 – 7.28 (m, 2H), 7.27 – 7.23 (m, 1H), 6.58 (d, J = 15.8 Hz, 1H), 6.25 (dt, J = 15.8, 6.4 Hz, 1H), 4.00 – 3.81 (m, 2H), 3.38 – 3.20 (m, 1H) and 1.24 (s, 9H) ppm. ^{13}C NMR (75.5 MHz, CDCl_3) δ_{C} : 136.5, 132.6, 128.6, 127.8, 126.5, 55.8, 47.8 and 22.6 ppm.

(*S,E*)-2-methyl-*N*-(3-(*p*-tolyl)allyl)propane-2-sulfonamide (L3)

Synthesised according to the General Procedure using *p*-methyl cinnamaldehyde (3.0 mmol, 439 mg, 1.5 equiv.) and (*S*)-tert-butanefulfonamide (2.0 mmol, 241 mg, 1 equiv.).

The reaction mixture was poured to 30 mL of brine, stirred and filtered. The filtrate was extracted with ethyl acetate, dried over anhydrous Na₂SO₄, and concentrated *in vacuo*. Purification by silica gel column chromatography was subsequently performed using DCM:ethyl acetate (7:3) as eluent to yield the title product as a white solid (200 mg, 40%). Characterisation data is consistent with the literature.⁷⁸


¹H NMR (300 MHz, CDCl₃) δ_H: 7.26 (d, *J* = 8.0 Hz, 2H), 7.11 (d, *J* = 8.0 Hz, 2H), 6.54 (d, *J* = 15.8 Hz, 1H), 6.19 (dt, *J* = 15.8, 6.4 Hz, 1H), 4.00 – 3.77 (m, 2H), 3.32 (apparent triplet, 1H), 2.32 (s, 3H), 1.23 (s, 9H) ppm. ¹³C NMR (75.5 MHz, CDCl₃) δ_C: 137.6, 133.7, 132.5, 129.3, 126.4, 125.5, 55.7, 47.9, 22.7, 21.2 ppm. HRMS (ESI) *m/z*: [M+Na]⁺ calc. for C₁₄H₂₁NOSNa⁺ 274.1236, found: 274.1239.

(*S,E*)-*N*-(3-(4-methoxyphenyl)allyl)-2-methylpropane-2-sulfonamide (L4)

Synthesised according to General Procedure A using *p*-methoxy cinnamaldehyde (3.75 mmol, 607 mg, 1.5 equiv.) and (*S*)-tert-butanefulfonamide (2.5 mmol, 303 mg, 1 equiv.).

The reaction mixture was poured to 30 mL of brine, stirred and filtered. The filtrate was extracted with ethyl acetate, dried over anhydrous Na₂SO₄, and concentrated *in vacuo*. Purification by silica gel column chromatography was subsequently performed using DCM:ethyl acetate (7:3) to yield the title product as a white solid (495 mg, 74%). Characterisation data is consistent with the literature.⁷⁸


¹H NMR (300 MHz, CDCl₃) δ: 7.30 (m, 2H), 6.85 (m, 2H), 6.52 (d, *J* = 15.8 Hz, 1H), 6.11 (dt, *J* = 15.8, 6.5 Hz, 1H), 3.99 – 3.82 (m, 2H), 3.80 (s, 3H), 3.25 (apparent triplet, 1H), 1.24 (s, 9H) ppm. ¹³C (75.5 MHz, CDCl₃) δ: 159.4, 132.2, 129.3, 127.7, 124.2, 114.0, 55.7, 55.3, 48.0, 22.7 ppm. HRMS (ESI) *m/z*: [M+Na]⁺ calc. for C₁₄H₂₁NO₂SN⁺: 290.11852, found: 290.11849.

(*S,E*)-*N*-(3-(4-(dimethylamino)phenyl)allyl)-2-methylpropane-2-sulfinamide (L5)

Synthesised according to General Procedure A using (*E*)-3-(4-dimethylamino)phenylacrylaldehyde (3.75 mmol, 657 mg, 1.5 equiv.) and (*S*)-tert-butanesulfinamide (2.5 mmol, 303 mg, 1 equiv.). The reaction mixture was poured to 30

mL of brine, stirred and filtered. The filtrate was extracted with ethyl acetate, dried over anhydrous Na_2SO_4 , and concentrated *in vacuo*. Purification by silica gel column chromatography was subsequently performed using DCM:ethyl acetate (7:3) to yield the title product as a red solid (343 mg, 49%).


^1H NMR (300 MHz, CDCl_3) δ_{H} : 7.29 – 7.23 (m, 2H), 6.70 – 6.63 (m, 2H), 6.48 (d, J = 15.8 Hz, 1H), 6.04 (dt, J = 15.8, 6.7 Hz, 1H), 3.99 – 3.75 (m, 2H), 3.22 (apparent triplet, 1H), 2.96 (s, 6H), 1.23 (s, 9H) ppm. ^{13}C (75.5 MHz, CDCl_3) δ_{C} : 150.2, 132.8, 127.4, 121.9, 112.4, 55.7, 48.2, 40.5, 22.7 ppm. HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ calcd. for $\text{C}_{15}\text{H}_{25}\text{N}_2\text{OS}$: 281.1682 found 281.1684.

(*S,E*)-*N*-(3-(4-fluorophenyl)allyl)-2-methylpropane-2-sulfinamide (L6)

Synthesised according to General Procedure A using (*E*)-3-(4-fluorophenyl)acrylaldehyde (3.75 mmol, 563 mg, 1.5 equiv.) and (*S*)-tert-butanesulfinamide (2.5 mmol, 303 mg, 1 equiv.).


The reaction mixture was poured to 30 mL of brine, stirred and filtered. The filtrate was extracted with ethyl acetate, dried over anhydrous Na_2SO_4 , and concentrated *in vacuo*. Purification by silica gel column chromatography was subsequently performed using 2% MeOH in DCM as eluent to yield the title product as a pale yellow solid (511 mg, 80%). Characterisation data is consistent with the literature.⁷⁸

^1H NMR (300 MHz, CDCl_3) δ_{H} : 7.38 – 7.30 (m, 2H), 7.05 – 6.95 (m, 2H), 6.54 (d, J = 15.9 Hz, 1H), 6.17 (dt, J = 15.9, 6.4 Hz, 1H), 4.01 – 3.79 (m, 2H), 3.29 (apparent triplet, 1H), 1.24 (s, 9H) ppm. ^{13}C (75.5 MHz, CDCl_3) δ_{C} : 162.3 (d, $^1J_{\text{CF}}$ = 248 Hz) 132.6 (d, $^4J_{\text{CF}}$ = 3 Hz), 131.3, 127.9 (d, $^3J_{\text{CF}}$ = 8 Hz), 126.3 (d, $^4J_{\text{CF}}$ = 2.3 Hz), 115.5 (d, $^2J_{\text{CF}}$ = 21 Hz), 55.8, 47.8, 22.6 ppm. ^{19}F (282 MHz, CDCl_3) δ_{F} : 114.1 ppm. HRMS (ESI-TOF) m/z : $[\text{M}+\text{Na}]^+$ calcd. for $\text{C}_{13}\text{H}_{18}\text{FNOSNa}^+$: 278.0985 found 278.0986.

(*S,E*)-2-methyl-*N*-(2-methyl-3-phenylallyl)propane-2-sulfonamide (L7)

Synthesised according to General Procedure A using α -methyl cinnamaldehyde (0.75 mmol, 110 mg, 1.5 equiv.) and (*S*)-tert-butanesulfonamide (0.5 mmol, 60 mg, 1 equiv.). The reaction mixture was poured to 30 mL of brine, stirred and filtered. The filtrate was extracted with ethyl acetate, dried over anhydrous Na_2SO_4 , and concentrated *in vacuo*. Purification by silica gel column chromatography was subsequently performed using 100% DCM as eluent to yield the product as a white solid (51 mg, 41%). Characterisation data is consistent with the literature.⁷⁰


^1H NMR (300 MHz, CDCl_3) δ_{H} : 7.36 – 7.31 (m, 2H), 7.29 – 7.7.25 (m, 2H), 7.24 – 7.20 (m, 1H), 6.50 (bs, 1H), 3.82 (AB fragment of ABX system $J = 14.0, 7.5, 5.2$ Hz, 2H), 3.33 (m, 1H), 1.91 (d, $J = 1.1$ Hz, 1H), 1.26 (s, 9H) ppm. ^{13}C NMR (75.5 MHz, CDCl_3) δ_{C} : 137.3, 135.3, 128.9, 128.2, 127.6, 126.6, 55.9, 54.0, 22.7 and 16.3 ppm. HRMS (ESI-TOF) m/z : $[\text{M}+\text{Na}]^+$ calcd. for $\text{C}_{14}\text{H}_{21}\text{NOSNa}^+$: 274.1236 found 274.1246.

(*S,E*)-*N*-(2-benzylideneheptyl)-2-methylpropane-2-sulfinamide (L8)

Synthesised according to General Procedure A using (*E*)-2-benzylideneheptanal (3.0 mmol, 202 mg, 1.5 equiv.) and (*S*)-tert-butanesulfinamide (2 mmol, 242 mg, 1 equiv.). The reaction mixture was poured to 30 mL of brine, stirred and filtered. The filtrate was extracted with ethyl acetate, dried over anhydrous


Na₂SO₄, and concentrated *in vacuo*. Purification by silica gel column chromatography was subsequently performed using DCM:Ethyl acetate (7:1) as eluent to yield the title product as an off-white solid (159 mg, 26%).

¹H NMR (300 MHz, CDCl₃) δ_H; 7.37 – 7.28 (m, 2H), 7.25 – 7.18 (m, 3H), 6.50 (s, 1H), 3.93 – 3.73 (m, 2H), 3.29 (apparent triplet, 1H), 2.37 – 2.20 (m, 2H), 1.91 – 1.79 (m, 1H), 1.57 – 1.41 (m, 2H), 1.35 – 1.20 (m, 12H including 9H *t*Bu), 0.91 – 0.83 (m, 3H) ppm. ¹³C NMR (75.5 MHz, CDCl₃) δ_C; 139.9, 137.4, 128.6, 128.2, 127.5, 126.6, 55.9, 51.3, 31.9, 29.0, 27.7, 22.7, 22.4, 13.9 ppm. HRMS (ESI) *m/z*: [M+Na]⁺ calc. for C₁₈H₂₉NOSNa⁺: 330.1862 found 330.1857.

(*S*)-*N*-((8-methoxy-2*H*-chromen-3-yl)methyl)-2-methylpropane-2-sulfinamide (L9)


Synthesised according to General Procedure A using 8-methoxy-2*H*-chromene-3-carbaldehyde (3.75 mmol, 715 mg, 1.5 equiv.) and (*S*)-tert-butanesulfinamide (2.5 mmol, 302 mg, 1 equiv.). The reaction mixture was poured to 30 mL of brine, stirred and filtered. The

filtrate was extracted with ethyl acetate, dried over anhydrous Na₂SO₄, and concentrated *in vacuo*. Purification by silica gel column chromatography was subsequently performed using DCM:Ethyl acetate (1:1) as eluent to yield the title product as a white solid (472 mg, 64%). ¹H NMR (300 MHz, CDCl₃) δ_H; 6.87 – 6.76 (m, 2H), 6.64 (dd, *J* = 7.1, 1.8 Hz, 1H), 6.40 (apparent triplet, 1H), 4.89 – 4.74 (m, 2H), 3.94 – 3.74 (m, 5H), 3.31 (apparent triplet, 1H), 1.23 (s, 9H) ppm. ¹³C NMR (75.5 MHz, CDCl₃) δ_C; 147.7, 142.1, 130.9, 122.7, 122.0, 121.2, 119.1, 112.2, 66.9, 56.0, 55.9, 47.7, 22.6 ppm. HRMS (ESI) *m/z*: [M+Na]⁺ calc. for C₁₅H₂₁NO₃SN⁺: 318.1134 found 318.1141.

(S)-N-(3,3-diphenylallyl)-2-methylpropane-2-sulfinamide (L10)


Synthesised according to General Procedure A using 3,3-diphenylacrylaldehyde (2.7 mmol, 561 mg, 1.5 equiv.) and (S)-tert-butanesulfinamide (1.8 mmol, 219 mg, 1 equiv.). The reaction mixture was poured to 30 mL of brine, stirred and filtered. The filtrate was extracted with ethyl acetate, dried over anhydrous Na₂SO₄, and concentrated *in vacuo*. Purification by silica gel column chromatography was subsequently performed using 1% MeOH in DCM as eluent to yield the title product as an off-white solid (304 mg, 54%). Characterisation data is consistent with the literature.⁷⁸

¹H NMR (300 MHz, CDCl₃) δ_H: 7.40 – 7.31 (m, 3H), 7.30 – 7.20 (m, 5H), 7.19 – 7.14 (m, 2H), 6.14 (t, *J* = 7.0 Hz, 1H), 3.93 – 3.72 (m, 2H), 3.24 (apparent triplet, 1H), 1.21 (s, 9H) ppm. ¹³C NMR (75.5 MHz, CDCl₃) δ_C: 144.6, 141.7, 138.9, 129.7, 128.4, 128.2, 127.6, 127.5, 125.6, 55.7, 44.9, 22.6 ppm. HRMS (ESI-TOF) *m/z*: [M+Na]⁺ calc. for C₁₉H₂₃NOSNa⁺: 336.1392 found 336.1394.

(S,E)-N-benzylidene-2-methylpropane-2-sulfinamide (L11)

Synthesised according to General Procedure A using benzaldehyde (3.0 mmol, 318 mg, 1.5 equiv.) and (S)-tert-butanesulfinamide (2.0 mmol, 241 mg, 1 equiv.). The reaction mixture was poured to 30 mL of brine, stirred and filtered. The filtrate was extracted with ethyl acetate, dried over anhydrous Na₂SO₄, and concentrated *in vacuo*. Purification by silica gel column chromatography was subsequently performed using 100% DCM to yield the title product as a pale-yellow oil (364 mg, 87%). Characterisation data is consistent with the literature.⁷⁹


¹H NMR (300 MHz, CDCl₃) δ_H: 8.59 (s, 1H), 7.87 – 7.83 (m, 2H), 7.55 – 7.43 (m, 3H), 1.27 (s, 9H) ppm. ¹³C NMR (75.5 MHz, CDCl₃) δ_C: 162.7, 134.1, 132.4, 129.4, 128.9, 57.8, 22.6 ppm. HRMS (ESI) *m/z*: [M+Na]⁺ calc. C₁₁H₁₅NOSNa⁺: for 232.0766 found 232.0765.

(S)-N-cinnamyl-4-methylbenzenesulfinamide (L12)

Synthesised according to General Procedure A using cinnamaldehyde (2.25 mmol, 297 mg, 1.5 equiv.) and (S)-4-methylbenzenesulfinamide (1.5 mmol, 233 mg, 1 equiv.).


The reaction mixture was poured to 30 mL of brine, stirred and filtered. The filtrate was extracted with ethyl acetate, dried over anhydrous Na_2SO_4 , and concentrated *in vacuo*. Purification by silica gel column chromatography was subsequently performed using 100% DCM to yield the title product as a yellow solid (106 mg, 26%). Characterisation data is consistent with the literature.⁸⁰

^1H NMR (500 MHz, CDCl_3) δ_{H} : 7.62 (d, $J = 8.2$ Hz, 2H), 7.34 – 7.20 (m, 7H), 6.49 (d, $J = 15.8$ Hz, 1H), 6.14 (dt, $J = 15.8, 6.7$ Hz, 1H), 4.20 (s, 1H), 3.88 – 3.79 (m, 1H), 3.63 – 3.55 (m, 1H), 2.40 (s, 3H) ppm. ^{13}C NMR (125 MHz, CDCl_3) δ_{C} : 141.3, 141.1, 136.4, 132.8, 129.6, 128.6, 127.8, 126.4, 126.0, 125.9, 43.3, 21.3 ppm. HRMS (ESI) m/z : $[\text{M}+\text{Na}]^+$ calc. for $\text{C}_{16}\text{H}_{17}\text{NOSNa}^+$: 294.0923 found 294.0924.

2-benzylacrylaldehyde

To a mixture of aqueous formaldehyde solution (37% formaldehyde in water, 5 mmol, 1 equiv.) and hydrocinnamaldehyde 95 mmol, 1 equiv.) in *i*PrOH (0.5 mL), was added propionic acid (0.5 mmol, 10 mol%) and pyrrolidine (0.5 mmol, 10 mol%). The reaction mixture was stirred at 45 °C for 2 hours. NaHCO_3 was added upon completion and the mixture was extracted with CH_2Cl_2 (3 x 10 mL). The extracts were washed with brine, dried using MgSO_4 and concentrated *in vacuo*. The resulting residue was purified by flash column chromatography on silica gel using Hexane:DCM (7:3) as the eluent to afford the title product as a pale yellow oil (149 mg, 20%). Characterisation data is consistent with the literature.⁸¹


^1H NMR (300 MHz, CDCl_3) δ_{H} : 9.59 (s, 1H), 7.31 – 7.24 (m, 2H), 7.23 – 7.14 (m, 3H), 6.08 6.05 (m, 1H), 6.03 – 6.00 (m, 1H) and 3.55 (s, 1H) ppm.

2-allyl-1,3-dimethylbenzene


To a Schlenk flask evacuated and refilled with nitrogen, 2,6-dimethyl phenyl boronic acid (650 mg, 5 mmol, 1 equiv.), allyl bromide (1.3 mL, 15 mmol, 3 equiv.), K₂CO₃ (1.4 g, 10 mmol, 2 equiv.) and Pd(OAc)₂ (22.4 mg, 2 mol%) were added. Freshly distilled toluene (10 mL) was then added and the reaction was heated to 110 °C for 16 hours. After completion, the reaction mixture was cooled and diluted with CH₂Cl₂ and filtered through a pad of Celite®. The mixture was then concentrated *in vacuo* and the resulting residue was further purified by column chromatography on silica gel using 100% hexane as the eluent to afford the title product as a clear oil. Characterisation data was consistent with the literature.⁸²

¹H NMR (300 MHz, CDCl₃) δ_H: 7.09 – 7.01 (m, 3H), 6.00 – 5.85 (m, 1H), 5.03 (dq, *J* = 10.1, 1.8 Hz, 1H), 4.89 (dq, *J* = 17.1, 1.8 Hz, 1H), 3.46 – 3.39 (m, 2H) and 2.32 (s, 6H) ppm. Characterisation data is consistent with the literature.

7.3. General Procedure for the Rh-catalysed asymmetric 1,4-addition of indolyl boronic acids




A 10 mL screwcap vial was charged with the appropriate ligand (0.05 equiv., 0.015 mmol), $[\text{Rh}(\text{C}_2\text{H}_4)_2\text{Cl}]_2$ (0.025 equiv., 0.0075 mmol) and an indolyl boronic acid (2 equiv., 0.6 mmol, 96 mg). The screwcap vial was then charged with a Michael-acceptor (1 equiv., 0.3 mmol) before being briefly flushed with N_2 . Solutions of KOH (2.5 M, 0.12 mL) and NaCl (3.0 M, 0.1 mL) in H_2O were then added before the solvent of 15 wt% PTS in H_2O was added (0.7 mL). The screwcap vial was added a magnetic stir-bar and the cap was sealed with parafilm before being added to a multi-reaction heating mantle at 40 °C and 700 rpm. The reaction was then stirred for 24 hours before being cooled to room temperature and diluted with ethyl acetate. The resulting mixture was then passed through a plug of silica before extracting with 3 x 10 mL ethyl acetate and washing with 1 x 10 mL brine and 2 x 10 mL H_2O . The resulting solution was dried over Na_2SO_4 before concentrating *in vacuo*. The crude product was then purified by column chromatography on silica gel using hexane:ethyl acetate as eluent to yield the final product(s).

(S)-3-(1*H*-indol-5-yl)cyclohexan-1-one (2)


Synthesised according to the General Procedure using cyclohexenone (0.3 mmol, 29 mg, 1 equiv.) and 5-indolyl boronic acid (0.6 mmol, 96 mg, 2 equiv.) to yield the title product as a clear oil (51 mg, 86%, 97:3 e.r.). The enantiomeric ratio was determined by chiral HPLC analysis on a Chiralcel® OD-3 column with hexane:2-propanol (90:10), flow = 1 mL/min at 25 °C and 230 nm. Retention times: 35.5 min, 51.5 min.

¹H NMR (300 MHz, CDCl₃) δ_H: 8.17 (bs, 1H), 7.48 (d, *J* = 0.8 Hz, 1H), 7.34 (d, *J* = 8.5 Hz, 1H), 7.20 (t, *J* = 2.8 Hz, 1H), 7.06 (dd, *J* = 8.5, 1.7 Hz, 1H), 6.52 (m, 1H), 3.16 – 3.05 (m, 1H), 2.70 – 2.53 (m, 2H), 2.52 – 2.33 (m, 2H), 2.21 – 2.08 (m, 1H), 2.00 – 1.87 (m, 1H), 1.87 – 1.73 (m, 1H) ppm. ¹³C NMR (75.5 MHz, CDCl₃) δ_C: 211.7, 136.1, 134.7, 128.1, 124.7, 121.8, 118.0, 111.6, 102.5, 49.8, 45.0, 41.3, 33.5 and 25.7 ppm. HRMS (ESI-TOF) *m/z*: [M+H]⁺ calcd. For C₁₄H₁₆NO⁺: 214.1226, found 214.1229. [α]_D²⁰ + 9.21 (c 1.27, CH₂Cl₂).

(S)-3-(1*H*-indol-5-yl)cyclopentan-1-one (22)


Synthesised according to the General Procedure using cyclopentenone (0.3 mmol, 25 mg, 1 equiv.) and 5-indolyl boronic acid (0.6 mmol, 96 mg, 2 equiv.) to yield the title product as a clear oil (49 mg, 81%, 98.5:1.5 e.r.). The enantiomeric ratio was determined by chiral HPLC analysis on a Chiralcel® OD-3 column with hexane:2-propanol (90:10), flow = 1 mL/min at 25 °C and 230 nm. Retention times: 40.6 min, 41.9 min.

¹H NMR (300 MHz, CDCl₃) δ_H: 8.28 (bs, 1H), 7.50 (apparent doublet, *J* = 0.9 Hz, 1H), 7.33 (d, *J* = 8.4 Hz, 1H), 7.18 (t, *J* = 2.8 Hz, 1H), 7.08 (dd, *J* = 8.4, 1.8 Hz, 1H), 6.52 – 6.49 (m, 1H), 3.57 – 3.42 (m, 1H), 2.75 – 2.63 (m, 1H), 2.53 – 2.22 (m, 4H), 2.11 – 1.94 (m, 1H) ppm. ¹³C NMR (75.5 MHz, CDCl₃) δ_C: 219.5, 134.8, 134.4, 128.1, 124.9, 121.1, 118.2, 111.3, 102.4, 46.6, 42.4, 39.1 and 31.8 ppm. HRMS (ESI-TOF) *m/z*: [M+H]⁺ calcd. for C₁₃H₁₄NO⁺: 200.1069, found 200.1069. [α]_D²⁰ + 64.75 (c 0.505, CH₂Cl₂).

(S)-3-(1H-indol-5-yl)cycloheptan-1-one (23)


Synthesised according to the General Procedure using cycloheptenone (0.3 mmol, 33 mg, 1 equiv.) and 5-indolyl boronic acid (0.6 mmol, 96 mg, 2 equiv.) to yield the title product as a clear oil (34 mg, 51%, 94:6 e.r.). The enantiomeric ratio was determined by chiral HPLC analysis on a Chiralcel® OD-3 column with hexane:2-propanol (90:10), flow = 1 mL/min at 25 °C and 230 nm. Retention times: 33.6 min, 49.7 min.

^1H NMR (300 MHz, CDCl_3) δ_{H} ; 8.18 (bs, 1H), 7.43 (bm, 1H), 7.31 (d, J = 8.4 Hz, 1H), 7.18 (t, J = 2.8 Hz, 1H), 7.01 (dd, J = 8.4, 1.7 Hz, 1H), 6.51 – 6.47 (m, 1H), 3.06 – 2.93 (m, 2H), 2.77 – 2.66 (m, 1H), 2.64 – 2.56 (m, 2H), 2.19 – 1.94 (m, 3H), 1.88 – 1.68 (m, 2H), 1.59 – 1.44 (m, 1H) ppm. ^{13}C NMR (75.5 MHz, CDCl_3) δ_{C} ; 214.1, 138.7, 134.5, 128.0, 124.6, 121.1, 117.8, 111.2, 102.4, 52.1, 44.0, 42.9, 39.8, 29.4 and 24.3 ppm. HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ calcd. For $\text{C}_{15}\text{H}_{18}\text{NO}^+$: 228.1383, found 228.1383. $[\alpha]_{\text{D}}^{20}$ + 32.70 (c 0.685, CH_2Cl_2).

(S)-4-(1H-indol-5-yl)tetrahydro-2H-pyran-2-one (24)

Synthesised according to the General Procedure using 5,6-dihydro-2H-pyran-2-one (0.3 mmol, 29 mg, 1 equiv.) and 5-indolyl boronic acid (0.6 mmol, 96 mg, 2 equiv.) to yield the title product as a clear oil (39 mg, 61%, 95:5 e.r.). The enantiomeric ratio was determined by chiral HPLC analysis on a Chiralcel® OD-3 column with hexane:2-propanol (80:20), flow = 1 mL/min at 25 °C and 230 nm. Retention times: 36.5 min, 44.7 min.


^1H NMR (600 MHz, CDCl_3) δ_{H} ; 8.21 (bs, 1H), 7.47 (unresolved doublet, 1H), 7.38 (d, J = 8.4 Hz, 1H), 7.23 (t, J = 2.7 Hz, 1H), 7.04 (dd, J = 8.4, 1.7 Hz, 1H), 6.55 – 6.52 (m, 1H), 4.55 – 4.49 (m, 1H), 4.44 – 4.37 (m, 1H), 3.37 – 3.29 (m, 1H), 2.96 (ddd, J = 17.7, 5.9 and 1.6 Hz, 1H), 2.72 (dd, J = 17.7, 10.6 Hz, 1H), 2.25 – 2.17 (m, 1H), 2.15 – 2.05 (m, 1H) ppm. ^{13}C NMR (125 MHz, CDCl_3) δ_{C} ; 171.2, 134.9, 134.4, 128.2, 124.9, 120.8, 118.1, 111.5, 102.6, 68.6, 38.2, 37.6 and 30.9 ppm. HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ calcd. for $\text{C}_{13}\text{H}_{14}\text{NO}_2^+$: 216.1019 found 216.1016. $[\alpha]_{\text{D}}^{22}$ - 17.23 (c 0.125, CH_2Cl_2).

(S)-3-(1*H*-indol-6-yl)cyclohexan-1-one (25)

Synthesised according to the General Procedure using cyclohexenone (0.3 mmol, 29 mg, 1 equiv.) and 6-indolyl boronic acid (0.6 mmol, 96 mg, 2 equiv.) to yield the title product as a clear

oil (47 mg, 74%, 97:3 e.r.). The enantiomeric ratio was determined by chiral HPLC analysis on a Chiralcel® OD-3 column with hexane:2-propanol (90:10), flow = 1 mL/min at 25 °C and 230 nm. Retention times: 33.2 min, 46.5 min.


¹H NMR (300 MHz, CDCl₃) δ_H: 8.28 (bs, 1H), 7.58 (d, *J* = 8.2 Hz, 1H), 7.19 (apparent doublet, 1H), (dd, *J* = 3.2, 2.4 Hz, 1H), 6.99 (dd, *J* = 8.2, 1.5 Hz, 1H), 6.52 – 6.48 (m, 1H), 3.17 – 3.04 (m, 1H), 2.71 – 2.53 (m, 2H), 2.51 – 2.30 (m, 2H), 2.19 – 2.05 (m, 2H), 1.98 – 1.71 (m, 2H) ppm. ¹³C NMR (75.5 MHz, CDCl₃) δ_C: 211.8, 138.5, 136.1, 126.7, 124.3, 120.9, 118.9, 108.8, 102.4, 49.6, 45.1, 41.3, 33.3 and 25.3 ppm. HRMS (ESI-TOF) *m/z*: [M+H]⁺ calcd. For C₁₄H₁₆NO⁺: 214.1226, found 214.1225. [α]_D²⁰ + 11.62 (c 0.31, CH₂Cl₂).

(S)-3-(1*H*-indol-6-yl)cyclopentan-1-one (26)

Synthesised according to the General Procedure using cyclopentenone (0.3 mmol, 25 mg, 1 equiv.) and 6-indolyl boronic acid (0.6 mmol, 96 mg, 2 equiv.) to yield the title product as a clear


oil (43 mg, 72%, 97.5:2.5 e.r.). The enantiomeric ratio was determined by chiral HPLC analysis on a Chiralcel® OD-3 column with hexane:2-propanol (90:10), flow = 1 mL/min at 25 °C and 230 nm. Retention times: 29 min, 32.7 min.

¹H NMR (300 MHz, CDCl₃) δ_H: 8.21 (bs, 1H), 7.60 (d, *J* = 8.2 Hz, 1H), 7.25 – 7.23 (bm, 1H), 7.18 (dd, *J* = 3.2, 2.4 Hz, 1H), 7.03 (dd, *J* = 8.2, 1.5 Hz, 1H), 6.54 – 6.51 (m, 1H), 3.61 – 3.46 (m, 1H), 2.76 – 2.64 (m, 1H), 2.54 – 2.37 (m, 3H), 2.37 – 2.23 (m, 1H), 2.13 – 1.96 (m, 1H) ppm. ¹³C NMR (75.5 MHz, CDCl₃) δ_C: 219.1, 137.1, 136.1, 126.7, 124.3, 120.9, 119.2, 108.8, 102.5, 46.4, 42.5, 38.9 and 31.7 ppm. HRMS (ESI-TOF) *m/z*: [M+H]⁺ calcd. For C₁₃H₁₄NO⁺: 200.1069, found 200.1066. [α]_D²⁰ + 67.50 (c 0.26, CH₂Cl₂).

(S)-3-(1*H*-indol-6-yl)cycloheptan-1-one (27)

Synthesised according to the General Procedure using cycloheptenone (0.3 mmol, 33 mg, 1 equiv.) and 6-indolyl boronic acid (0.6 mmol, 96 mg, 2 equiv.) to yield the title product as a clear oil (64 mg, 94%, 96:4 e.r.). The enantiomeric ratio was determined by chiral HPLC analysis on a Chiralcel® OD-3 column with hexane:2-propanol (80:20, 0.1% TFA), flow = 1 mL/min at 25 °C and 230 nm. Retention times: 18.3 min, 19.4 min.


¹H NMR (300 MHz, CDCl₃) δ_H: 8.14 (bs, 1H), 7.56 (d, *J* = 8.2 Hz, 1H), 7.19 (bs) and 7.16 (dd, *J* = 3.2, 2.4 Hz) (overlapping signals at 7.19 and 7.16 ppm, 2H), 6.96 (dd, *J* = 8.2, 1.5 Hz, 1H), 6.53 – 6.49 (m, 1H), 3.07 – 2.93 (m, 1H), 2.79 – 2.66 (m, 1H), 2.65 – 2.55 (m, 1H), 2.20 – 1.93 (m, 3H), 1.88 – 1.65 (m, 2H), 1.57 – 1.44 (m, 1H) ppm. ¹³C NMR (75.5 MHz, CDCl₃) δ_C: 213.8, 141.2, 136.0, 126.4, 124.1, 120.8, 118.9, 108.5, 102.5, 51.9, 44.0, 43.0, 39.7, 29.3 and 24.3 ppm. HRMS (ESI-TOF) *m/z*: [M+H]⁺ calcd. For C₁₅H₁₈NO⁺: 228.1383, found 228.1386 [α]_D²⁰ +35.24 (c 0.21, CH₂Cl₂).

(S)-4-(1*H*-indol-6-yl)tetrahydro-2*H*-pyran-2-one (28)

Synthesised according to the General Procedure using 5,6-dihydro-2*H*-pyran-2-one (0.3 mmol, 29 mg, 1 equiv.) and 6-indolyl boronic acid (0.6 mmol, 96 mg, 2 equiv.) to yield the title product as a clear oil (48 mg, 74%, 92:8 e.r.).


The enantiomeric ratio was determined by chiral HPLC analysis on a Chiralcel® OD-3 column with hexane:2-propanol (80:20), flow = 1 mL/min at 25 °C and 230 nm. Retention times: 35.0 min, 39.5 min.

¹H NMR (300 MHz, CDCl₃) δ_H: 8.19 (bs, 1H), 7.54 (d, *J* = 8.2 Hz, 1H), 7.16 – 7.11 (m, 2H), 6.90 (dd, *J* = 8.2, 1.5 Hz, 1H), 6.49 – 6.43 (m, 1H), 4.48 – 4.26 (m, 2H), 3.35 – 3.21 (m, 1H), 2.89 (ddd, *J* = 18.0, 6.0, 1.5 Hz, 1H), 2.72 – 2.59 (m, 1H), 2.22 – 2.09 (m, 1H) and 2.09 – 1.93 (m, 1H) ppm. ¹³C NMR (75.5 MHz, CDCl₃) δ_C: 171.2, 136.8, 136.0, 126.9, 124.6, 121.1, 118.8, 108.6, 102.5, 68.7, 37.9, 37.5 and 30.9 ppm. HRMS (ESI-TOF) *m/z*: [M+H]⁺ calcd. For C₁₃H₁₄NO₂⁺: 216.1019, found 216.1016. [α]_D²⁰ -17.41 (c 0.125, CH₂Cl₂).

(S)-3-(1*H*-indol-4-yl)cyclohexan-1-one (29)


Synthesised according to the General Procedure using cyclohexenone (0.3 mmol, 29 mg, 1 equiv.) and 4-indolyl boronic acid (0.6 mmol, 96 mg, 2 equiv.) to yield the title product as a clear oil (47 mg, 73%, 97.5:2.5 e.r.). The enantiomeric ratio was determined by chiral HPLC analysis on a Chiralcel® OD-3 column with hexane:2-propanol (90:10), flow = 1 mL/min at 25 °C and 230 nm. Retention times: 40.5 min, 48.6 min.

¹H NMR (300 MHz, CDCl₃) δ_H: 8.25 (bs, 1H), 7.30 (d, *J* = 8.1 Hz, 1H), 7.24 – 7.14 (m, 2H), 6.98 (d, *J* = 7.2 Hz, 1H), 6.64 – 6.55 (m, 1H), 3.56 – 3.42 (m, 1H), 2.78 – 2.67 (m, 2H), 2.57 – 2.36 (m, 2H), 2.27 – 2.12 (m, 2H), 2.11 – 1.95 (m, 1H) and 1.94 – 1.77 (m, 1H) ppm. ¹³C NMR (75.5 MHz, CDCl₃) δ_C: 211.7, 136.4, 135.9, 126.2, 123.9, 122.3, 116.0, 109.6, 100.6, 48.1, 42.1, 41.5, 31.9 and 25.7 ppm. HRMS (ESI-TOF) *m/z*: [M+H]⁺ calcd. For C₁₄H₁₆NO⁺: 214.1226, found 214.1227. [α]_D²⁰ +20.48 (c 0.105, CH₂Cl₂).

(S)-3-(1*H*-indol-4-yl)cyclopentan-1-one (30)

Synthesised according to the General Procedure using cyclopentenone (0.3 mmol, 25 mg, 1 equiv.) and 4-indolyl boronic acid (0.6 mmol, 96 mg, 2 equiv.) to yield the title product as a clear oil (52 mg, 87%, 96.5:3.5 e.r.). The enantiomeric ratio was determined by chiral HPLC analysis on a Phenomenex® Amy-2 column with hexane:2-propanol (91:9), flow = 1 mL/min at 25 °C and 218 nm. Retention times: 20.0 min, 22.0 min.


¹H NMR (300 MHz, CDCl₃) δ_H: 8.33 (bs, 1H), 7.30 (d, *J* = 8.2 Hz, 1H), 7.24 – 7.21 (m, 1H), 7.17 (t, *J* = 7.3 Hz, 1H), 6.97 (d, *J* = 7.3 Hz, 1H), 6.62 – 6.58 (m, 1H), 3.93 – 3.78 (m, 1H), 2.82 – 2.62 (m, 1H), 2.62 – 2.43 (m, 3H), 2.43 – 2.29 (m, 1H) and 2.28 – 2.13 (m, 1H) ppm. ¹³C NMR (75.5 MHz, CDCl₃) δ_C: 219.3, 135.9, 135.0, 126.7, 124.0, 122.2, 115.9, 109.8, 100.8, 45.2, 39.9, 38.7 and 29.9 ppm. HRMS (ESI-TOF) *m/z*: [M+H]⁺ calcd. For C₁₃H₁₄NO⁺: 200.1069, found 200.1069. [α]_D²⁰ +38.31 (c 0.83 CH₂Cl₂).

(S)-3-(1*H*-indol-4-yl)cycloheptan-1-one (31)

Synthesised according to the General Procedure using cycloheptenone (0.3 mmol, 33 mg, 1 equiv.) and 4-indolyl boronic acid (0.6 mmol, 96 mg, 2 equiv.) to yield the title product as a clear oil (28 mg, 41%, 97:3 e.r.). The enantiomeric ratio was determined by chiral HPLC analysis on a Phenomenex® Amy-2 column with hexane:2-propanol (91:9), flow = 1 mL/min at 25 °C and 218 nm.

Retention times: 26.4 min, 29.9 min.


^1H NMR (500 MHz, CDCl_3) δ_{H} : 8.19 (bs, 1H), 7.20 – 7.17 (m, 1H), 7.14 – 7.12 (m, 1H), 7.07 (t, $J = 8.0$ Hz, 1H), 6.85 (d, $J = 7.4$ Hz, 1H), 6.53 – 6.50 (m, 1H), 3.27 (tt, $J = 11.4, 2.4$ Hz, 1H), 3.00 (dd, $J = 14.4, 2.4$ Hz), 2.72 (dt, $J = 14.4, 2.4$ Hz, 1H), 2.64 – 2.53 (m, 2H), 2.20 – 2.14 (m, 1H), 2.07 – 1.93 (m, 2H), 1.88 – 1.77 (m, 1H), 1.75 – 1.64 (m, 1H), 1.54 – 1.44 (m, 1H) ppm. ^{13}C NMR (125 MHz, CDCl_3) δ_{C} : 213.04, 137.8, 134.9, 124.8, 122.8, 121.2, 114.9, 108.3, 99.7, 49.5, 42.9, 39.1, 37.0, 28.6 and 23.4 ppm. HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ calcd. For $\text{C}_{15}\text{H}_{18}\text{NO}^+$: 228.1383, found 228.1384. $[\alpha]_{\text{D}}^{20} +43.76$ (c 0.945 CH_2Cl_2).

(S)-3-(1*H*-indol-7-yl)cyclopentane-1-one (32)

Synthesised according to the General Procedure using cyclopentenone (0.3 mmol, 25 mg, 1 equiv.) and 7-indole boronic acid (0.6 mmol, 96 mg, 2 equiv.) to yield the title product as a clear oil (33 mg, 55%, 98.5:1.5 e.r.) The enantiomeric ratio was determined by chiral HPLC analysis on a Phenomenex® Amy-2 column with hexane:2-propanol (90:10), flow = 1


mL/min at 25 °C and 230 nm. Retention times: 25.8 min, 29.0 min.

^1H NMR (300 MHz, CDCl_3) δ_{H} : 8.29 (bs, 1H), 7.56 (d, $J = 7.7$ Hz, 1H), 7.27 – 7.19 (m, 1H), 7.15 – 7.02 (m, 2H), 6.63 – 6.56 (m, 1H), 3.81 – 3.69 (m, 1H), 2.82 – 2.67 (m, 1H), 2.60 – 2.44 (m, 3H), 2.43 – 2.30 (m, 1H) and 2.29 – 2.15 (m, 1H) ppm. ^{13}C NMR (75.5 MHz, CDCl_3) δ_{C} : 218.4, 134.4, 128.1, 125.4, 124.1, 120.1, 119.5, 118.1, 103.4, 44.7, 38.4, 37.6 and 29.4 ppm. $[\alpha]_{\text{D}}^{20} -28.55$ (c 0.33 in CH_2Cl_2).

(S)-4-(1H-indolo-5-yl)octan-2-one (39)


Synthesised according to the General Procedure using (*E*)-oct-3-en-2-one (0.3 mmol, 38 mg, 1 equiv.) and 5-indolyl boronic acid (0.6 mmol, 96 mg, 2 equiv.) to yield the title product as a clear oil (58 mg, 80%, 96:4 e.r.). The enantiomeric ratio was determined by chiral HPLC analysis on a Chiralcel® OD-3 column with hexane:2-propanol (80:20), flow = 1 mL/min at 25 °C and 230 nm. Retention times: 7.1 min, 7.5 min.

^1H NMR (300 MHz, CDCl_3) δ_{H} : 8.15 (bs, 1H), 7.42 (s, 1H), 7.29 (d, J = 8.3 Hz, 1H), 7.16 (t, J = 2.7 Hz, 1H), 7.01 (dd, J = 8.3, 1.7 Hz, 1H), 6.51 – 6.46 (m, 1H), 3.25 – 3.11 (m, 1H), 2.84 – 2.66 (m, 2H), 1.98 (s, 3H), 1.73 – 1.54 (m, 3H), 1.32 – 1.05 (m, 4H), 0.80 (t, J = 7.2 Hz, 3H) ppm. ^{13}C NMR (75.5 MHz, CDCl_3) δ_{C} : 208.9, 135.9, 134.7, 128.0, 124.4, 121.8, 119.2, 110.9, 102.4, 51.8, 41.7, 36.8, 30.7, 29.7, 22.7 and 13.9 ppm. HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ calcd. for $\text{C}_{16}\text{H}_{22}\text{NO}^+$: 244.1695 found 244.1693. $[\alpha]_{\text{D}}^{20}$ + 2.41 (c 0.435 in CH_2Cl_2).

(S)-4-(1H-indol-5-yl)-4-phenylbutan-2-one (38)


Synthesised according to General Procedure B using (*E*)-4-phenylbut-3-en-2-one (0.3 mmol, 44 mg, 1 equiv.) and 5-indolyl boronic acid (0.6 mmol, 96 mg, 2 equiv.) to yield the title product as a clear oil (71 mg, 90%, 96:4 e.r.).

^1H NMR (500 MHz, CDCl_3) δ_{H} : 8.08 (bs, 1H), 7.49 (s, 1H), 7.29 – 7.22 (m, 5H), 7.18 – 7.12 (m, 2H), 7.05 (dd, J = 8.4, 1.6 Hz, 1H), 6.50 – 6.45 (m, 1H), 4.68 (t, J = 7.6 Hz, 1H), 3.29 – 3.16 (m, 2H), 2.06 (s, 3H) ppm. ^{13}C NMR (125 MHz, CDCl_3) δ_{C} : 207.5, 144.8, 135.4, 134.6, 128.5, 128.0, 127.7, 126.2, 124.5, 122.5, 119.2, 111.2, 102.6, 50.3, 46.3 and 30.7 ppm. HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ calcd. for $\text{C}_{18}\text{H}_{18}\text{NO}^+$: 264.1382 found 264.1382. $[\alpha]_{\text{D}}^{20}$ -30.37 (c 0.45 in CH_2Cl_2).

4-(1*H*-indol-5-yl)-5-methylhexan-2-one (40)

Synthesised according to General Procedure B using (*E*)-5-methylhex-3-en-2-one (0.3 mmol, 34 mg, 1 equiv.) and 5-indolyl boronic acid (0.6 mmol, 96 mg, 2 equiv.) to yield the title product as a clear oil (64 mg, 93%).


^1H NMR (300 MHz, CDCl_3) δ_{H} : 8.11 (bs, 1H), 7.39 (s, 1H), 7.28 (d, J = 8.4 Hz, 1H), 7.16 (t, J = 2.8 Hz, 1H), 6.99 (dd, J = 8.4, 1.7 Hz, 1H), 6.50 – 6.46 (m, 1H), 3.03 – 2.93 (m, 1H), 2.84 (d, J = 7.4 Hz, 2H), 1.94 (s, 3H), 1.92 – 1.81 (m, 1H), 0.96 (d, J = 6.6 Hz, 3H), 0.76 (d, J = 6.7 Hz, 3H) ppm. ^{13}C NMR (75.5 MHz, CDCl_3) δ_{C} : 209.1, 134.7, 134.5, 127.8, 124.4, 122.7, 119.9, 110.7, 102.5, 48.5, 48.4, 33.8, 30.6, 20.9 and 20.5 ppm. HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ calcd. for $\text{C}_{15}\text{H}_{20}\text{NO}^+$: 230.1539 found 230.1532. $[\alpha]_{\text{D}}^{20}$ +12.20 (c 0.25, CH_2Cl_2).

Methyl (*S*)-3-(1*H*-indol-5-yl)-3-phenylpropanoate (41)

Synthesised according to General Procedure B using methyl cinnamate (0.3 mmol, 49 mg, 1 equiv.) and 5-indolyl boronic acid (0.6 mmol, 96 mg, 2 equiv.) to yield the title product as a clear oil (69 mg, 82%, 89:11 e.r.). The enantiomeric ratio was determined by chiral HPLC analysis on a Chiralcel® OD-3 column with hexane:2-propanol


(80:20), flow = 1 mL/min at 25 °C and 230 nm. Retention times: 13.0 min, 14.2 min

^1H NMR (300 MHz, CDCl_3) δ_{H} : 8.08 (bs, 1H), 7.50 (unresolved doublet, 1H), 7.29–7.23 (m, 4H), 7.23 – 7.19 (m, 1H), 7.18 – 7.12 (m, 1H), 7.11 (t, J = 2.8 Hz, 1H), 7.02 (dd, J = 8.4, 1.7 Hz, 1H), 6.49 – 6.44 (m, 1H), 4.66 (t, J = 8.0 Hz, 1H), 3.55 (s, 3H), 3.12 (d, J = 8.0 Hz, 2H) ppm. ^{13}C NMR (75.5 MHz, CDCl_3) δ_{C} : 172.7, 144.5, 135.1, 134.6, 128.5, 128.0, 127.7, 126.3, 124.5, 122.4, 119.1, 111.2, 102.6, 51.6, 47.1 and 41.2 ppm. HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ calcd. for $\text{C}_{18}\text{H}_{18}\text{NO}_2^+$: 280.1332 found 280.1327. $[\alpha]_{\text{D}}^{20}$ -30.07 (c 0.46 in CH_2Cl_2).

(S)-2-hydroxy-2-(1*H*-indol-5-yl)-1,2-diphenylethan-1-one (43)

Synthesised according to General Procedure C using benzil (0.3 mmol, 63 mg, 1 equiv.) and 5-indolyl boronic acid (0.6 mmol, 96 mg, 2 equiv.) to yield the title product as a clear oil (93 mg, 95%, 95:5 e.r.). The enantiomeric ratio was determined by chiral HPLC analysis on a Chiralcel® OD-3 column with hexane:2-propanol (90:10), flow = 1 mL/min at 25 °C and 230 nm. Retention times: 23.6 min, 29.7 min.

¹H NMR (300 MHz, CDCl₃) δ_H: 8.20 (bs, 1H), 7.78 – 7.70 (m, 2H), 7.65 – 7.62 (m, 1H), 7.52 – 7.45 (m, 2H), 7.45 – 7.29 (m, 5H), 7.28 – 7.18 (m, 5H), 6.52 – 6.47 (m, 1H), 4.96 (s, 1H). ¹³C NMR (75.5 MHz, CDCl₃) δ_C: 201.4, 142.5, 135.6, 135.3, 133.7, 132.7, 130.9, 128.5, 128.2, 128.0, 127.9, 127.6, 124.8, 122.7, 120.7, 111.1, 103.3 and 85.5 ppm. HRMS (ESI-TOF) *m/z*: [M+Na]⁺ calcd. for C₂₂H₁₇NO₂Na⁺: 350.1151 found 350.1146. [α]_D²⁰ -16.29 (c 1.24 in CH₂Cl₂).

8,9,10,11-tetrahydro-7*H*-7,11-methanoazocino[3,2,1-*h*]indol-7-ol

Synthesised according to General Procedure A using cyclohexenone (0.3 mmol, 29 mg, 1 equiv.) and 7-indolyl boronic acid (0.6 mmol, 96 mg, 2 equiv.) to yield the title product as a clear oil (41 mg, 65%).

¹H NMR (300 MHz, CDCl₃) δ_H: 7.45 (dd, *J* = 8.0, 0.9 Hz, 1H), 7.37 (d, *J* = 3.1 Hz, 1H), 7.03 (dd, *J* = 8.0, 7.0 Hz, 1H), 6.89 (d, *J* = 7.0 Hz, 1H), 6.50 (d, *J* = 3.1 Hz, 1H), 3.49 – 3.41 (m, 1H), 2.55 (s, 3H), 2.22 (dd, *J* = 11.9, 3.1 Hz, 1H), 2.17 – 2.09 (m, 1H), 2.06 – 1.96 (m, 1H), 1.88 (td, *J* = 13.0, 4.6 Hz, 1H), 1.81 – 1.67 (m, 2H), 1.53 – 1.45 (m, 1H), 0.79 – 0.58 (m, 1H) ppm. ¹³C NMR (75.5 MHz, CDCl₃) δ_C: 135.7, 125.3, 125.1, 121.3, 119.9, 118.3, 117.4, 101.6, 83.8, 41.1, 38.9, 35.7, 32.2 and 19.4 ppm. HRMS (ESI-TOF) *m/z*: [M+H]⁺ calcd. for C₁₄H₁₆NO⁺: 214.1226 found 214.1228. [α]_D²⁰ -78.57 (c 0.56 in CH₂Cl₂).

Crystal Data:

Compound	31	27	26
Formula	C ₁₅ H ₁₇ NO	C ₁₅ H ₁₇ NO	C ₁₃ H ₁₃ NO
$D_{calc.}/\text{g cm}^{-3}$	1.218	1.296	1.232
m/mm^{-1}	0.593	0.081	0.078
Formula Weight	227.29	227.29	199.24
Colour	clear colourless	clear colourless	clear colourless
Shape	block-shaped	plate-shaped	prism-shaped
Size/mm ³	0.34×0.27×0.06	0.19×0.16×0.04	0.61×0.13×0.05
T/K	100(2)	100(2)	100(2)
Crystal System	orthorhombic	orthorhombic	monoclinic
Flack Parameter	0.00(5)	0.2(7)	0.0(3)
Hooft Parameter	-0.00(4)	0.1(6)	-0.1(3)
Space Group	$P2_12_12_1$	$P2_12_12_1$	$P2_1$
$a/\text{\AA}$	6.89790(10)	5.4762(2)	10.0067(3)
$b/\text{\AA}$	7.22490(10)	9.2507(4)	7.5023(2)
$c/\text{\AA}$	24.8791(3)	22.9984(9)	14.3585(4)
a°	90	90	90
b°	90	90	94.993(2)
g°	90	90	90
$V/\text{\AA}^3$	1239.89(3)	1165.07(8)	1073.85(5)
Z	4	4	4
Z'	1	1	2
Wavelength/ $\text{\AA}$	1.54184	0.71073	0.71073
Radiation type	Cu K α	Mo K α	Mo K α
$Q_{min}/^\circ$	3.553	2.373	2.043
$Q_{max}/^\circ$	70.154	32.203	32.187
Measured Refl's.	11481	19681	29940
Indep't Refl's	2337	3634	6597
Refl's $I \geq 2\sigma(I)$	2324	3125	5637
R_{int}	0.0146	0.0580	0.0272
Parameters	158	154	298
Restraints	0	0	19
Largest Peak	0.143	0.471	0.294
Deepest Hole	-0.148	-0.270	-0.257
GooF	1.073	1.044	1.064







wR_2 (all data)	0.0723	0.1503	0.1169
wR_2	0.0722	0.1422	0.1115
R_1 (all data)	0.0281	0.0670	0.0535
R_1	0.0281	0.0548	0.0429

Crystal Analysis Experimental

31: Single clear colourless block-shaped crystals of **31** recrystallised from a mixture of CHCl_3 and hexane by slow evaporation. A suitable crystal with dimensions $0.34 \times 0.27 \times 0.06 \text{ mm}^3$ was selected and mounted on a MITIGEN holder with silicon oil on a ROD, Synergy Custom system, HyPix-Arc 100 diffractometer. The crystal was kept at a steady $T = 100(2) \text{ K}$ during data collection. The structure was solved with the ShelXT 2014/5 (Sheldrick, 2014) solution program using dual methods and by using Olex2 1.5-alpha (Dolomanov *et al.*, 2009) as the graphical interface. The model was refined with ShelXL 2016/6 (Sheldrick, 2015) using full matrix least squares minimisation on F^2 .

27: Single clear colourless plate-shaped crystals of **27** recrystallised from CHCl_3 by slow evaporation. A suitable crystal with dimensions $0.19 \times 0.16 \times 0.04 \text{ mm}^3$ was selected and mounted on a MITIGEN holder with silicon oil on a ROD, Synergy Custom system, HyPix diffractometer. The crystal was kept at a steady $T = 100(2) \text{ K}$ during data collection. The structure was solved with the ShelXT 2014/5 (Sheldrick, 2014) solution program using dual methods and by using Olex2 1.5-alpha (Dolomanov *et al.*, 2009) as the graphical interface. The model was refined with ShelXL 2016/6 (Sheldrick, 2015) using full matrix least squares minimisation on F^2 .

26: Single clear colourless prism-shaped crystals of **26** recrystallised from CHCl_3 by slow evaporation. A suitable crystal with dimensions $0.61 \times 0.13 \times 0.05 \text{ mm}^3$ was selected and mounted on a MITIGEN holder silicon oil on a ROD, Synergy Custom system, HyPix diffractometer. The crystal was kept at a steady $T = 100(2) \text{ K}$ during data collection. The structure was solved with the ShelXT 2014/5 (Sheldrick, 2014) solution program using dual methods and by using Olex2 1.5-alpha (Dolomanov *et al.*, 2009) as the graphical interface. The model was refined with ShelXL 2016/6 (Sheldrick, 2015) using full matrix least squares minimisation on F^2 .



8. References

- (1) Takao, K. I.; Munakata, R.; Tadano, K. I. *Chem. Rev.* **2005**, *105*, 4779–4807.
- (2) Byrne, P. A.; Gilheany, D. G. *Chem. Soc. Rev.* **2013**, *42*, 6670–6696.
- (3) Maryanoff, B. E.; Reitz, A. B. *Chem. Rev.* **1989**, *89*, 863–927.
- (4) Biffis, A.; Centomo, P.; Del Zotto, A.; Zecca, M. *Chem. Rev.* **2018**, *118*, 2249–2295.
- (5) Clayden, J. Greaves, N. Warren, Stuart. in *Clayen's Organic Chemistry, Chapter 22*, Oxford University Press, Oxford, **2012**.
- (6) Komnenos, T. *Justus Liebigs Ann Chem* **1883**, *218*, 145–167.
- (7) Michael, A. *Journal Fur Praktische Chemie* **1887**, *35*, 349–356.
- (8) Kharasch, M. S.; Tawney, P. O. *J. Am. Chem. Soc* **1941**, *63*, 2308–2316.
- (9) Lipshutz, B. H.; Kozlowski, J. A.; Breneman, C. M.; Li Li Me-Cu, M. X.; -Cu -Me Lr, M.; Sloan, A. P.; J Am Chem Soc, J. J.; Chem Commun, J. J.; Org, J. J. *J. Am. Chem. Soc.* **1985**, *107*, 3197–3204.
- (10) Soai, K.; Yokoyama, S.; Hayasaka, T. *J. Org. Chem.* **1988**, *53*, 4148–4149.
- (11) Soai, K.; Hayasaka, T.; Ugajin, S. *Chem. Lett.* **1988**, 1570–1571.
- (12) Evans, D. A.; Seidel, D. *J. Am. Chem. Soc.* **2005**, *127*, 9958–9959.
- (13) Cacchi, S.; Palmieri, G. *Tetrahedron* **1983**, *39*, 3373–3383.
- (14) Cacchi, S.; Misiti, D.; Palmieri, G. *Tetrahedron* **1981**, *37*, 2941–2946.
- (15) Ahn, K.-H.; Klassen, B.; Lippard, S. J. *Organometallics* **1990**, *9*, 3178–3181.
- (16) Sibi, M. P.; Manyem, S. *Tetrahedron* **2000**, *56*, 8033–8061.
- (17) Sawamura, M.; Hamashima, H.; Ito, Y. *J. Am. Chem. Soc.* **1992**, *114*, 8295–8296.
- (18) Sakai, M.; Hayashi, H.; Miyaura, N. *Organometallics* **1997**, *16*, 4229–4232.
- (19) Takaya, Y.; Ogasawara, M.; Hayashi, T.; Sakai, M.; Miyaura, N. *J. Am. Chem. Soc.* **1998**, *120*, 5579–5580.
- (20) Hayashi, T. *Pure Appl. Chem.* **2004**, *76*, 465–475.
- (21) Fagnou, K.; Lautens, M. *Chem. Rev.* **2003**, *103*, 169–196.

- (22) Hayashi, T.; Takahashi, M.; Takaya, Y.; Ogasawara, M. *J. Am. Chem. Soc.* **2002**, *124*, 5052–5058.
- (23) Hayashi, T.; Ueyama, K.; Tokunaga, N.; Yoshida, K. *J. Am. Chem. Soc.* **2003**, *125*, 11508–11509.
- (24) Shintani, R.; Okamoto, K.; Hayashi, T. *Org. Lett.* **2005**, *7*, 4757–4759.
- (25) Duan, W. L.; Iwamura, H.; Shintani, R.; Hayashi, T. *J. Am. Chem. Soc.* **2007**, *129*, 2130–2138.
- (26) Defieber, C.; Paquin, J. F.; Serna, S.; Carreira, E. M. *Org. Lett.* **2004**, *6*, 3873–3876.
- (27) Xu, M. H.; Wang, W.; Lin, G. Q. *Org. Lett.* **2000**, *2*, 2229–2232.
- (28) Wang, W.; Xu, M. H.; Lei, X. S.; Lin, G. Q. *Org. Lett.* **2000**, *2*, 3773–3776.
- (29) Xu, M. H.; Wang, W.; Xia, L. J.; Lin, G. Q. *J. Org. Chem.* **2001**, *66*, 3953–3962.
- (30) Jin, S. S.; Wang, H.; Xu, M. H. *Chem. Comm.* **2011**, *47*, 7230–7232.
- (31) Takaya, Y.; Ogasawara, M.; Hayashi, T. *Tetrahedron Lett.* **1999**, *40*, 6957–6961.
- (32) Cammidge, A. N.; Goddard, V. H. M.; Gopee, H.; Harrison, N. L.; Hughes, D. L.; Schubert, C. J.; Sutton, B. M.; Watts, G. L.; Whitehead, A. J. *Org. Lett.* **2006**, *8*, 4071–4074.
- (33) Molander, G. A.; Ellis, N. *Acc. Chem. Res.* **2007**, *40*, 275–286.
- (34) Thierig, D.; Umland, F. *Naturwissenschaften* **1967**, *21*, 563–563.
- (35) Pucheault, M.; Darses, S.; Genet, J.-P. *Tetrahedron Lett.* **2002**, *43*, 6155–6157.
- (36) Pucheault, M.; Darses, S.; Genêt, J. P. *Eur. J. Org. Chem.* **2002**, 3552–3557.
- (37) Yamamoto, Y.; Takizawa, M.; Yu, X. Q.; Miyauro, N. *Angew. Chem., Int. Ed. Engl.* **2008**, *47*, 928–931.
- (38) Hayashi, T.; Senda, T.; Takaya, Y.; Ogasawara, M. *J. Am. Chem. Soc.* **1999**, *121*, 11591–11592.
- (39) Hayashi, T.; Senda, T.; Ogasawara, M. *J. Am. Chem. Soc.* **2000**, *122*, 10716–10717.
- (40) Senda, T.; Ogasawara, M.; Hayashi, T. *J. Org. Chem.* **2001**, *66*, 6852–6856.
- (41) Chen, G.; Tokunaga, N.; Hayashi, T. *Org. Lett.* **2005**, *7*, 2285–2288.

- (42) Shintani, R.; Duan, W. L.; Hayashi, T. *J. Am. Chem. Soc.* **2006**, *128*, 5628–5629.
- (43) Dian, L.; Marek, I. *Angew. Chem.* **2018**, *130*, 3744–3748.
- (44) Goetzke, F. W.; Hell, A. M. L.; van Dijk, L.; Fletcher, S. P. *Nat. Chem.* **2021**, *13*, 880–886.
- (45) Mishra, S.; Karabiyikoglu, S.; Fletcher, S. P. *J. Am. Chem. Soc.* **2023**, *145*, 14221–14226.
- (46) Albrecht, F.; Sowada, O.; Fistikci, M.; Boysen, M. M. K. *Org. Lett.* **2014**, *16*, 5212–5215.
- (47) Yoshida, K.; Hayashi, T. *Heterocycles* **2003**, *59*, 605.
- (48) Chai, G. L.; Zhang, P.; Yao, E. Z.; Chang, J. J. *Org. Chem.* **2022**, *87*, 9197–9209.
- (49) Yu, X. Q.; Yamamoto, Y.; Miyaura, N. *Synlett* **2009**, 994–998.
- (50) Ye, B.; Yao, J.; Wu, C.; Zhu, H.; Yao, W.; Jin, L.; Dou, X. *ACS Catal.* **2022**, *12*, 2434–2440.
- (51) Malapit, C. A.; Luvaga, I. K.; Caldwell, D. R.; Schipper, N. K.; Howell, A. R. *Org. Lett.* **2017**, *19*, 4460–4463.
- (52) Cox, P. A.; Leach, A. G.; Campbell, A. D.; Lloyd-Jones, G. C. *J. Am. Chem. Soc.* **2016**, *138*, 9145–9157.
- (53) Sravanthi, T. V.; Manju, S. L. *Eur. J. Pharm. Sci.* **2016**, *91*, 1–10.
- (54) Sundberg, R. in *The Chemistry of Indoles*, **1970**, pp. 1–92.
- (55) Dalpozzo, R. *Chem. Soc. Rev.* **2015**, *44*, 742–778.
- (56) Lipshutz, B. H.; Ghorai, S.; Cortes-Clerget, M. *Chem. Eur. J.* **2018**, *24*, 6672–6695.
- (57) Shen, T.; Zhou, S.; Ruan, J.; Chen, X.; Liu, X.; Ge, X.; Qian, C. *Adv. Colloid Interface Sci.* **2021**, *287*, 102299.
- (58) Lipshutz, B. H.; Isley, N. A.; Moser, R.; Ghorai, S.; Leuser, H.; Taft, B. R. *Adv. Synth. Catal.* **2012**, *354*, 3175–3179.
- (59) Khiar, N.; Valdivia, V.; Salvador, Á.; Chelouan, A.; Alcudia, A.; Fernández, I. *Adv. Synth. Catal.* **2013**, *355*, 1303–1307.
- (60) Cortes-Clerget, M.; Akporji, N.; Zhou, J.; Gao, F.; Guo, P.; Parmentier, M.; Gallou, F.; Berthon, J. Y.; Lipshutz, B. H. *Nat. Commun.* **2019**, *10*, 2169.

- (61) Khiar, N.; Valdivia, V.; Salvador, Á.; Chelouan, A.; Alcudia, A.; Fernández, I. *Adv. Synth. Catal.* **2013**, *355*, 1303–1307.
- (62) Salmi, C.; Letourneux, Y.; Brunel, J. M., *Lett. Org. Chem.* **2006**, *3*, 396–401.
- (63) Rodríguez, A.; Del Mar Graciani, M.; Angulo, M.; Moyá, M. L. *Langmuir* **2007**, *23*, 11496–11505.
- (64) Gabriel, C. M.; Lee, N. R.; Bigorne, F.; Klumphu, P.; Parmentier, M.; Gallou, F.; Lipshutz, B. H. *Org. Lett.* **2017**, *19*, 194–197.
- (65) Lipshutz, B. H.; Ghorai, S.; Cortes-Clerget, M. *Chem. Eur. J.* **2018**, *24*, 6672–6695.
- (66) Khiar, N.; Salvador, Á.; Chelouan, A.; Alcudia, A.; Fernández, I. *Org. Biomol. Chem.* **2012**, *10*, 2366–2368.
- (67) Li, Y.; Xu, M. H. *Chem. Commun.* **2014**, *50*, 3771–3782.
- (68) Sipos, G.; Drinkel, E. E.; Dorta, R. *Chem. Soc. Rev.* **2015**, *44*, 3834–3860.
- (69) Trost, B. M.; Rao, M. *Angew. Chem. Int. Ed.* **2015**, *127*, 5112–5130.
- (70) Borrego, L. G.; Recio, R.; Alcarranza, M.; Khiar, N.; Fernández, I. *Adv. Synth. Catal.* **2018**, *360*, 1273–1279.
- (71) Wang, Z.; Xu, M. H. *Org. Biomol. Chem.* **2018**, *16*, 4633–4640.
- (72) Wang, H.; Jiang, T.; Xu, M. H. *J. Am. Chem. Soc.* **2013**, *135*, 971–974.
- (73) Morton, D.; Pearson, D.; Field, R. A.; Stockman, R. A. *Org. Lett.* **2004**, *6*, 2377–2380.
- (74) Lipshutz, B. H.; Isley, N. A.; Moser, R.; Ghorai, S.; Leuser, H.; Taft, B. R. *Adv. Synth. Catal.* **2012**, *354*, 3175–3179.
- (75) Prieto, M.; Zurita, E.; Rosa, E.; Muñoz, L.; Lloyd-Williams, P.; Giralt, E. *J. Org. Chem.* **2004**, *69*, 6812–6820.
- (76) Wang, Y.; Xie, F.; Lin, B.; Cheng, M.; Liu, Y. *Chem. Eur. J.* **2018**, *24*, 14302–14315.
- (77) Zhu, T. S.; Jin, S. S.; Xu, M. H. *Angew. Chem. Int. Ed.* **2012**, *51*, 780–783.
- (78) Wu, X.; Ma, W.; Tang, W.; Xue, D.; Xiao, J.; Wang, C. *Chem. Eur. J.* **2022**, *28*, e202201829

- (79) Petrone, D. A.; Yoon, H.; Weinstabl, H.; Lautens, M. *Angew. Chem. Int. Ed.* **2014**, *53*, 7908–7912.
- (80) Lv, X.; Xiang, Q.; Zeng, Q. *Org. Prep. Proced. Int.* **2014**, *46*, 164–175.
- (81) Kudriashova, E. S.; Yarushina, M. A.; Gavryushin, A. E.; Grishin, I. D.; Malysheva, Y. B.; Otvagin, V. F.; Fedorov, A. Y. *Org. Lett.* **2023**, *25*, 4996–5000.
- (82) Warsitz, M.; Doye, S. *Chem. Eur. J.* **2020**, *26*, 15121–15125.

Appendix

Access to Electron-Rich Dibenzofurans through NBu₄OAc-Mediated Palladium Catalysis

Mark Power,^[a] Katrina Mackey,^[a] Mark E. Light,^[b] David J. Jones,^[c] and Gerard P. McGlacken^{*[a]}

Dibenzofuran and its derivatives are ubiquitous and important medicinal and natural products. Many contain electron-rich aryl rings. Forming the key intramolecular Ar–Ar bond using traditional cross-coupling is difficult. The C–H functionalisation (C–H activation) approach is, in principle, far more useful. However, we previously found that the well-established conditions, which promote C–H functionalisation through Concerted Metalation-

Deprotonation (CMD), proved unsatisfactory. Herein, we report a Pd-catalysed C–H functionalisation protocol that works with electron-rich arenes. We use tetrabutylammonium acetate (NBu₄OAc), which we suspect can act as base, ligand and solvent, rendering this protocol a simple and efficient route to electron-rich dibenzofurans.

Introduction

The dibenzofuran framework **1**, and its analogues, represent a prominent class of natural products and biologically active entities.^[1–3] Consequently, synthetic routes toward dibenzofurans have garnered keen interest from synthetic chemists.^[4–16] Retrosynthetic analysis of dibenzofuran reveals two separate intramolecular coupling strategies (Figure 1A): C–C bond formation through a diarylether **2** (Pathway A), or C–O bond formation through a biaryl motif **3** (Pathway B). Direct arylation has been applied successfully to form a decent range of dibenzofurans. Fagnou, in particular, demonstrated the power of the strategy to target C–H bonds in this context.^[6–8] The mechanism which evolved from the early studies on this work was termed Concerted Metalation-Deprotonation (CMD) or Ambiphilic Metal-Ligand Assistance (AMLA).^[17–19] This mechanistic pathway usually relies on the ‘acidity’ of the aryl C–H bond and thus, is less applicable to electron-rich substrates. As such, the methodology can be less successful, depending on the electronic properties of the diarylether substituent.^[4–16] That




Figure 1. Background to dibenzofurans.

said, it should be noted that a number of mechanisms can be envisaged here,^[20,21] most recently one which relies on the transmetalation step (rather than the C–H cleavage step) to determine regioselectivity.^[22] Recently we reported a methodology on the synthesis of substituted dibenzofurans through a palladium-mediated intramolecular direct arylation of a diarylether utilising a quinoline ligand (Figure 1B).^[14] This method proved particularly useful for electron-deficient systems,^[23] but the scope of the transformation was very limited for more valuable electron-rich examples. Naturally occurring and medicinally relevant dibenzofuran derivatives frequently contain electron-rich aryl rings and electron-donating groups (Figure 1C)^[2,24] and thus, there is a need for practical and robust methodologies that access these highly valuable targets.

More broadly, the optimisation of chemical structures by altering the electron donating and withdrawing properties of substituents is a common approach in medicinal chemistry,

[a] M. Power, Dr. K. Mackey, Dr. G. P. McGlacken
School of Chemistry, University College Cork
Ireland and Analytical and Biological Chemistry Research Facility (ABCRF)
University College Cork
T12 YN60 Cork (Ireland)
E-mail: g.mcglacken@ucc.ie

[b] Dr. M. E. Light
Chemistry Department, University of Southampton
University Road, Southampton SO17 1BJ (United Kingdom)

[c] Dr. D. J. Jones
EaStCHEM School of Chemistry
University of Edinburgh Joseph Black Building
David Brewster Road, Edinburgh, EH9 3FJ (United Kingdom)

Supporting information for this article is available on the WWW under <https://doi.org/10.1002/ejoc.202300790>

© 2023 The Authors. European Journal of Organic Chemistry published by Wiley-VCH GmbH. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.


material sciences and numerous other areas of chemical synthesis.^[25] Thus, it is important that new methodologies incorporating electron donating and electron withdrawing substituents are developed, to further access the required chemical space. Therefore, even for the most innovative new methodologies, accessing the full breadth of substrate scope is challenging.^[26–30]

Results and Discussion

As mentioned, previous work in our group investigated an intramolecular C–H activation approach to forming dibenzofurans, which faltered when electron-rich substrates were employed.^[14] During the evaluation of the substrate scope, we noticed rapid formation of palladium black when electron-rich substrates were used.

We initially considered that the use of a palladium scavenger such as tetrabutylammonium acetate (NBu₄OAc) might prevent palladium aggregation, leading to better conversion. We hoped this reagent could also act as a base, avoiding the need for added inorganic base.^[31] Indeed, initial investigations improved the yield for electron-rich substrates over our previous results, and good to excellent yields (up to 96% isolated) were observed (Table, entry 1–3). Lowering the temperature of the reaction gave reduced yields (Table 1 entry, 4). With these conditions to hand, we were able to reduce the Pd loading (2.5 mol%) while maintaining excellent yield (Table 1, entry 5). We also investigated the use of tetramethylammonium acetate (NMe₄OAc), but this gave lower yield (Table 1, entry 6). Finally, the potentially synergistic use of NBu₄Cl and K₂CO₃^[32] was trialled in the system but gave a lower yield of 67% (Table 1, entry 7). Various other conditions were tried but gave inferior results (see Supporting Information for details).

Table 1. Reaction optimisation of the electron-rich model substrate.

					
Entry	Base	Pd(OAc) ₂ [mol %]	Ligand [mol %]	t [h]	Yield ^[a] [%]
1	NBu ₄ OAc	5	SPhos (10)	24	81
2	NBu ₄ OAc	5	PCy ₃ .HBF ₄ (10)	24	96 ^[b]
3	NBu ₄ OAc	5	PCy ₃ .HBF ₄ (10)	16	66
4 ^[c]	NBu ₄ OAc	5	PCy ₃ .HBF ₄ (10)	24	41
5	NBu ₄ OAc	2.5	PCy ₃ .HBF ₄ (5)	24	95 ^[b]
6	NMe ₄ OAc	2.5	PCy ₃ .HBF ₄ (5)	24	74
7	NBu ₄ Cl & K ₂ CO ₃	2.5	PCy ₃ .HBF ₄ (5)	24	67


[a] Measured using ¹H NMR spectroscopy with 1,3,5-trimethoxybenzene as an internal standard; [b] compound is isolated after column chromatography; [c] reaction is run at 100 °C instead of 125 °C.

With conditions optimised, we tested this protocol to access a range of dibenzofurans (Scheme 1). It was also important to us that C–H functionalisation could occur on either ring, irrespective of the nature of the substituent, which of course meant that the halogenated aryl ring could also be derivatised. Both these goals were met, and in the case of **5a** and **5b**, C–H functionalisation was enacted on both the halogen-bearing and the halogen-free aryl ring, while also showing tolerance to fluorinated precursors. Another electron-rich substrate was synthesised in **5c** giving an excellent yield and regioselectivity (90% and 96:4). The high yield of **5c** was pleasing to see as this particular substrate was classed as a limitation when investigated using our previously developed methodology. Similarly, the reaction conditions allowed the *m*-methoxy dibenzofuran **5d** to be formed in 94%, with a regioselectivity of 97:3.

Diarylamines were also found to be compatible with the protocol allowing the carbazole motif **5e** to be isolated in 89% yield, in comparison to a moderate yield of 50%, previously reported.^[14] Further functionalisation was demonstrated with the acetyl substituted compound **5f** which was furnished in excellent yield (95%). Finally, heterocyclic dibenzofurans were also tolerated and we were delighted to see that benzofuropyridine **5g** was formed, and isolated in 84% yield.

Overall, the methodology successfully handled a range of substrates including electron-deficient, electron-rich and heteroaromatic diarylethers. Importantly, the methodology also functioned well, irrespective of which ring contained the halogen group, providing flexibility as a synthetic tool towards dibenzofuran targets.


Given that this protocol had clearly surpassed our previously published work and given the ubiquity of the dibenzofurans with multiple methoxy groups, we challenged our methodology with highly electron-rich diarylether precursors, reminiscent of naturally occurring dibenzofuran scaffolds.



Scheme 1. Substrate scope of the intramolecular ring closure to furnish derivatised dibenzofurans.

To a methodology relying on a CMD/AMLA mechanism, we suspected these substrates would represent a significant challenge.^[19] However, in our case, product **6a** could be formed in a yield of 91% and surprisingly, even the trimethoxy derivative of **6b** could be formed in 90% yield. Crystal structures were obtained for **6a** and **6b** (Scheme 2). A lower yield of 42% was obtained for substrate **6c**, nevertheless, this is a good, usable yield considering the electronic and steric challenges this substrate poses. An excellent yield of 95% was also observed for the dimethyl substrate **6d** using this protocol.

We next investigated the efficiency of the reaction in the absence of phosphine ligand. Pleasingly NBu₄OAc facilitated the ring closure, giving 70% of product formed using 2.5 mol% of palladium acetate in dioxane (Table 2, entry 1). Building on this initial success, we examined the use of excess NBu₄OAc in the absence of phosphine ligand and solvent. Gratifyingly, we were able to remove the need for both added ligand and added solvent using the organic base neat, obtaining a 93% yield (Table 2 entry 3). This interesting result leads us to believe that the NBu₄OAc can potentially play a tripartite role in the reaction: as solvent, base and ligand. It also exhibits potential for performing these reactions in a green fashion with no



Scheme 2. Substrate scope of electron-rich arene precursors.

Table 2. Phosphine free and PBu ₄ OAc investigations.				
Entry	Catalyst	Base [equiv.]	Solvent	Yield ^[a] [%]
1	Pd(OAc) ₂	NBu ₄ OAc (2)	1,4-dioxane	70
2	Pd(OAc) ₂	NBu ₄ OAc (5)	Neat	81
3	Pd(OAc) ₂	NBu ₄ OAc (10)	Neat	93 ^[b]
4 ^[c]	Pd(OAc) ₂	PBu ₄ OAc (2)	1,4-dioxane	81
5	PdCl ₄ (NBu ₄) ₂	NBu ₄ OAc (2)	1,4-dioxane	20

[a] Measured using ¹H NMR spectroscopy with 1,3,5-trimethoxybenzene as an internal standard; [b] yield is isolated after column chromatography; [c] reaction is run for 2 h.

Table 3. Comparison of our methodology with the literature conditions.

Entry	Ligand (6 mol%)	Solvent	Base (2 equiv.)	Ratio ^[a] 8:9
1- Fagnou ⁷	P ^t Bu ₂ Me.HBF ₄	DMA	K ₂ CO ₃	6.9:1 ^[b]
2	PCy ₃ .HBF ₄	1,4-dioxane	NBu ₄ OAc	1:1

[a] Ratio is measured by ¹H NMR spectroscopy; [b] ratio is as reported in the literature – we performed the same reaction and found the same isomer to predominantly form, but in varying ratios.

requirement for solvent (DMF and NMP are commonly used in these type of protocols), added phosphines, or inorganic base.

Finally, Liu and co-workers have shown that an alternative base, in the form of a phosphonium salt, can reduce reaction time as well as temperature in N-aryl coupling reactions.^[33] Thus, tetrabutylphosphonium acetate (PBu₄OAc) was employed in our reaction, and interestingly within 2 hours, gave the desired product in 81% (Table 2, entry 4). Additionally, Hull and co-workers have shown that tetraalkylammonium salts can form active catalytic species with palladium chloride.^[34] This palladate species was trialed in our system but proved inferior, giving only 20% yield (Table 2, entry 5).

Fagnou noted that intramolecular C–H bond functionalisation is not significantly influenced by the electronic nature of the arene, and that this is uncharacteristic of an S_EAr pathway.^[35] Indeed he noted that under his (CMD) conditions, in an intramolecular competition experiment, it is the H *ortho* to F that is cleaved (Table 3, entry 1). The same substrate using our conditions, gave a *ca.* 1:1 ratio of both constitutional isomers. Overall it is likely that a different mechanism is operative here, most likely involving electrophilic palladation.^[36] Further mechanistic investigations are underway and will be reported in due course.

Conclusions

In conclusion, we have developed a robust, efficient methodology to synthesise a range of dibenzofurans. In particular, difficult-to-access, electron-rich scaffolds, in good to excellent yields. Tetraalkylammonium salts, particularly NBu₄OAc, proved the linchpin, and appears to act as solvent, ligand and base in the reaction.

Experimental Section

General Information

Solvents and reagents were used as obtained from commercial sources and without purification. Column chromatography was

carried out using 60 Å (35–70 µm) silica. TLC was carried out on precoated silica gel plates (Merck 60 PF254). The developed plates were visualised under UV light. Melting points were obtained on a uni-melt Thomas Hoover Capillary melting point apparatus. NMR spectra were run in CDCl₃ or (CD₃)₂SO using TMS as the internal standard at 25 °C unless otherwise specified. ¹H NMR (600 spectra) ¹H NMR (500 MHz) spectra, ¹H NMR (400 MHz) spectra and ¹H NMR (300 MHz) spectra were recorded on Bruker Avance 600, Bruker Avance 500, Bruker Avance 400 and Bruker Avance 300 NMR spectrometers respectively. ¹³C (150 MHz) spectra, ¹³C (125 MHz) spectra, ¹³C (100 MHz) spectra and ¹³C (75.5 MHz) spectra were recorded on Bruker Avance 600, Bruker Avance 500, Bruker Avance 400 and Bruker Avance 300 NMR spectrometers respectively in proton decoupled mode. ¹⁹F NMR (376 MHz) and ¹⁹F NMR (282 MHz) spectra were recorded on a Bruker Avance 400 and Bruker Avance 300 NMR spectrometers respectively in proton decoupled mode. Chemical shifts δ_H and δ_C are expressed as parts per million (ppm), positive shift being downfield from TMS; coupling constants (*J*) are expressed in hertz (Hz). Splitting patterns in ¹H NMR spectra are designated as s (singlet), br s (broad singlet), d (doublet), dd (doublet of doublets), dt (doublet of triplets), t (triplet), q (quartet) and m (multiplet). For ¹³C NMR spectra, the number of attached protons for each signal was determined using the DEPT pulse sequence run in the DEPT-90 and DEPT-135 modes. Nominal mass spectra were recorded on a Waters Quattro Micro triple quadrupole spectrometer (QAA1202) in ESI mode using 50% acetonitrile–water containing 0.1% formic acid as eluent. High resolution mass spectra (HRMS) were recorded on a Waters LCT Premier Time of Flight spectrometer (KD160) or a Waters Vion IMS mass spectrometer (SAA055 K) in ESI mode using 50% acetonitrile–water containing 0.1% formic acid as eluent. Samples (max. 1 mg) were dissolved in acetonitrile, methanol, water or 10% DMSO/ acetonitrile. The Microanalysis Laboratory, National University of Ireland, Cork, performed elemental analysis using a Perkin-Elmer 240 and Exeter Analytical CE440 elemental analysers.

Experimental Procedure for the synthesis of compounds 1, 5a–g and 6a–d

Diarylether (1 equiv.), Pd(OAc)₂ (2.5 mol%), PCy₃·HBF₄ (5 mol%), NBu₄OAc (2 equiv.) and 1,4-dioxane (2 mL/mmol) were added to a sealed reaction vial equipped with a magnetic stir bar. The reaction mixture was stirred at 125 °C for 24 hours in a multi-reaction heating mantle. After 24 hours the reaction mixture was cooled to room temperature and diluted with DCM (15 mL), filtered through a pad of Celite® and the solvent was concentrated under reduced pressure. The resulting residue was then purified by column chromatography using hexanes:DCM as eluent on silica gel to elute the title products.

Supporting Information

Additional references cited within the Supporting Information.^[37–48]

Acknowledgements

This research was supported by the Irish Research Council (GOIPG/2019/952) and Science Foundation Ireland, through the Research Frontiers Programme (21/FFP-A/8784) and the Synthesis and Solid State Pharmaceutical Centre (SSPC) (SFI/12/RC/

2275 and SFI/ 846 12/RC2275_P2). Open Access funding provided by IReL.

Conflict of Interests

The authors declare no conflict of interest.

Data Availability Statement

The data that support the findings of this study are available in the supplementary material of this article.

Keywords: Dibenzofuran · palladium · catalysis, tetraalkylammonium salt · electron-rich

- [1] S. R. Patpi, L. Pulipati, P. Yogeewari, D. Sriram, N. Jain, B. Sridhar, R. Murthy, A. T. Devi, S. V. Kalivendi, S. Kantevari, *J. Med. Chem.* **2012**, *55*, 3911–3922.
- [2] B. E. Love, *Eur. J. Med. Chem.* **2015**, *97*, 377–387.
- [3] A. Momotake, N. Lindegger, E. Niggli, R. J. Barsotti, G. C. R. Ellis-Davis, *Nat. Methods* **2006**, *3*, 35–40.
- [4] J. Liu, A. E. Fitzgerald, N. S. Mani, *J. Org. Chem.* **2008**, *73*, 2951–2954.
- [5] Y. Wei, N. Yoshikai, *Org. Lett.* **2011**, *13*, 5504–5507.
- [6] L. C. Campeau, P. Thansandote, K. Fagnou, *Org. Lett.* **2005**, *7*, 1857–1860.
- [7] L. C. Campeau, M. Parisien, A. Jean, K. Fagnou, *J. Am. Chem. Soc.* **2006**, *128*, 581–590.
- [8] B. Liégault, D. Lee, M. P. Huestis, D. R. Stuart, K. Fagnou, *J. Org. Chem.* **2008**, *73*, 5022–5028.
- [9] H. Zhao, K. Yang, H. Zheng, R. Ding, F. Yin, N. Wang, Y. Li, B. Cheng, H. Wang, H. Zhai, *Org. Lett.* **2015**, *17*, 5744–5747.
- [10] N. Panda, I. Mattan, D. K. Nayak, *J. Org. Chem.* **2015**, *80*, 6590–6597.
- [11] J. W. Lockner, D. D. Dixon, R. Risgaard, P. S. Baran, *Org. Lett.* **2011**, *13*, 5628–5631.
- [12] C. Wang, I. Piel, F. Glorius, *J. Am. Chem. Soc.* **2009**, *131*, 4194–4195.
- [13] B. Xiao, T. Gong, Z. Liu, D. Luo, J. Xu, L. Liu, *J. Am. Chem. Soc.* **2011**, *133*, 9250–9253.
- [14] K. Mackey, D. J. Jones, L. M. Pardo, G. P. McGlacken, *Eur. J. Org. Chem.* **2021**, *2021*, 495–498.
- [15] T. Matsuzawa, K. Uchida, S. Yoshida, T. Hosoya, *Org. Lett.* **2017**, *19*, 5521–5524.
- [16] S. Prado, V. Toum, B. Saint-Joanis, S. Michel, M. Koch, S. T. Cole, F. Tillequin, Y. L. Janin, *Synthesis* **2007**, *10*, 1566–1570.
- [17] P. Gandeepan, T. Muller, D. Zell, G. Cera, S. Warratz, L. Ackermann, *Chem. Rev.* **2019**, *119*, 2192–2452.
- [18] Y. Boutadla, D. L. Davies, S. A. Macgregor, *Dalton Trans.* **2009**, 5820–5831.
- [19] M. Lafrance, K. Fagnou, *J. Am. Chem. Soc.* **2006**, *128*, 16496–16497.
- [20] K. M. Engle, D.-H. Wang, J.-Q. Yu, *J. Am. Chem. Soc.* **2010**, *132*, 14137–14151.
- [21] S. I. Gorelsky, *Coord. Chem. Rev.* **2013**, *257*, 153–164.
- [22] D. Kim, G. Choi, W. Kim, D. Kim, Y. K. Kang, H. H. Soon, *Chem. Sci.* **2021**, *12*, 363–373.
- [23] The introduction of electronic withdrawing groups (e.g. F and CF₃) to heterocyclic systems is an important strategy see R. Filler, Y. Kobayashi, L. M. E. Yagupolskii, *Organofluorine Compounds in Medicinal Chemistry and Biomedical Applications*, Elsevier, Amsterdam, Netherlands, **1993** and S. L. Clarke, G. P. McGlacken, *Tetrahedron* **2015**, *19*, 2906–2913 and citations therein.
- [24] W. Zhang, W. Wei, J. Shi, C. Chen, G. Zhao, R. Jiao, *Bioorg. Med. Chem. Lett.* **2015**, *25*, 2698–2701.
- [25] S. Dastmalchi, M. Hamzeh-Mivehroud, B. Sokouti in *Quantitative Structure-Activity Relationship, A Practical Approach*, 1st ed., Routledge CRC Press, USA, **2021**.
- [26] Y.-H. Zhang, B.-F. Shi, J.-Q. Yu, *J. Am. Chem. Soc.* **2009**, *131*, 5072–5074.
- [27] M. Li, M. Shang, H. Xu, X. Wang, H.-X. Dai, J.-Q. Yu, *Org. Lett.* **2019**, *21*, 540–544.

- [28] L.-Y. Liu, J. X. Qiao, K.-S. Yeung, W. R. Ewing, J.-Q. Yu, *J. Am. Chem. Soc.* **2019**, *141*, 14870–14977.
- [29] R. E. Tundel, K. W. Anderson, S. L. Buchwald, *J. Org. Chem.* **2006**, *71*, 430–433.
- [30] M. A. Mantell, M. R. Lasky, M. Lee, M. Remy, M. S. Sanford, *Org. Lett.* **2021**, *23*, 5213–5217.
- [31] F. Bellina, M. Lessi, C. Manzini, *Eur. J. Org. Chem.* **2013**, 5621–5630.
- [32] T. Jeffrey, *Tetrahedron* **1996**, *52*, 10113–10130.
- [33] C. Yang, Y. Fu, Y. Huang, J. Yi, Q. Guo, L. Liu, *Angew. Chem. Int. Ed. Engl.* **2009**, *48*, 7398–7401.
- [34] D. G. Kohler, S. N. Gockel, J. L. Kennemur, P. J. Waller, K. L. Hull, *Nat. Chem.* **2018**, *10*, 333–340.
- [35] D. Lapointe, K. Fagnou, *Chem. Lett.* **2010**, *39*, 1118–1126.
- [36] For a discussion on the mechanism of Direct Arylation see: a) D. Alberico, M. E. Scott, M. Lautens, *Chem. Rev.* **2007**, *107*, 174–238; b) G. P. McGlacken, L. M. Bateman, *Chem. Soc. Rev.* **2009**, *38*, 2447–2464.

Manuscript received: August 1, 2023
Revised manuscript received: September 6, 2023
Accepted manuscript online: September 13, 2023
Version of record online: September 28, 2023

Organolithium Bases in Flow Chemistry: A Review

Mark Power, Emma Alcock, and Gerard P. McGlacken*



Cite This: *Org. Process Res. Dev.* 2020, 24, 1814–1838



Read Online

ACCESS |



Metrics & More



Article Recommendations

ABSTRACT: Flow chemistry is a continually emerging and ever-growing area of synthetic organic chemistry. It provides an orthogonal approach to traditional batch chemistry, oftentimes allowing for more efficient routes to desired target molecules. It is generally accepted that flow chemistry offers a valuable change to the process landscape. From a process perspective, there are many advantages associated with flow chemistry over traditional batch chemistry, the most prominent of which is an increased safety profile with the use of highly reactive chemical species, such as organolithiums. These reagents are highly valuable species for the efficient synthesis of pharmaceutical intermediates. Disadvantageously, use of these reagents on commercial scale is severely hindered by the highly energetic nature of the reaction intermediates and their concomitant safety risk. Flow chemistry provides a viable platform for use of these reagents, offering a high degree of control over reaction parameters. In this review, we present a comprehensive account of the published literature implementing the use of organolithium reagents as strong bases for deprotonation reactions in flow systems.

KEYWORDS: *flow chemistry, organolithium, base, deprotonation*

INTRODUCTION

The recent and rapid development of flow chemistry has in many cases led to an orthogonal approach to traditional batch chemistry. The translation of a synthetic protocol from batch to continuous flow, along with the development of new continuous flow chemistry, can have a plethora of benefits, including the development of new reactivity patterns, improved reaction efficiency, and enhanced scalability.^{1–3} However, a cornerstone of flow chemistry is its enhanced safety profile. This facet of flow chemistry allows highly reactive reagents to be applied to large-scale reactions, which would not be feasible using flask chemistry. A review by Stevens and co-workers⁴ illustrates how many hazardous reagents such as diazo, diazonium, azide, and organometallic species are successfully and safely utilized in continuous processing.

Organometallic species such as organolithium and Grignard reagents are principal species in many organic transformations, but their scale-up is often hindered by their highly reactive nature. Flow chemistry has enabled a safer regime for the employment of organometallics, and reviews by Nagaki,⁵ Luisi,⁶ and Piccardi⁷ have showcased many examples of organometallic chemistry transferred from a flask operation to a flow platform.

Organolithium reagents are among the most reactive and arguably important species in organic synthesis, and their use is widespread across numerous synthetic transformations. The polar C–Li bond allows the reagent to act as a strong base or nucleophile in the formation of new C–C bonds. However, despite the undoubted usefulness of organolithium species in organic synthesis, their safety profile often hinders their scalability. The heat dissipation required when these reagents are used is difficult to achieve, and therefore, their use on an

industrial scale has proven to be an onerous task. Additionally, large-scale use of organolithium reagents results in the formation of precipitates, presenting the additional challenge of solubility. A continuous flow chemistry platform provides a viable alternative to traditional batch chemistry for these reactions. The high surface-to-volume ratio available in microreactors offers a means to circumvent a number of problems due to much improved methods of heat dissipation and, in turn, temperature control and energy transfer. Indeed, in certain applications even higher reaction temperatures may be tolerated in flow.


Consequently, the use of organolithium reagents in continuous flow systems is a very topical area of research. Organolithiums can be used to facilitate lithium–halogen exchange reactions or as strong bases in the construction of new molecular entities. The excellent reviews by Nagaki,⁵ Luisi,⁶ and Piccardi⁷ predominantly examine organolithium-mediated lithium–halogen exchange reactions.

This review aims to outline developments concerning the use of organolithium bases in continuous processes. To date, the concept of performing a deprotonation step via an organolithium species in flow chemistry has not been covered in a comprehensive review. Herein we evaluate the existing literature involving the use of organolithium species as strong bases in continuous processes. One of our aims is to describe the rationale and infrastructure behind translating a process

Special Issue: Flow Chemistry Enabling Efficient Synthesis

Received: March 6, 2020

Published: April 30, 2020



from batch to continuous flow, as well as detailing the scalability.

This review categorizes the available literature by the organolithium base selected for the scheme, namely, *n*-butyllithium (*n*BuLi), lithium diisopropylamide (LDA), lithium bis(trimethylsilyl)amide (lithium hexamethyldisilazide, LiHMDS), and other organolithium bases, including phenyllithium (PhLi), *sec*-butyllithium (*s*BuLi), and *n*-hexyllithium (*n*HexLi). It is worth noting that the use of *tert*-butyllithium (*t*BuLi) in continuous flow chemistry remains absent in the available literature. The structures of these organolithiums and their respective pK_a values are shown in Figure 1.^{8,9} Figure 2 depicts the symbols used throughout to illustrate the variety of flow chemistry components discussed in this review.




Figure 1. Chemical structures of organolithium bases. Quoted pK_a values are of the conjugate acid. The previously published value of 40 for *n*-hexyllithium⁸ is surprising low, and is likely to be closer to that of *n*-butyllithium (ca. 50).




Figure 2. Overview of continuous flow symbols.

■ *N*-BUTYLLITHIUM

n-Butyllithium is one of the most commonly employed organolithium reagents in organic synthesis.¹⁰ A publication by Ley and co-workers outlines the use of *n*BuLi in the construction of disubstituted alkynes.¹¹ The authors designed a low-temperature continuous flow platform where *n*BuLi and a variety of monosubstituted aryl alkynes were used to generate a series of disubstituted alkynes. The design of the system

involves a series of five reactor coils, arranged to mimic the batch reaction. In batch, this reaction has inherent reactivity issues, resulting in the need for precise temperature control. The intermediate ortho-fluorinated aryllithium species has the tendency to undergo ortho elimination if the temperature is not accurately controlled. This ortho elimination pathway produces an unstable benzyne intermediate, which, coupled with the exothermic nature of this decomposition, presents a potential safety risk upon scale-up. A flow chemistry system allows for precise reaction and temperature control, consequently removing the undesired ortho elimination pathway and the concurrent safety risk.

This continuous process used three loading loops to supply the five-coil platform with their respective reagents. The alkyne moiety and the organolithium base were both pumped through precooling units before coming together in the first reactor (RX 1) to generate the carbanion intermediate. This intermediate then progressed to meet a suitable electrophile, supplied to the system through a loading loop and a subsequent precooling unit to react in reactor 2 (RX 2). All of the reactors and precooling units were maintained at $-40\text{ }^{\circ}\text{C}$. The authors tested five combinations of substituted aromatic alkynes and electrophile substrates on this platform to successfully afford products of type 1 in yields of 86–90% (Figure 3). Optimization of temperature and *n*BuLi equivalents allowed the substrate scope to be expanded to *N*-methylimidazole and an Evans oxazolidinone auxiliary in yields of 75% and 53%, respectively. Substituted fluoroaromatic substrates were also tolerated when reacted with different electrophiles at $-50\text{ }^{\circ}\text{C}$ via fluorine directed ortho lithiation. The authors reported 13 such examples of ortho-substituted aryl products 2 in yields of 62–92% (Figure 4). It is worth noting that the presence of a nitrile group on the fluoroaromatic system meant that only the use of LDA yielded the desired product. It is thought that the steric bulk of LDA was necessary to prevent addition to the nitrile group. These substituted fluoroaromatic substrates were additionally reacted with CO_2 at $-50\text{ }^{\circ}\text{C}$ to produce carboxylic acids 3 in yields of 64–74% (Figure 5). The nitrile-containing fluoroaromatic once again required LDA to yield the desired product.

In work by Yoshida,¹² “flash chemistry” is used to avoid the issues concerning competing β -elimination associated with the use of 2-halovinylolithium in batch mode, thereby allowing the creation of synthetically useful substituted alkenes by the use of these unstable intermediates before they decompose. Initially, deprotonation of *trans*-1,2-dichloroethene by *n*BuLi yields 1,2-dichlorovinylolithium. In batch, this step requires cryogenic conditions and is usually performed at $-78\text{ }^{\circ}\text{C}$ or below. At $0\text{ }^{\circ}\text{C}$ in batch operation, with a slight excess of *n*BuLi and subsequent addition of benzaldehyde, no conversion to the desired product was attained. A flow scheme was designed to replicate these reaction conditions. The *trans*-1,2-dichloroethene and *n*BuLi were delivered to the system via syringe pumps and then brought together in a T-mixer to react for a short residence time. The resulting carbanion was then progressed to a second T-mixer, where it was mixed with an electrophile stream to generate the desired product. It was noticed that an increase in residence time of the deprotonation step could favor the undesired β -elimination of the *trans*-1,2-dichlorovinylolithium. Additionally, in continuous flow, a much higher temperature of $0\text{ }^{\circ}\text{C}$ gave optimal results. Lower temperatures resulted in a much reduced yield at a given residence time. Figure 6 illustrates a multistep flow platform




Figure 3. Initial five-coil setup for deprotonation and electrophile quench of alkynes, *N*-methylimidazole, and an Evans oxazolidinone auxiliary.




Figure 4. Five-coil setup for the synthesis of aromatic building blocks using a fluorine-directed ortho lithiation approach.




Figure 5. Five-coil setup coupled with a tube-in-tube reactor to deliver CO₂ as the electrophile for the ortho-lithiated fluoroaromatics.




Figure 6. Flow platform for the synthesis of disubstituted dichloroalkenes.




Figure 7. Flow platform for the synthesis of asymmetric disubstituted alkynes.




Figure 8. Flow system for the synthesis of a key intermediate in the production of efavirenz.

where subsequent deprotonation by *s*BuLi occurs after the electrophilic addition. A variety of electrophiles can be used to quench this intermediate, resulting in the formation of disubstituted dichloroalkene products **4** in yields of 62–73% (Figure 6). It is worth noting that in this scheme, a single deprotonation and substitution using only *n*BuLi and one electrophile was possible, and the authors also synthesized these monosubstituted alkenes in yields of 85–93%.

The authors then turned their attention to synthesizing disubstituted alkynes from *trans*-1,2-dichloroethene using a similar flow setup. The key difference in this procedure was the residence time of the first deprotonation, which was lengthened to 50.2 s to promote β -elimination, followed by a subsequent deprotonation by excess *n*BuLi. A quench with different electrophiles resulted in the formation of various disubstituted alkynes of type **5** in yields of 28–91% (Figure 7). The authors established a correlation between the residence time and the yield of either the alkene or alkyne product,

where the reaction conditions employed can be manipulated to generate either product in yields of up to 90%.

A publication by Watts and co-workers reported the transfer of the synthesis of efavirenz, a potent non-nucleoside reverse transcriptase inhibitor (NNRTI), from the common batch process to a continuous flow system.¹³ The traditional batch synthesis commonly utilizes *s*BuLi¹⁴ or the significantly more hazardous *t*BuLi¹⁵ to facilitate the deprotonation step. Using continuous flow chemistry, *n*BuLi can be used in place of these reagents, offering a much more convenient synthetic route. A continuous process was designed whereby the substrate and organolithium base were reacted to form a lithiated intermediate, which advanced to meet the trifluoroacetylating agent, forming the product **6** in up to 70% yield after an anhydrous silica quench. As an added benefit, the batch process requires *N,N,N',N'*-tetramethyl-1,2-ethylenediamine (TMEDA) as an additive, while continuous flow circumvents this requirement, consequently simplifying the purification




Figure 9. Continuous process to facilitate $n\text{BuLi}$ -mediated coupling in a key step during the synthesis of eribulin mesylate.




Figure 10. Continuous flow synthesis of dichlorocarbinols.

process. Optimization of the reaction conditions resulted in the reaction being conducted at $-40\text{ }^{\circ}\text{C}$ with a total residence time of 8.6 min using 2.5 equiv of $n\text{BuLi}$ and 2 equiv of trifluoroacetylating agent. The flow process is outlined with MX plates (used for their mixing structure) and VS plates (simply used to create the desired residence time) (Figure 8).

Similarly, work by Tagami and co-workers employs $n\text{BuLi}$ in the synthesis of the active pharmaceutical ingredient (API) eribulin mesylate in a continuous flow system.¹⁶ Eribulin mesylate is a fully synthetic derivative of the structurally complex marine natural product halichondrin B, approved by the U.S. Food and Drug Administration in 2010 for the treatment of breast cancer.¹⁷ In batch, the use of $n\text{BuLi}$ requires cryogenic conditions to complete this step. However,

with the continuous flow setup devised by the authors, a more attainable temperature of $-10\text{ }^{\circ}\text{C}$ afforded better conversion to product. In the continuous process, a solution of 7 is fed to the system by syringe pumps at 20 mL/min to meet a stream of $n\text{BuLi}$ supplied by a syringe pump to facilitate deprotonation α to the sulfone. The lithiated species then advances to meet aldehyde 8, generating the desired product 9 in 95% yield (Figure 9). Advantageously, continuous operation of this process for 87 min led to the same conversion and product quality. Reactions performed at $10\text{ }^{\circ}\text{C}$ initially increased yield to 96.5%, but longer runs led to degradation of the desired product over time.

A 2017 paper by Hafner et al. describes a robust procedure for the generation and subsequent use of thermally unstable




Figure 11. Continuous process for a fundamental Matteson homologation step in the synthesis of vaborbactam.

CHCl_2Li .¹⁸ The use of CHCl_2Li has been widely reported in the literature, but the thermal instability of the species limits its application to industrial use. Additionally, when an organolithium base such as $n\text{BuLi}$ is used to generate CHCl_2Li , cryogenic conditions of -78 to -100 °C are required to prevent the formation of a carbene species and consecutive degradation pathways. These temperature requirements add to the limitations on using CHCl_2Li on an industrial scale, but application of this reaction to a continuous flow scheme would obviate these limitations. These species serve as synthetically useful building blocks for many organic compounds. The authors devised a flow scheme where dichloromethane (DCM) and $n\text{BuLi}$ are first supplied to the system by syringe pumps and reacted for a short residence time of 0.5 s to generate CHCl_2Li . This lithiated species is then exposed to an electrophile for a residence time of 0.5 s. Initial optimization found that a total residence time of 1 s, 1.3 equiv of DCM, 1.2 equiv of $n\text{BuLi}$, and a combined flow rate of ~ 20 mL/min run at a temperature of -30 °C allowed the desired product to be successfully obtained in 96% yield when 3-methoxybenzaldehyde was used. Subsequently, a variety of carbonyl-containing compounds were examined, including electron-rich, electron-poor, and heterocyclic electrophiles, which afforded the corresponding carbinols with a throughput of 4.25 mmol/min (~ 1 g/min) on a multigram scale. The authors also found that carbonyl compounds bearing pendent electrophilic functionalities such as bromine, fluorine, and nitro groups were well-tolerated. These electrophiles proved problematic in batch, displaying a tendency to undergo undesired side reactions or decompose in the presence of the organolithium. The flow protocol was used to generate nine dichlorocarbinols **10** in 82–99% yield (Figure 10). Additionally, CHCl_2Li -mediated chain homologation of phenylboronic esters gave α -chloroboronic esters in yields of 70–89%.

Similarly, Schuster and co-workers reported the optimization of a continuous flow reaction setup for the synthesis of **11**, a key intermediate of the API vaborbactam.¹⁹ A review by

Hughes also outlined a 2016 patent by Rempex for this synthesis.²⁰ Vaborbactam is a cyclic boronic acid β -lactamase inhibitor that is commonly used to treat complicated bacterial urinary tract infections. The synthesis of a key intermediate in the process was translated to a flow platform because batch operation required extremely low temperatures and the reaction was sensitive to stoichiometry and mixing effects. An initial batch route involved a complex six-step synthesis furnishing vaborbactam in a yield of 30%.²¹ The synthesis involved a Matteson homologation, which required the anion CHCl_2Li . DCM is sufficiently deprotonated by $n\text{BuLi}$ when tetrahydrofuran (THF) is used as a cosolvent to prevent precipitation of $n\text{BuLi}$ at low temperature. The anion generated is fed into a subsequent reactor to meet the pinanediol boronate, where the Matteson homologation step occurs. Twelve GMP batches of this product were run, affording an average 89% yield to produce 880 kg of product. In batch, this step required temperatures of -95 to -100 °C and gave the desired compound in 75% yield with a diastereomeric ratio (d.r.) of 85:15. The employment of continuous flow technology allowed the temperature to be raised to a more manageable -60 °C. Additionally, the reaction performance in flow resulted in a greatly increased d.r. of 95:5 and a yield of 91%. Finally, the reproducibility of the synthesis in flow was far greater than that of the corresponding reaction in batch. The flow reaction was performed on a scale to produce 835 mg/min of intermediate **11** in the vaborbactam synthesis (Figure 11).

In the same review, Hughes described the continuous flow synthesis of lifitegrast, an API used to overcome dry eye.²⁰ In patents granted to SARcode, lifitegrast is prepared from three fragments that are coupled through amide coupling steps.²² The preparation of one fragment involves a low-temperature carboxylation step. SARcode recently filed a patent outlining the difficulties in batch scale-up, which resulted in lower yields and a tar-like material. To circumvent these issues, a continuous flow platform was designed for this particular




Figure 12. Continuous flow carboxylation to yield a central fragment in the synthesis of lifitegrast.




Figure 13. Continuous processing of the generation of lithiated methoxyallene and nucleophilic addition to benzophenone.

step.²³ The starting material and TMEDA were introduced together at $-78\text{ }^{\circ}\text{C}$, where they then met a stream of 2.5 M $n\text{BuLi}$. The 2.5 M solution was preferentially chosen over the 1.5 M solution of $n\text{BuLi}$ because it was found to have more consistent lot-to-lot quality. However, the commercially available 2.5 M $n\text{BuLi}$ contained residues that had to be filtered out before use to avoid precipitates that would cause damage to the pumps. Filters were installed prior to the pumps to allow a steady flow of the feedstock base. Lowering the residence time to 3.6 min as well as increasing the starting material concentration to 10% resulted in a higher conversion upon scale-up. Reaction with CO_2 in a subsequent reactor required a residence time of 1.6 min for complete conversion. The patent also noted that the reaction of excess $n\text{BuLi}$ with CO_2 generated valeric acid, which proved to be problematic because it froze in the lines. However, under the optimal conditions, reproducible product yields of 88–91% were achieved in several runs at 4–5 kg scale with a consistent product purity of 97–98%. SARcode prepared a total of 22 kg of carboxylated product **12** (Figure 12). The flow process enabled higher yield, reproducibility, and purity to be achieved on scale.

A publication by Stevens and co-workers addresses the thermal instability and safety concerns associated with the use of methoxyallene, or more specifically, the lithiated species.²⁴ Use of this lithiated species often provides the most efficient

route to targets such as APIs, but these routes are often excluded because of the lack of scale-up potential. Stevens envisioned that the precise control over the reaction parameters and the exquisite heat transfer properties of a flow system would allow a successful translation of the unsafe batch synthesis to a continuous flow platform. Through many rounds of process optimization, a three-step telescoped process was devised. Methyl propargyl ether was pumped by high-performance reciprocating pumps (syringe pumps) to meet a stream of KO^tBu in dry THF, fed to the system through a sample loop, to generate the methoxyallene species with excellent conversion. Subsequently, the methoxyallene species generated was lithiated by a stream of $n\text{BuLi}$ pumped to the reactor by two parallel syringe pumps. Syringe pumps, alongside sample loops, are often the chosen injection method of organolithium reagents for safety and chemical resistance reasons. As seen with many organolithium deprotonations in flow systems, efficient mixing is the cornerstone to successful conversions. The authors found that a regular T-connector and helical static mixing elements inserted in a tubular reactor afforded the optimal results, leading to conversions of up to 97%. The lithiated methoxyallene progressed to meet a stream of benzophenone, furnishing the desired product **13** in a yield of 94% with a throughput of 28.5 g/h (Figure 13).




Figure 14. Continuous flow system for oxadiazole deprotonation and substitution.




Figure 15. Flow synthesis of a tetrasubstituted iodoarene.

LITHIUM DIISOPROPYLAMIDE

LDA is a strong non-nucleophilic base generated from diisopropylamine and $n\text{BuLi}$. Common to most organometallics, the use of LDA often requires cryogenic and carefully controlled reaction conditions.¹⁰ Flow chemistry helps to alleviate issues associated with the use of LDA.

In a publication by Barker and co-workers, the batch and corresponding flow lithiation reactions of 1,3,4-oxadiazoles are reported.²⁵ These 1,3,4-oxadiazoles are common motifs in bioactive compounds, such as raltegravir and zibotentan. Prior to this paper, it was reported that α -lithiation of 1,3,4-oxadiazoles resulted in ring fragmentation.²⁶ However, the authors in this case reported the α -lithiation of 1,3,4-oxadiazoles in batch mode with yields of up to 91%. Since the batch reaction required a temperature of $-30\text{ }^{\circ}\text{C}$, the authors sought to develop a flow setup to achieve less harsh reaction conditions. The reaction was performed initially on a small-scale flow system where the 1,3,4-oxadiazole and LDA solutions were transferred using peristaltic pumps to meet in a reactor coil, producing the lithiated species, which was subsequently quenched in a second reactor coil by a variety of electrophiles, also supplied via peristaltic pumps. In continuous flow, the optimal residence time of 2.8 s achieved complete consumption of starting material and a yield of 86%. Most importantly, the continuous process was successfully performed at a much higher temperature of $0\text{ }^{\circ}\text{C}$. This temperature proved unsuccessful in batch because of decomposition of the lithiated species. Various electrophiles were well-tolerated, yielding highly functionalized oxadiazoles **14** in yields of up to 86% (Figure 14). These results were then applied to the synthesis of a key synthetic precursor of a

cathepsin K inhibitor. An in-flow lithiation–substitution of the substrate 2-methyl-5-phenyl-1,3,4-oxadiazole with pivaldehyde was achieved in 95% yield.

C–H lithiation facilitated by LDA is used to enable the iodination of 4-fluoro-2-(trifluoromethyl)benzonitrile in a publication by Dunn et al.²⁷ The desired product is a key intermediate in the preparation of a selective androgen receptor modulator API. Both LDA and PhLi (discussed later) were identified as effective bases for the C–H lithiation step. The authors of this paper previously carried out this reaction on a gram scale, where a batch procedure yielded 44% conversion to the 3-iodo product **15**. Increasing the reaction to the kilogram scale was detrimental to the reaction outcome, giving the product in only 11% yield.²⁸ The moderate to low yields achieved were a result of the formation of multiple byproducts. The authors hypothesized that the lithiated species was unstable under the reaction conditions and decomposed during the longer addition times. Localized hot spots, common to larger-scale reactions, specifically resulting from the exotherm associated with the iodination step, were also thought to negatively impact the yield. A possible solution to this issue involved the use of additional synthetic steps as well as a significant increase in material cost. Therefore, a continuous flow chemistry platform was designed to alleviate the energy transfer issues thought to be hindering the batch reaction. A small-scale reaction set was first performed to investigate the metalation step. Here it became clear that careful control of short reaction times, maintenance of low temperatures during exothermic processes, and precise reaction stoichiometry are key to ensuring optimal yield. The metalation and iodination steps are rapid and possess associated exotherms, so flow




Figure 16. Flow deprotonation and alkylation reactions via “memory of chirality”.

chemistry was targeted as an alternative approach. In situ NMR and IR were used to study the conversion of the 5-[Li] species to the thermodynamically preferred 3-[Li] species. These mechanistic insights drove the optimization of the second-generation flow process, which utilized standard syringe or HPLC pumps to supply the process with substrate, LDA, and I_2 streams, where LDA resulted in a 30:1 preference for the desired 3-[Li] species. This optimized process produced a 67% isolated yield with a throughput of 425 g/L/h (Figure 15). Remarkably, this flow process decreased the time required to synthesize 10 kg of product **15** from over a month to less than a week.

A publication by Alezra and co-workers outlines a three-step synthesis of quaternary α -amino acids based on the concept of memory of chirality (MOC).²⁹ The synthesis involves an intermolecular alkylation of an enolate where the initial chirality of the starting α -amino acid is “memorized” only at low temperatures by a chiral conformation of a tertiary aromatic amide. The strict temperature requirements meant that the reaction was extremely difficult to scale. This prompted the authors to develop a flow chemistry platform applicable to the synthesis. A flow chemistry scheme was devised by Alezra and co-workers in a subsequent paper.³⁰ Initially, the authors investigated an optimization of the two steps in this alkylation reaction in a flow-based system. With ethyl iodoacetate as their alkylating agent, analysis of the reaction parameters revealed the optimum conditions to be a temperature of $-55\text{ }^\circ\text{C}$ and a residence time of 35 s. The authors next turned their attention to the optimization of the alkylation step, where a variety of electrophiles were screened alongside parameters of temperature and *N,N'*-dimethylpropyleneurea (DMPU) addition. A continuous flow process was engineered where three syringe pumps and two T-mixers were used to initially deprotonate the chiral substrate and subsequently trap the anion formed with various electrophiles. Overall, the enantiomeric excess obtained using the flow system was slightly lower than that of the batch method. However, the flow system enabled a residence time of less than 3 min and the use of a superior temperature, allowing the reaction to be considered scalable. Four separate electrophiles were used and gave yields of amino acids **16** between 42 and 99% (Figure 16) and enantiomeric excess (ee) values of 57–89%. A gram-scale synthesis was also conducted with ethyl iodoacetate, and 1.2 g of product was obtained in 82% yield

with 89% ee at $-70\text{ }^\circ\text{C}$. However, despite the improved utility of the flow reaction, the reaction was found to be more sensitive to the nature of the electrophile in the flow process compared with the batch process.

As a base, LDA was investigated by the Ley group in a search for reactivity patterns not possible in batch mode.³¹ The authors decided to focus on homologation reactions using dibromomethane esters. Here the dibromomethane must be cleanly metalated as a key first step. Consuming LDA at $-90\text{ }^\circ\text{C}$ can take several minutes in this reaction, so short mixing times are undesirable. However, the lithiated dibromomethane species generated from the first step is an unstable species with a short half-life, with decomposition taking place even at temperatures as low as $-90\text{ }^\circ\text{C}$. Consequently, generating this species is unsuited to large-scale batch reactions. Flow chemistry was applied to the methodology and displayed efficient mixing with well-controlled residence times, thus alleviating the decomposition issues seen in batch. A continuous process was devised in which CH_2Br_2 and LDA were supplied by peristaltic pumps to be precooled in 0.5 mL coils at $-90\text{ }^\circ\text{C}$, with LDA delivered via a sample loop. The anion was formed in an initial 8 mL reactor coil over a 4 min residence time and was subsequently reacted with a variety of heterocycles. Pyridines, thiophenes, or isoxazoles were all tolerated in this reaction, and the yields obtained in flow were higher than those of the corresponding batch process. Additionally, heterocycles that were reported to fail under batch conditions were successfully reacted with dibromomethane in a flow system. The authors also focused their attention on developing new reactivity patterns not possible in batch mode involving the use of esters with an α -proton. In batch mode, the use of esters with α -protons resulted only in starting material. When lithiated dibromomethane was added to an ester, it could be protonated to form dibromoketone **17**, or a second equivalent of base could deprotonate the ester at the α -position to form the α -dibromo enolate intermediate. However, if an α -proton is present in the ester, the second equivalent of base will preferentially remove this over the dibromo proton, and thus, protonation of the kinetic intermediate reforms the starting material. The authors deduced that efficient mixing and suppression of back-mixing would allow the intermediate to exist long enough to be quenched by acid and not react with a second equivalent of base. Furthermore, the precise temperature control enabled by




Figure 17. Synthesis of dibromoketones using LDA for dibromomethane deprotonation in a flow system.




Figure 18. LDA-mediated carboxylation of heterocycles in flow.

the flow setup would allow harnessing of unstable intermediates that could not survive in batch. In batch attempts, several runs obtained an optimal yield of 10% of 1,1-dibromo-3-phenylpentan-2-one product. In a continuous flow system, there was an increase in the yield to 49% with 42% recovery of the starting material (Figure 17). Increasing the amount of lithiated dibromomethane species to 4.4 equiv resulted in a dramatic increase in the yield of **17** to 95%. As a result, more complex substrates could be utilized and successfully subjected to these conditions. It was found that substrates that were considered poor in batch were successful in flow, albeit in modest yields. The authors finally demonstrated a scaled example of their chemistry in which 1.74 g of the dibromoketone from α -methylcinnamyl ethyl ester was obtained in 25 min in 87% yield.

Kappe and co-workers described a method for the direct lithiation of terminal alkynes and heterocycles with subsequent carboxylation.³² Their paper outlines the use of two organolithium bases: LiHMDS and LDA. LDA was used for the conversion of heterocyclic substrates to their corresponding carboxylic acids. A flow system was designed where a variety of heterocycles were supplied to the system to meet a stream of LDA. The organolithium base deprotonated the heterocycle

after a residence time of 3 s to yield an anion that progressed to meet CO₂. The CO₂ was introduced to the system through a mass flow controller at a rate of 30 mL/min and facilitated carboxylation after a residence time of 0.5 s. The carboxylate synthesized was then quenched by a mixture of water and acetic acid (10:1). Attempts to quench the reaction with only water resulted in immediate clogging of the system, so acetic acid was required. Kappe reported that six heterocyclic substrates were tolerated to form products **18** in yields of 43–79% (Figure 18). Increasing the number of equivalents of LDA proved to be an ineffective method of increasing the yield but increasing the number of CO₂ equivalents to 1.9 did result in a small increase in yield.

LDA was once again utilized by Kappe and co-workers in a report wherein the authors showcased the ability to monitor a multistep continuous flow process by multiple inline analytical techniques known as process analytical technology (PAT).³³ The authors chose to study a multistep organolithium transformation that involved treating an ester substrate with LDA to yield the corresponding enolate, which was subsequently reacted with an electrophilic aldehyde. The flow microreactor system used for the reaction was coupled to in-line IR spectroscopy, in-line NMR spectroscopy, and online




Figure 19. Use of PAT instruments in a flow system to optimize ester deprotonation and addition to an electrophile.




Figure 20. Generation of α -hydroxy amides in a flow system.

UPLC to allow real-time reaction monitoring. Product quantification was made possible through the use of in-line ^1H NMR spectroscopy. ReactIR was used to quantify the irreversible deprotonation by LDA. The carbonyl stretch of the starting material can be observed at 1730 cm^{-1} and rapidly disappears because of deprotonation by LDA even at the shortest attempted residence time of 3.9 s. Additionally, a concentration versus response curve for the ester showed its limit of quantification to be $\sim 10\%$ of the initial concentration used, implying that over 90% of the material was successfully deprotonated. As with most flow processes, the authors initially optimized the system through investigation of temperature, LDA loading, and electrophile loading variability, and the process was found to operate most favorably at $20\text{ }^\circ\text{C}$, which was of great benefit in terms of energy savings because cooling was not required. The authors then demonstrated the scale-up possibilities of this platform by operating the process over 70

min to produce **19** with a productivity rate of 4.2 g/h (Figure 19).

■ LDA PREPARED IN SITU

LDA is a readily available organometallic reagent, marketed in various solutions and concentrations, allowing for end-user convenience. However, the use of commercial LDA is not without its limitations. Problems with reliable supply and fluctuations in quality and accurate concentration certainly limit the use of commercial LDA. For this reason, LDA is commonly generated in situ by the reaction of $n\text{BuLi}$ with diisopropylamine (DIPA). In situ generation of LDA results in increased accuracy and reactivity.³⁴ For production of LDA in a continuous flow system, an additional reactor coil can be added to the setup to pregenerate LDA.

In 2017, Knochel and co-workers utilized the in situ generation of LDA for the formation of α -hydroxy amides.³⁵ They developed an ambient temperature flow method for




Figure 21. LDA-mediated epimerization in a flow system.




Figure 22. Flow platform to facilitate the efficient synthesis of a key intermediate in the steps to AZD6906 synthesis.

nucleophilic amidation and thioamidation to yield carbamoyl-lithium intermediates. Subsequent reaction of these intermediates with carbonyl-containing compounds successfully furnished α -hydroxy amides **20** in good to excellent yields of 58–95% (Figure 20). Ketal, acetal, and aryl halide functionalities were well-tolerated in this reaction. The process was also successfully extended to include the synthesis of α -keto amides in moderate to good yields of 61–82% by employing Weinreb amides and structurally related *N*-morpholino amides. Additionally, the lithiation of thioformamides in the presence of *N*-morpholine benzamides provided a reliable route to valuable α -keto thioamides in 41–98% yield using this protocol. Furthermore, the authors found that under these optimized flow conditions, no side products derived from lithiation of the electrophile were found.

In similar work published by Ossola and co-workers, a continuous flow system was engineered to promote the epimerization of 3-(*tert*-butoxycarbonyl)-3-azabicyclo[3.1.0]hexane-2-carboxylic acid. This chemistry, facilitated by the *in situ* generation of LDA, provides a flow chemistry platform for the synthesis of unnatural amino acids, allowing for known literature procedures to be significantly shortened.³⁶ The authors outlined numerous methods attempted to successfully epimerize the substrate **21**. LDA was identified as the most suitable organolithium to enable this epimerization. Advantageously, the authors also identified short reaction times as a key factor in the success of the epimerization. Short reaction

times of <60 s would be difficult to conduct in batch mode, and a consequential decrease in yield would be expected. A continuous process was envisaged to facilitate the short reaction times necessary for these epimerizations, allowing for process scale-up. *n*BuLi and diisopropylamine were readily mixed at $-20\text{ }^\circ\text{C}$ to generate LDA, which progressed to meet (S)-cis-**21** at $-15\text{ }^\circ\text{C}$, yielding (R)-trans-**21** (Figure 21). The authors successfully produced 17 g of (R)-trans-**21** using this method in 55% yield with a throughput of 55 g/h, demonstrating the scalability of the process.

A paper by Pontén and co-workers at AstraZeneca recently highlighted the use of continuous flow chemistry in the synthesis of the gastroesophageal reflux inhibitor AZD6906.³⁷ Several problems were encountered throughout the batch synthesis of this API. Initial batch reactions required the use of cryogenic reaction conditions to overcome a potential exotherm and degradation of starting material. This would lead to numerous problems on scale-up. Second, the highly toxic reagent methylchlorophosphine presented serious safety concerns. Finally, for the batch reaction to proceed, the costly phosphonate reagent **22** was required in 2-fold excess to prevent the acidic protons of the product from quenching the anion created *in situ*. To overcome these issues, a continuous flow system was devised. It was anticipated that a flow system would prevent exposure of product to the anion formed, therefore removing the requirement for an additional equivalent of **22**. It would also reduce chemist exposure to the




Figure 23. Continuous flow lithiation of ethyl diazoacetate.




Figure 24. Continuous process for the regioselective lithiation–borylation of 3-hexylthiophene.

hazardous methyldichlorophosphine. An optimization period identified a reaction temperature of 35 °C, a residence time of 90 s, and an LDA concentration of 1.25 M to yield the best results while concurrently allowing issues of solubility and clogging to be avoided. The authors discontinued the use of commercial-grade LDA because of interbatch variability. Because the number of equivalents of LDA employed was critical to the reaction, the authors instead turned to generating the 3 equiv of LDA required in situ. This allowed for more consistent reaction results to be achieved and made the previously required degassing process redundant. Under these conditions, 1.3 kg of phosphinate **22** was processed, yielding sufficient amounts of **23** to proceed to the final stage of API synthesis (Figure 22).

Wirth and co-workers reported the optimization of a continuous flow system for the safe and efficient use of ethyl diazoacetate to access tertiary diazoalcohols in good yields.³⁸ As is common with the use of diazo compounds, the use of

ethyl diazoacetate is accompanied by an undesirable safety profile and poor thermal stability.³⁹ This diazo reagent is commonly combined with LDA to generate highly reactive ethyl lithiodiazoacetate. This lithiated reagent decomposes rapidly even at low temperatures, seriously hindering its use in batch reactions, where low-yielding and varying reaction results are commonly encountered. These authors described a flow chemistry platform using syringe and peristaltic pumps to allow more efficient and safe handling of this chemical species. LDA was generated in-line by combining streams of *n*BuLi and diisopropylamine and subsequently reacted with ethyl diazoacetate to produce the lithiated species. Trapping of this lithiodiazoacetate reagent with various ketones furnished diazo alcohols **24** in yields of 12–71% (Figure 23). In addition to the efficient handling of the unstable lithiodiazoacetate species, the yield of products generated in flow is higher than that in the corresponding batch reaction, providing a much more reliable method.




Figure 25. Continuous flow process for ester deprotonation and α -functionalization.




Figure 26. LiHMDS-mediated deprotonation and addition to ester substrates.

Work by Wong and co-workers also exploits the in-line generation of LDA for the construction of organic electronic materials. The metalating agent is used in a lithiation–borylation sequence for the generation of thiophene building blocks.⁴⁰ These building blocks can then be further functionalized to allow direct access to a range of high-performance organic electronic materials. The authors initially employed *n*BuLi as the base for the process. However, the regioselectivity of the reaction soon became an issue. Generation of mixtures of 2- and 5-substituted products, particularly boronic esters, which proved difficult to separate, prompted the authors to switch to LDA. The steric properties of LDA prompted exclusive lithiation at the 5-position. The authors described a telescoped procedure where LDA is generated in-line and reacted with the thiophene substrate. Subsequent reaction with the boronic ester gave product **25** with high regioselectivity

(17:1) in an excellent yield of 88% (Figure 24). The synthesis had a total residence time of 37 min and operated under more efficient temperatures than those observed in batch mode. The flow chemistry platform can be efficiently scaled up without the requirement for cryogenic conditions and without sacrificing the selectivity found in batch.

A final example of in-line LDA generation in a continuous flow system was described by Kappe and co-workers.⁴¹ Their work involved a multistep process to directly functionalize esters at the α -position via their enolates (Figure 25). Because of inherent reactivity issues associated with lithium enolates, it was postulated this reaction would be ideally suited to a continuous flow platform. The authors first optimized a reaction sequence using *tert*-butyl propionate, where it was found that with 2 equiv of LDA and a 30 s residence time at a temperature of 0 °C, the desired product was obtained in




Figure 27. *n*BuLi deprotonation using a dual-loop system in the first step of the preparation of a family of casein kinase I inhibitors.




Figure 28. Flow process for the carboxylation of alkyne substrates using CO₂.

yields of up to 90%. The flow system also incorporated an ultrasound bath in which the section of the flow setup involving the electrophile addition was immersed as a precautionary measure to circumvent issues arising from solid formation. The authors then turned their attention to optimizing a reaction using methyl propionate, which lacks the bulky *O*^tBu group and consequently has more complex selectivity issues. Homo-Claisen condensation products are a commonly observed byproduct from this reaction. This reaction requires a temperature of -78 °C during the enolate formation step. However, the authors suggested that the reaction is most likely not limited by mass transfer and instead that the poor selectivity results from similar reaction rates for the ester deprotonation reaction and the homo-Claisen condensation reaction. Six examples of α -alkylated esters of type **26** were reported to be successfully generated in 29–80% yield. Additionally, scaling of the process was simply achieved

by collecting the crude reaction mixture from the output for longer periods of time.

■ LITHIUM BIS(TRIMETHYLSILYL)AMIDE

Lithium bis(trimethylsilyl)amide, also called lithium hexamethyldisilazide (LiHMDS), is a lithiated organosilicon compound that is commonly used as a strong, non-nucleophilic base.⁴² A publication by Ley and co-workers outlines the synthesis of a family of casein kinase I inhibitors using a continuous flow system.⁴³ Analogues of imidazo[1,2-*b*]-pyridazine were prepared via a three-step sequence involving the formation of a ketone moiety, α -bromination, and subsequent condensation with 3-aminopyridazine to yield a key fragment of the target molecule (Figure 26). The authors designed a scalable multistep assembly to efficiently and directly deliver pure product on a multigram scale. The first step of the three-step sequence involved the use of LiHMDS.




Figure 29. Continuous flow chlorohomologation of aromatic esters leading to α -chloro- or α,α' -dichloroketones.

Using high-pressure pumps, the authors observed difficulties with the use of organolithiums, associated with rapid decomposition and difficulties with exotherm control. To sidestep these issues, a dual-sample-loop injection system was developed. One sample loop served to deliver the organolithium base to the system, while the second loop stored a second loading of base for later injection. This dual sample loop was cooled through submersion in a Dewar flask of water/dry ice before addition. LiHMDS was employed to deprotonate picoline substrates **27**, which reacted with esters to afford products of type **28** (Figure 26). However, LiHMDS was unable to deprotonate a particular 2-picoline substrate, so the authors turned to *n*BuLi. Because of competitive nucleophilic addition of the organolithium to the ester function, the fluorophenyl ester and picoline substrate could not be premixed (Figure 27). Instead, the picoline substrate and *n*BuLi were mixed in a T-mixer and allowed to react in a 5 mL coiled reactor held at $-78\text{ }^{\circ}\text{C}$. The azaenolate generated was then quenched by the ester in a 15 mL reactor coil at ambient temperature. This reaction sequence produced the corresponding ketone **29** in 65% yield on a 50 mmol scale.

A paper previously discussed outlining work by Kappe and co-workers using LDA in continuous flow for the carboxylation of heterocycles also described the application of this system to the carboxylation of alkynes.³² LiHMDS was the organolithium base used in this reaction to rapidly furnish a variety of carboxylic acids in less than 5 s. Only a slight excess of LiHMDS was required. The LiHMDS and the alkyne were pumped by HPLC pumps and loaded in individual sample loops to meet in a T-mixing unit before passing through a 0.1 mL coiled reactor for a residence time of 3 s to allow lithiation occur. The lithiated alkyne then progressed to a second T-mixer, where CO_2 was introduced. The product of the carboxylation then advanced to a third and final T-mixer, where it was quenched by H_2O , producing carboxylic acids **30** in good to excellent yields of 66–90% (Figure 28). Both electron-rich and electron-poor aromatic alkynes were well-tolerated, but the phenol and 3-ethynylpyridine substrates tested were unsuccessful because of precipitation of the organometallic intermediate in the reactor.

A paper by Knochel and co-workers described a continuous flow system that uses LiHMDS and chloroacetic acid to enable selective chloromethylation of functionalized esters.⁴⁴ This

Claisen homologation reaction was, for the first time, extended to bischloromethylation using dichloroacetic acid, resulting in a direct route to the underexplored α,α' -dichloroketones. The authors reported a flow system capable of producing both α -chloro- and α,α' -dichloroketones in good to excellent yields in several seconds. The ester and chloroacetic acid are premixed and precooled before being supplied to the system via a peristaltic pump. This mixture is combined with precooled LiHMDS in a T-mixer to generate the lithiated intermediate. This intermediate is then quenched by HCl to produce α -chloro- or α,α' -dichloroketones **31** (Figure 29). The reaction scheme is highly economical in terms of reagents and reaction time, has a breadth of application across a wide variety of substrates, and demonstrates potential for successful scale-up.

A paper by Kappe and co-workers described a scalable continuous flow system designed for the concise synthesis of α -difluoromethylamino acids.⁴⁵ The difluoromethyl group (CHF_2), delivered by the reagent fluoroform (CHF_3), is a moiety found in an increasing number of pharmaceutical and agrochemical products. Fluoroform is an attractive source for the introduction of this motif and is generated on a large scale as a reaction byproduct. Its global warming potential means the release of the gas into the atmosphere is restricted. The organolithium base LiHMDS is employed to deprotonate both an ester substrate and fluoroform, with the latter forming an electrophilic singlet difluorocarbene. This difluorocarbene moiety can then react with the anionic ester substrate, enabling the synthesis of α -difluoromethylamino acids **32**. These compounds are potent and selective irreversible inhibitors of their respective α -amino acid decarboxylases. This served as motivation for the authors to extend this flow methodology to the synthesis of eflornithine. The authors first performed batch reactions that proved to be unsuccessful, yielding only 2% conversion after 6 h. Resulting from this, the authors turned their attention to developing a continuous flow system to provide a more efficient route to the target. The continuous flow system uses two syringe pumps to feed the ester and LiHMDS into the system. The deprotonation occurs at $-30\text{ }^{\circ}\text{C}$ in a 2 mL reactor coil with a residence time of 4 min. Fluoroform is then introduced into the system with the aid of a mass flow controller. The solution is processed through two remaining reactors for a total residence time of 20 min. The




Figure 30. Continuous flow α -difluoromethylation using fluoroform.




Figure 31. Continuous processing of ingenol mebutate.




Figure 32. Continuous flow processing of asymmetric intramolecular cyclizations via "memory of chirality".

optimum reaction conditions were found to use 2 equiv of base. The process is applicable to several substrates, yielding good results when monoesters, malonates, and amino acids **32** were examined (Figure 30). Although the process is readily scalable, application on an industrial scale would have to involve a plan for removal and, ideally, recycling of excess fluoroform.

A 2017 patent application from Alphora also involves the use of LiHMDS in a continuous flow system toward a more efficient route to ingenol mebutate (**35**),⁴⁶ a protein kinase C

activator that is approved in the U.S. and Europe for the topical treatment of actinic keratosis, which can potentially develop into skin cancer. The Baran group found that only 1.1 mg of ingenol mebutate could be isolated from 1 kg of plant material.⁴⁷ However, ingenol (**33**) itself can be obtained in much larger quantities of 275 mg/kg from the seeds of the plant *Euphorbia lathryis*. Thus, a semisynthesis of ingenol mebutate from ingenol was attempted. Leo Laboratories developed a multistep batch synthesis involving protection and deprotection of the hydroxyl group to provide ingenol




Figure 33. Continuous flow synthesis of a key intermediate for API development via PhLi deprotonation.




Figure 34. Continuous flow system to generate laterally substituted aziridines.

mebutate in 37% yield.⁴⁸ In an attempt to streamline the synthesis, Alphora devised a more direct route to ingenol mebutate using a flow chemistry platform. The flow system involved a premixed solution of the organolithium base and ingenol undergoing acylation, facilitated by the use angelic anhydride (34) at 0 °C, followed by a 1 M HCl quench at 25 °C (Figure 31). This continuous process allowed for a single-step, protecting-group-free synthesis of ingenol mebutate in 40% yield with much improved regioselectivity for C3.

Finally, work by Vilé et al. identified LiHMDS as the optimal organolithium base for a continuous flow platform that facilitates the enantiospecific cyclization of methyl *N*-(*tert*-butoxycarbonyl)-*N*-(3-chloropropyl)-D-alaninate to 2-methylproline derivative 36 via the previously mentioned “memory of chirality” approach.⁴⁹ Flow technology was applied to this reaction scheme to improve the scalability and safety profile and to remove the need for cryogenic conditions. Additionally, the authors anticipated improved throughput from a flow-based system. A continuous flow platform was devised in which the substrate was delivered by a HPLC pump to meet 1.2 equiv of LiHMDS in a 1 mL reactor coil at −10 °C for a residence time of 30 s (Figure 32). The reactions were first performed on a 1 g scale, where the use of LiHMDS enabled an isolated yield of 36 of 96% with 97% ee. The authors then scaled the initial 1 g process to run continuously for 6 h with a

productivity of 11 g/h to yield 66 g of pure product while preserving the enantioselectivity. The exquisite control of reaction parameters usually required for MOC protocols positions flow approaches as an ideal technology to properly apply these concepts in practice. The designed flow process proved to be superior to the corresponding batch operation, as it operates a temperature of −10 °C, compared with the batch temperature of −60 °C, with a residence time of 30 s, compared with the batch reaction time of 2 h. Additionally, the continuous setup allows the process to be readily scaled to a multigram scale.

■ OTHER ORGANOLITHIUM BASES

Phenyllithium. Phenyllithium, or lithobenzene, is an alternative to the commonly used organolithium reagents discussed above.¹⁰ Although not as prevalent in the literature as *n*BuLi or LDA, it is often employed to carry out similar reactions. In a previously discussed paper by Dunn et al.,²⁷ PhLi was also used as an organolithium base to enable the iodination of 4-fluoro-2-(trifluoromethyl)benzonitrile. This process proceeds via C–H lithiation and subsequent treatment with iodine under continuous flow conditions. PhLi was chosen by the authors since it was seen to promote the formation of the 3-iodo isomer to a greater extent than LDA, which resulted in varying amounts of the unwanted 5-iodo




Figure 35. Continuous flow system enabling lateral lithiation–thermal isomerization of aziridines.




Figure 36. Continuous processing of the Mannich-type addition required in the manufacturing of verubecestat.

isomer. The initial continuous process designed by the authors involved mixing of PhLi and 4-fluoro-2-(trifluoromethyl)benzonitrile in a 10 mL reactor coil at $-70\text{ }^{\circ}\text{C}$ for 20 min to facilitate the lithiation step. The lithiated intermediate progressed to meet a stream of I_2 delivered by a syringe pump in a second reactor coil for a residence time of 10 min, affording the desired 3-iodo product **37** on a gram scale with a throughput of $57\text{ g L}^{-1}\text{ h}^{-1}$ in 63% yield (Figure 33). The authors then attempted to run the process on the pilot scale, but progress was hindered by the tendency of PhLi to add to the nitrile, lowering the yield to 50%. Additionally, this caused solid formation during longer runs. Despite these clogging events, 6.85 kg of product was generated over ca. 7 days of continuous processing involving multiple start/stop declogging events.

sec-Butyllithium. sBuLi is another organolithium base that is often used in synthesis as a powerful organolithium reagent.¹⁰ sBuLi is a stronger base than nBuLi but is less nucleophilic. Work by Luisi and coworkers investigated an alternative route to C4-functionalized 1,2,3,4-tetrahydroisoquinolines (THIQs) because of their significant relevance within

medicine.⁵⁰ A flow chemistry platform consisting of three syringe pumps, two independently sized T-mixers, and two tube reactors was designed to carry out these functionalizations. The enantiopure substrate and sBuLi are supplied independently to the system, furnishing the lithiated intermediate. Various electrophiles are then introduced to the system to yield the desired products **38/39**. It became apparent to the authors that the reaction was temperature-dependent. Contingent upon the reaction temperature, two possible mechanistic pathways were possible. When the temperature was held at $-48\text{ }^{\circ}\text{C}$ for the duration of the reaction, production of a range of laterally substituted aziridines **38** was possible in yields of 48–90% (Figure 34). Subsequent to deprotonation, increasing the temperature to $0\text{ }^{\circ}\text{C}$ allowed for the synthesis of C4-functionalized THIQs **39** in yields of 54–95% (Figure 35). The devised continuous flow process allowed for comprehensive isomer control. Furthermore, it allowed the direct synthesis of THIQs, of which only two known examples exist in batch.

n-Hexyllithium. nHexLi is an organolithium base that can usually be used in place of nBuLi.⁵¹ It is often used on plant




Figure 37. Continuous flow platform for *n*HexLi-mediated α -lithiation and subsequent oxidation.

scale as a cost-effective and industrially safe organolithium reagent. Additionally, in terms of flow chemistry, liquid byproducts are often easier to deal with than their gaseous counterparts. Thaisrivongs et al. reported the design of a continuous flow chemistry platform for the synthesis of verubecestat, a drug that reached Phase III trials for Alzheimer's disease before being discontinued.⁵² The batch synthesis of this drug candidate was problematic from the outset. The protocol proceeds via a Mannich-type addition of a methyl sulfonamide to a chiral Ellman-type sulfinyl ketimine. Excess sulfonamide and cryogenic reaction conditions were required for the batch procedure, even after several optimization attempts. The authors hypothesized that the mixing rate of the reactive species generated in the initial step was the key parameter for optimal conversion to the desired target. It was found that both the nucleophile and lithium anion irreversibly deprotonate the electrophile, competing with the Mannich-type reaction. It was thought a flow system would offer improved mixing and could alter this key parameter, preventing the irreversible deprotonation, by limiting the exposure of the ketimine from its lithiated intermediate. In the development of the continuous platform, the authors investigated the effects of four different variables: (1) mixers, (2) flow rates, (3) residence times, and (4) stoichiometry. Knowing that lithiation of the substrate was a relatively fast reaction, the authors rationalized that once the two input streams were completely homogenized, *n*HexLi would fully deprotonate the ketimine. Two different integration tees were identified as competent mixers, and ultimately the Koflo Stratos static tube mixer was chosen. Encouraged by successful mixing results, the authors proceeded to devise a scheme in which a third and fourth pump were added to facilitate the Mannich-type reaction and an in-line quench. After optimization, the designed system afforded a yield of 87% and a diastereoselectivity of 92:8 for **40** (Figure 36). Finally, the authors studied the effect of stoichiometry on the reaction, where preliminary batch experiments were used as a foundation for the continuous flow process. Several flow runs showed that when equimolar amounts of all of the reagents were used, only 64% conversion was observed. However, when 1.5 equiv of nucleophile, 1.7 equiv of *n*HexLi, and 1.8 equiv of methyl sulfonamide were employed, optimal conversion was

achieved. Additionally, the flow system removed the requirement for cryogenic reaction conditions, and reaction temperatures between -10 and 1 °C offered optimal results. Disappointingly, the authors were met with a challenge when attempting to scale the reaction to kilogram scale. Clogging was observed, and the problem appeared to increase with a rise in temperature. A decomposition event was thought to occur at the point of *n*HexLi mixing with methyl sulfonamide at the increased temperature. To avoid this issue, the heat exchangers and micromixers were cooled to -20 °C, which when coupled with optimized flow rates and stoichiometry enabled the reaction to be successfully run for over 1 h with a constant conversion of 90–91%.

Work by Luisi and co-workers illustrates the use of *n*HexLi in a continuous flow system to generate a dilithium enolate intermediate pivotal in the synthesis of cyclopentyl mandelic acid (CPMA, **41**).⁵³ The authors describe a telescoped process in which *n*HexLi and phenylcyclopentylacetic acid are mixed in a coiled reactor at 20 °C for a residence time of 5 min to yield the dilithium enolate intermediate. The flow platform designed uses syringe pumps to feed the reagents to the system and a sample loop to deliver *n*HexLi to the system. The intermediate then progresses to meet molecular oxygen in a second coiled reactor at 20 °C to yield the desired product **41** (Figure 37). The optimization initially used a continuous flow setup for each step of the synthesis independently. With the optimized parameters in hand, a telescoped process was examined, yielding a conversion of 57% and an isolated yield of 44%. Minor modifications to the system resulted in an increase in both conversion and isolated yield to 90% and 65%, respectively. This process is superior to the traditional methods employed to access CPMA, as the use of *n*HexLi and less than 10% O_2 in N_2 allows the platform to be considered industrially safe and scalable.

tert-Butyl esters are commonly found moieties in APIs and natural products. Luisi and co-workers reported a concise continuous flow system for the introduction of this functionality into various organic compounds.⁵⁴ Aryl and heteroaryl alkynes are reacted with *n*HexLi in a microfluidic system to perform direct *tert*-butoxycarbonylation. *n*HexLi is first reacted with the alkyne substrate, which is then progressed to meet a stream of $(Boc)_2O$, resulting in the generation of




Figure 38. Continuous flow system to enable *tert*-butoxycarbonylation of aryl and heteroaryl substrates.




Figure 39. Continuous flow platform for lithiation of allene gas to facilitate the generation of homopropargyl β -amino alcohol.

esters **42** in yields of 50–95% (Figure 38). This process proceeds at temperatures ranging from -40 to 20 °C. Syringe pumps feed reagents to the system, where they are precooled in P1, P2, and P3. The substrate and *n*HexLi are brought together in a T-mixer before reacting to generate the deprotonated species. The temperature applied to the system is substrate-dependent, and a wide variety of substrates are well-tolerated.

Work by Bio and co-workers used *n*HexLi to facilitate the preparation of a chiral β -amino alcohol through asymmetric propargylation in flow.⁵⁵ The direct metalation of allene gas is a potentially attractive strategy for propargylation reactions. Allene is an inexpensive and readily available reagent, but its use is accompanied by a serious safety concern. Furthermore, cryogenic conditions are required for the lithiation step. Continuous flow technology affords methodology where allene gas can be utilized efficiently for this reaction protocol. The requirement for cryogenic conditions can be eliminated on account of the improved heat transfer in flow technology. The use of an MFC allows gases to be accurately used in a continuous flow system. The authors found that allene gas could be rapidly dissolved as gas/liquid slugs in THF by controlling the flow rate of the THF delivered by a HPLC pump and that of allene gas delivered by the MFC. The deprotonation step was initially analyzed by FlowIR, where the

lithiated allene species appeared as a strong absorbance at 1864 cm^{-1} . The formation of the dilithiated allene species became apparent by the appearance of an absorption at 1900 cm^{-1} . This species proved to be problematic because it precipitated, resulting in clogging of the reactor, which was noticeable by a sharp increase in system pressure. Slow laminar flow and poor mixing causes a low allene versus *n*HexLi ratio, which was postulated as the cause of this issue. This problem was rectified simply by increasing the amount of allene gas added to the system in combination with the use of high-speed spinning-motioned stir bars, which ensured sufficient mixing and prevented clogging. These modifications enabled the continuous synthesis of allenyllithium at 0 °C for multiple hours. Further optimization identified the most efficient chiral ligand and necessary additive to establish a continuous platform for asymmetric allenylzinc propargylation. The flow process began with the allene/THF dissolution meeting a stream of *n*HexLi to generate the allenyllithium reagent. This was subsequently transmetalated with a chiral zinc complex (Zn^*) to furnish a chiral allenylzinc complex, whose formation was monitored by FlowIR. This complex proceeded to meet a solution of enantiopure Boc-L-alaninal (**43**) in a 25 mL continuous stirred tank reactor (CSTR) at room temperature. The authors found that the product d.r. was sensitive to the mode of mixing between the aldehyde and the allenylzinc chiral complex. The




Figure 40. LT unit continuous processing of DFT and DFBA.

CSTR was chosen because it produced the optimal d.r. for the reaction. The product was outflowed to a 50 mL tubular reactor to create the desired overall residence time of 10.6 min at ambient temperature to provide for the asymmetric propargylation (Figure 39). This continuous setup produced the desired β -amino alcohol **44** in 85% yield with a d.r. of 32:1 and a production rate of 15 g/h.

The final example of the use of *n*HexLi in continuous flow involved the scale-up of a robust lab-scale procedure to an industrial scale. A publication by Mleczko and co-workers reported the use of *n*HexLi and fluoroaromatic compounds to generate 2,3-difluorotoluene (DFT, **45**) or 2,3-difluorobenzaldehyde (DFBA, **46**) (Figure 40).⁵⁶ DFT is useful as an intermediate for the synthesis of pharmaceuticals and electronics and in the agrochemical industry. However, the lithiated intermediate generated en route is a highly reactive species that is known to participate in several runaway reactions. These authors used preliminary microreactor technology (MRT)-based laboratory experiments as a foundation for scaling DFT and DFBA synthetic processes. MRT was viewed as a preferable route to scale the process because of its superior heat transfer capabilities. Both synthetic routes have significant associated exotherms, leading to potential runaway reactions in a large-scale batch reactor. Thus, the laboratory studies with the fluoroaromatics were performed in a low-temperature (LT) microreactor. The reactions were performed at a temperature of $-45\text{ }^{\circ}\text{C}$ with a throughput of 10 g/h. In these reaction runs, DFT and DFBA were successfully synthesized in yields of 95% and 90%, respectively. The authors then repeated these experiments in an industrial standard LT unit. The LT unit used three parallel piston-membrane pumps to minimize pulsations in the continuous process. Temperatures were also measured directly in the product stream, downstream from the reaction modules.

Because of the exotherm associated with the process step, the process required a residence time of ~ 5 min to efficiently remove the heat produced, particularly in the challenging DFT route. In order to sustain stable operation during the DFT synthesis, the throughput had to be reduced from 1.07 to 0.5 kg/h. Higher throughputs led to runaway reactions in the second stage of the process. Using the optimized conditions in the LT unit gave a yield of 95% for both DFT and DFBA synthesis. Additionally, it was possible to scale the DFBA and DFT processes by factors of 100 and 50, respectively, with no negative impact on performance. Overall, the continuous process was superior to the corresponding batch process. A regioselectivity of 94% was achieved in the continuous process, in contrast to 90% in the batch operation. Furthermore, through the MRT operation approximately 40 kg of product was synthesized in 24 h using a total volume of 3 L. In batch mode, only 20 kg of product could be produced per 400 L batch in 24 h. Finally, a more scalable temperature of $-45\text{ }^{\circ}\text{C}$ was required in the continuous flow process, unlike the temperature of $-70\text{ }^{\circ}\text{C}$ necessary in batch mode.

CONCLUSION

Deprotonation chemistry using organolithium bases is a mainstay of organic synthesis. However, many organolithium reagents come with a nonideal safety profile, and typically this type of chemistry is carried out at low temperature (often $-78\text{ }^{\circ}\text{C}$). Thus, scale-up of these protocols in an industrial context is difficult. At the very least, direct synthetic routes that prove highly efficient at small scale are replaced by more convoluted ones on scale-up. Ultimately, predicted issues surrounding scale-up can lead to new chemistries and thus new molecular entities and associated biological activities being unexplored.

Flow chemistry has the potential to avoid most of the pitfalls associated with organolithium chemistry in batch through the

use of highly efficient mass and heat transfer, precise control of residence times, and mixing apparatus.

This review aims to underline the importance and associated benefits of continuous processing for the handling and employment of organolithium reagents in organic synthesis, paying specific attention to deprotonation chemistry. The papers cited herein demonstrate how cryogenic conditions are easier to control or can be eliminated in flow processes, leading to reductions in the number of synthetic steps, shorter processing times, more selective reactions, higher conversions, and improved safety profiles. Continuous flow chemistry has also allowed many unsuccessful or so-far-impossible batch mode reactions to be successfully performed.

Flow platforms offer variety within their systemic design where individual system modules can be interchanged for specific reaction control. Different pumps can be used for different reaction requirements. For example, on small scales, syringe pumps used alongside sample loops are often the chosen injection apparatus for organolithium reagents because of their improved safety and chemical resistance profiles. Furthermore, process analytical technology (PAT) tools are becoming more commonly integrated into continuous processes to identify key parameters for reaction success, aiding the efficiency and scalability of a given process. Finally, flow enables efficient telescoping of reaction schemes. In simple yet critically important examples, we see the generation of LDA in situ, which avoids issues around concentration and precipitation associated with the commercially available base.

All that said, it would be remiss to exclude the challenges still faced when using organolithium reagents in continuous flow. Thus, this review also highlights these problems, which include the persistent formation of precipitates, which leads to clogging of reaction systems. Importantly, however, some strategies are emerging to alleviate this problem, such as the filtering of feed stock solutions, accurate temperature control, and the development of clean-in-place techniques.

Additionally, certain elements of established small-scale organolithium batch chemistry are still widely unexplored in flow. For example, powerful asymmetric processes involving lithium (aza)enolates^{57–60} have not been investigated in flow. Furthermore, flow chemistry offers the potential to re-engage with the use of *t*BuLi as a reagent. The safety profile of *t*BuLi often causes chemists and industrialists to avoid its use. However, *t*BuLi is a very useful reagent for many organic reactions,¹⁰ and undoubtedly flow chemistry has the potential to add this reagent to our repertoire.

While flow chemistry is now considered a mainstream technology in pharma,⁶¹ the examples depicted in this review showcase how organolithium-base-mediated methodologies, which are often deemed difficult to scale-up because of their safety profile and heat transfer properties, can be cleanly handled and scaled in flow.

AUTHOR INFORMATION

Corresponding Author

Gerard P. McGlacken – School of Chemistry, Analytical and Biological Chemistry Research Facility (ABCRF), and Synthesis and Solid State Pharmaceutical Centre (SSPC), University College Cork, Cork T12 YN60, Ireland; orcid.org/0000-0002-7821-0804; Email: g.mcglacken@ucc.ie

Authors

Mark Power – School of Chemistry and Analytical and Biological Chemistry Research Facility (ABCRF), University College Cork, Cork T12 YN60, Ireland

Emma Alcock – School of Chemistry and Analytical and Biological Chemistry Research Facility (ABCRF), University College Cork, Cork T12 YN60, Ireland

Complete contact information is available at:
<https://pubs.acs.org/10.1021/acs.oprd.0c00090>

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

This work was supported by the Irish Research Council. The authors thank Dr. David Jones and Aobha Hickey for proof-checking.

REFERENCES

- (1) Fitzpatrick, D. E.; Ley, S. V. Engineering Chemistry for the Future of Chemical Synthesis. *Tetrahedron* **2018**, *74*, 3087–3100.
- (2) Gérardy, R.; Emmanuel, N.; Toupy, T.; Kassian, V. E.; Tshibalonza, N. N.; Schmitz, M.; Monbaliu, J. C. M. Continuous Flow Organic Chemistry: Successes and Pitfalls at the Interface with Current Societal Challenges. *Eur. J. Org. Chem.* **2018**, *2018*, 2301–2351.
- (3) Plutschack, M. B.; Pieber, B.; Gilmore, K.; Seeberger, P. H. The Hitchhiker's Guide to Flow Chemistry. *Chem. Rev.* **2017**, *117*, 11796–11893.
- (4) Movsisyan, M.; Delbeke, E. I. P.; Berton, J. K. E. T.; Battilocchio, C.; Ley, S. V.; Stevens, C. V. Taming Hazardous Chemistry by Continuous Flow Technology. *Chem. Soc. Rev.* **2016**, *45*, 4892–4928.
- (5) Nagaki, A. Recent Topics of Functionalized Organolithiums Using Flow Microreactor Chemistry. *Tetrahedron Lett.* **2019**, *60*, 150923.
- (6) Colella, M.; Nagaki, A.; Luisi, R. Flow Technology for the Genesis and Use of (Highly) Reactive Organometallic Reagents. *Chem. - Eur. J.* **2020**, *26*, 19–32.
- (7) Zhao, T.; Micouin, L.; Piccardi, R. Synthesis of Organometallic Compounds in Flow. *Helv. Chim. Acta* **2019**, *102*, e1900172.
- (8) Henderson, R. K.; Hill, A. P.; Redman, A. M.; Sneddon, H. F. Development of GSK's Acid and Base Selection Guides. *Green Chem.* **2015**, *17*, 945–949.
- (9) Green, P.; Zuev, D. Phenyllithium. In *Encyclopedia of Reagents for Organic Synthesis*; John Wiley & Sons: Chichester, U.K., 2001.
- (10) Clayden, J. In *Organolithiums: Selectivity for Synthesis*; Pergamon Press: Oxford, U.K., 2002; p 23.
- (11) Newby, J. A.; Blaylock, D. W.; Witt, P. M.; Pastre, J. C.; Zacharova, M. K.; Ley, S. V.; Browne, D. L. Design and Application of a Low-Temperature Continuous Flow Chemistry Platform. *Org. Process Res. Dev.* **2014**, *18*, 1211–1220.
- (12) Nagaki, A.; Matsuo, C.; Kim, S.; Saito, K.; Miyazaki, A.; Yoshida, J. Lithiation of 1,2-Dichloroethene in Flow Microreactors: Versatile Synthesis of Alkenes and Alkynes by Precise Residence-Time Control. *Angew. Chem., Int. Ed.* **2012**, *51*, 3245–3248.
- (13) Chada, S.; Mandala, D.; Watts, P. Synthesis of a Key Intermediate towards the Preparation of Efavirenz Using *n*-Butyllithium. *J. Flow Chem.* **2017**, *7*, 37–40.
- (14) Radesca, L. A.; Lo, Y. S.; Moore, J. R.; Pierce, M. E. Synthesis of HIV-1 Reverse Transcriptase Inhibitor DMP 266. *Synth. Commun.* **1997**, *27*, 4373–4384.
- (15) Muchowski, J. M.; Venuti, M. C. Ortho Functionalization of *N*-(*tert*-butoxycarbonyl)aniline. *J. Org. Chem.* **1980**, *45*, 4798–4801.
- (16) Fukuyama, T.; Chiba, H.; Kuroda, H.; Takigawa, T.; Kayano, A.; Tagami, K. Application of Continuous Flow for DIBAL-H Reduction and *n*-BuLi Mediated Coupling Reaction in the Synthesis of Eribulin Mesylate. *Org. Process Res. Dev.* **2016**, *20*, 503–509.

- (17) Lin, N. U.; Burstein, H. J. EMBRACE, Eribulin, and New Realities of Advanced Breast Cancer. *Lancet* **2011**, 377, 878–880.
- (18) Hafner, A.; Mancino, V.; Meisenbach, M.; Schenkel, B.; Sedelmeier, J. Dichloromethylolithium: Synthesis and Application in Continuous Flow Mode. *Org. Lett.* **2017**, 19, 786–789.
- (19) Stueckler, C.; Hermesen, P.; Ritzén, B.; Vasiloiu, M.; Poechlauer, P.; Steinhöfer, S.; Pelz, A.; Zinganell, C.; Felfel, U.; Boyer, S.; Goldbach, M.; De Vries, A.; Pabst, T.; Winkler, G.; LaVopa, V.; Hecker, S.; Schuster, C. Development of a Continuous Flow Process for a Matteson Reaction: From Lab Scale to Full-Scale Production of a Pharmaceutical Intermediate. *Org. Process Res. Dev.* **2019**, 23, 1069–1077.
- (20) Hughes, D. L. Applications of Flow Chemistry in Drug Development: Highlights of Recent Patent Literature. *Org. Process Res. Dev.* **2018**, 22, 13–20.
- (21) Hecker, S. J.; Reddy, K. R.; Totrov, M.; Hirst, G. C.; Lomovskaya, O.; Griffith, D. C.; King, P.; Tsvikovski, R.; Sun, D.; Sabet, M.; Tarazi, Z.; Clifton, M. C.; Atkins, K.; Raymond, A.; Potts, K. T.; Abendroth, J.; Boyer, S. H.; Loutit, J. S.; Morgan, E. E.; Durso, S.; Dudley, M. N. Discovery of a Cyclic Boronic Acid β -Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases. *J. Med. Chem.* **2015**, 58, 3682–3692.
- (22) Zeller, J. R.; Venkatraman, S.; Brot, E. C. A.; Iyer, S.; Hall, M. LFA-1 Inhibitor and Methods of Preparation and Polymorph Thereof. US 9,085,553 B2, July 21, 2015.
- (23) Tweedle, S.; Venkatraman, S.; Liu, S.; Zeller, J.; Brot, E.; Hamlin, M.; Newman, M.; McLaws, M.; Rosenberg, J.; Lathbury, D. Continuous Flow Carboxylation Reaction. US 2016/0090361 A1, March 31, 2016.
- (24) Seghers, S.; Heugebaert, T. S. A.; Moens, M.; Sonck, J.; Thybaut, J. W.; Stevens, C. V. Design of a Mesoscale Continuous-Flow Route toward Lithiated Methoxyallene. *ChemSusChem* **2018**, 11, 2248–2254.
- (25) Wong, J. Y. F.; Tobin, J. M.; Vilela, F.; Barker, G. Batch Versus Flow Lithiation—Substitution of 1,3,4-Oxadiazoles: Exploitation of Unstable Intermediates Using Flow Chemistry. *Chem. - Eur. J.* **2019**, 25, 12439–12445.
- (26) Micetich, R. G. Lithiation of Five-Membered Heteroaromatic Compounds. The Methyl Substituted 1,2-Azoles, Oxadiazoles, and Thiadiazoles. *Can. J. Chem.* **1970**, 48, 2006–2015.
- (27) Dunn, A. L.; Leitch, D. C.; Journet, M.; Martin, M.; Tabet, E. A.; Curtis, N. R.; Williams, G.; Goss, C.; Shaw, T.; O'Hare, B.; Wade, C.; Toczko, M. A.; Liu, P. Selective Continuous Flow Iodination Guided by Direct Spectroscopic Observation of Equilibrating Aryl Lithium Regioisomers. *Organometallics* **2019**, 38, 129–137.
- (28) Turnbull, P. S.; Cadilla, R. Indolecarbonitriles as Selective Androgen Receptor Modulators. US 9,533,948 B2, January 3, 2017.
- (29) Branca, M.; Gori, D.; Guillot, R.; Alezra, V.; Kouklovsky, C. Tertiary Aromatic Amide for Memory of Chirality: Access to Enantioenriched α -Substituted Valine. *J. Am. Chem. Soc.* **2008**, 130, 5864–5865.
- (30) Mambrini, A.; Gori, D.; Kouklovsky, C.; Kim, H.; Yoshida, J.; Alezra, V. Memory of Chirality in a Flow-Based System: Enantioselective Synthesis of Quaternary α -Amino Acids Using Flow Microreactors. *Eur. J. Org. Chem.* **2018**, 2018, 6754–6757.
- (31) Hartwig, J.; Metternich, J. B.; Nikbin, N.; Kirschning, A.; Ley, S. V. Continuous Flow Chemistry: A Discovery Tool for New Chemical Reactivity Patterns. *Org. Biomol. Chem.* **2014**, 12, 3611–3615.
- (32) Pieber, B.; Glasnov, T.; Kappe, C. O. Flash Carboxylation: Fast Lithiation–Carboxylation Sequence at Room Temperature in Continuous Flow. *RSC Adv.* **2014**, 4, 13430–13433.
- (33) Sagmeister, P.; Williams, J. D.; Hone, C. A.; Kappe, C. O. Laboratory of the Future: A Modular Flow Platform with Multiple Integrated PAT Tools for Multistep Reactions. *React. Chem. Eng.* **2019**, 4, 1571–1578.
- (34) Gupta, L.; Hoepker, A. C.; Singh, K. J.; Collum, D. B. Lithium Diisopropylamide-Mediated Ortholithiations: Lithium Chloride Catalysis. *J. Org. Chem.* **2009**, 74, 2231–2233.
- (35) Ganiek, M. A.; Becker, M. R.; Berionni, G.; Zipse, H.; Knochel, P. Barbier Continuous Flow Preparation and Reactions of Carbamoyllithiums for Nucleophilic Amidation. *Chem. - Eur. J.* **2017**, 23, 10280–10284.
- (36) Bakonyi, B.; Furegati, M.; Kramer, C.; La Vecchia, L.; Ossola, F. Synthesis of All Four Stereoisomers of 3-(tert-Butoxycarbonyl)-3-azabicyclo[3.1.0]hexane-2-carboxylic Acid. *J. Org. Chem.* **2013**, 78, 9328–9339.
- (37) Gustafsson, T.; Sörensen, H.; Pontén, F. Development of a Continuous Flow Scale-Up Approach of Reflux Inhibitor AZD6906. *Org. Process Res. Dev.* **2012**, 16, 925–929.
- (38) Müller, S. T. R.; Hokamp, T.; Ehrmann, S.; Hellier, P.; Wirth, T. Ethyl Lithiodiazoacetate: Extremely Unstable Intermediate Handled Efficiently in Flow. *Chem. - Eur. J.* **2016**, 22, 11940–11942.
- (39) Clark, J. D.; Shah, A. S.; Peterson, J. C.; Patelis, L.; Kersten, R. J. A.; Heemskerk, A. H.; Grogan, M.; Camden, S. The Thermal Stability of Ethyl Diazoacetate. *Thermochim. Acta* **2002**, 386, 65–72.
- (40) Seyler, H.; Haid, S.; Kwon, T. H.; Jones, D. J.; Bäuerle, P.; Holmes, A. B.; Wong, W. W. H. Continuous Flow Synthesis of Organic Electronic Materials – Case Studies in Methodology Translation and Scale-up. *Aust. J. Chem.* **2013**, 66, 151–156.
- (41) von Keutz, T.; Strauss, F. J.; Cantillo, D.; Kappe, C. O. Continuous Flow Multistep Synthesis of α -Functionalized Esters via Lithium Enolate Intermediates. *Tetrahedron* **2018**, 74, 3113–3117.
- (42) Wu, G.; Huang, M. Organolithium Reagents in Pharmaceutical Asymmetric Processes. *Chem. Rev.* **2006**, 106, 2596–2616.
- (43) Venturoni, F.; Nikbin, N.; Ley, S. V.; Baxendale, I. R. The Application of Flow Microreactors to the Preparation of a Family of Casein Kinase I Inhibitors. *Org. Biomol. Chem.* **2010**, 8, 1798–1806.
- (44) Ganiek, M. A.; Ivanova, M. V.; Martin, B.; Knochel, P. Mild Homologation of Esters through Continuous Flow Chloroacetate Claisen Reactions. *Angew. Chem., Int. Ed.* **2018**, 57, 17249–17253.
- (45) Köckinger, M.; Ciaglia, T.; Bersier, M.; Hanselmann, P.; Gutmann, B.; Kappe, C. O. Utilization of Fluoroform for Difluoromethylation in Continuous Flow: A Concise Synthesis of α -Difluoromethyl-Amino Acids. *Green Chem.* **2018**, 20, 108–112.
- (46) Jordan, R. W. Continuous Flow Process for the Preparation of Ingenol-3-mebutate. US 9,758,464 B2, September 12, 2017.
- (47) Jørgensen, L.; McKerrall, S. J.; Kuttruff, C. A.; Ungeheuer, F.; Felding, J.; Baran, P. S. 14-Step Synthesis of (+)-Ingenol from (+)-3-Carene. *Science* **2013**, 341, 878–882.
- (48) Höberg, T.; Grue-Sorenson, G.; Liang, X.; Horneman, A. M.; Petersen, A. K. Method of Producing Ingenol-3-angelate. US 9,676,698 B2, June 13, 2017.
- (49) Vilé, G.; Schmidt, G.; Richard-Bildstein, S.; Abele, S. Enantiospecific Cyclization of Methyl N-(Tert-Butoxycarbonyl)-N-(3-Chloropropyl)-D-Alaninate to 2-Methylproline Derivative via 'Memory of Chirality' in Flow. *J. Flow Chem.* **2019**, 9, 19–25.
- (50) Giovine, A.; Musio, B.; Degennaro, L.; Falcichio, A.; Nagaki, A.; Yoshida, J.; Luisi, R. Synthesis of 1,2,3,4-Tetrahydroisoquinolines by Microreactor-Mediated Thermal Isomerization of Laterally Lithiated Arylaziridines. *Chem. - Eur. J.* **2013**, 19, 1872–1876.
- (51) Rathman, T. L. Hexyllithium. In *Encyclopedia of Reagents for Organic Synthesis*; John Wiley & Sons: Chichester, U.K., 2001.
- (52) Thaisrivongs, D. A.; Naber, J. R.; McMullen, J. P. Using Flow To Outpace Fast Proton Transfer in an Organometallic Reaction for the Manufacture of Verubecestat (MK-8931). *Org. Process Res. Dev.* **2016**, 20, 1997–2004.
- (53) De Angelis, S.; Hone, C. A.; Degennaro, L.; Celestini, P.; Luisi, R.; Kappe, C. O. Sequential α -Lithiation and Aerobic Oxidation of an Arylacetic Acid—Continuous-Flow Synthesis of Cyclopentyl Mandelic Acid. *J. Flow Chem.* **2018**, 8, 109–116.
- (54) Degennaro, L.; Maggilli, D.; Carlucci, C.; Fanelli, F.; Romanazzi, G.; Luisi, R. A Direct and Sustainable Synthesis of Tertiary Butyl Esters Enabled by Flow Microreactors. *Chem. Commun.* **2016**, 52, 9554–9557.
- (55) Li, H.; Sheeran, J. W.; Clausen, A. M.; Fang, Y.; Bio, M. M.; Bader, S. Flow Asymmetric Propargylation: Development of

Continuous Processes for the Preparation of a Chiral β -Amino Alcohol. *Angew. Chem., Int. Ed.* **2017**, *56*, 9425–9429.

(56) Laue, S.; Haverkamp, V.; Mleczko, L. Experience with Scale-Up of Low-Temperature Organometallic Reactions in Continuous Flow. *Org. Process Res. Dev.* **2016**, *20*, 480–486.

(57) McSweeney, C. M.; Foley, V. M.; McGlacken, G. P. The asymmetric Alkylation of Dimethylhydrazones; Intermolecular Chirality Transfer Using Sparteine as Chiral Ligand. *Chem. Commun.* **2014**, *50*, 14817–14819.

(58) Cano, R.; Zakarian, A.; McGlacken, G. P. Direct Asymmetric Alkylation of Ketones: Still Unconquered. *Angew. Chem., Int. Ed.* **2017**, *56*, 9278–9290.

(59) Job, A.; Janeck, C. F.; Bettray, W.; Peters, R.; Enders, D. The SAMP-/RAMP-Hydrazone Methodology in Asymmetric Synthesis. *Tetrahedron* **2002**, *58*, 2253–2329.

(60) Franklin, A. S.; Paterson, I. Recent Developments in Asymmetric Aldol Methodology. *Contemp. Org. Synth.* **1994**, *1*, 317–338.

(61) Porta, R.; Benaglia, M.; Puglisi, A. Flow Chemistry: Recent Developments in the Synthesis of Pharmaceutical Products. *Org. Process Res. Dev.* **2016**, *20*, 2–25.

■ NOTE ADDED AFTER ASAP PUBLICATION

This paper originally published ASAP on 5/14/20. The caption for Figure 1 has been modified and the new version of the paper was reposted on 5/29/20.



The α -alkylation of ketones in flow†

Cite this: *React. Chem. Eng.*, 2023, 8, 1839

Ella Cooper,‡ Emma Alcock,‡ Mark Power and Gerard McGlacken *

Received 17th April 2023,
Accepted 29th April 2023

DOI: 10.1039/d3re00229b

rsc.li/reaction-engineering

The α -deprotonation and alkylation of ketones is a fundamental transformation in organic chemistry. However, the apparent simplicity of this process belies its complexity. Oftentimes experimental conditions are non-ideal, and yields are low. Herein, we directly target these issues, and provide a continuous flow methodology which leads to excellent yields, reduces reaction time, avoids cryogenic temperatures, minimises exposure to alkylolithiums/alkylhalides, and can be scaled-out.

The α -deprotonation and alkylation of ketones is a fundamental transformation in organic chemistry, taught at undergraduate level.¹ Ketone lithium enolates are utilised in particular,² and are applied ‘pervasively’³ both in academia² and industry.⁴ The abundance of commercially available ketones which are potentially enolisable (>10 000)⁵ bolsters the applicability of simple alkylation protocols.

Although a conceptually simple transformation, the practical α -alkylation of a ketone (Fig. 1) is plagued with issues. Firstly, the transformation can be low yielding.^{6–8} This is usually as a result of either: i) incomplete enolisation, ii) incomplete alkylation or iii) problematic side reactions. Aldol-type reactions/condensations, *O*-alkylation, dialkylation and persistent presence of starting ketone, are the most common issues. To alleviate these problems and effect some control over the reactivity of highly energetic lithium enolate intermediates, cryogenic reaction conditions (usually $-78\text{ }^{\circ}\text{C}$) are employed. Efficient ketone alkylation remains a key goal and a highly rewarding endeavour for organic chemists.⁹

Seminal reports by Enders and Corey¹⁰ described an alternative approach for the synthesis of α -substituted ketones. In this work, *N,N*-dimethylhydrazones (DMHs) were used as ketone surrogates allowing access to a range of α -substituted ketones in good yields. Despite the widespread

application of the DMH strategy,¹¹ the use of dimethylhydrazine in stoichiometric quantities, and issues around the formation of toxic by-products formed upon ketone reinstatement, makes this alternative protocol a very unattractive choice. The classic Stork enamine protocol¹² has advantages, but again is not a direct alkylation of ketones.

Overall, we envisaged that the direct alkylation of ketones could be improved upon, and a number of the issues (*vide supra*) could be obviated by using continuous flow technology. In addition to the challenges associated with the previously discussed issues, reactor clogging due to aggregation of organometallic speciation,^{13,14} was a concern of ours, but we anticipated that use of a peristaltic pump, at least during the process of alkylation and LiBr formation, would obviate these issues.

Listed as one of IUPACs top emerging technologies in chemistry in 2019,¹⁵ continuous flow chemistry has emerged from an enabling technology to a new platform for improved chemistry. The development of continuous flow chemistry





Fig. 1 The α -alkylation of ketones: issues alleviated in continuous flow.

School of Chemistry and Analytical and Biological Chemistry Research Facility, University College Cork, T12 YN60 Cork, Ireland. E-mail: g.mcglacken@ucc.ie

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d3re00229b>

‡ Authors contributed equally.





Scheme 1 The α -alkylation of propiophenone using BnBr.

can provide a plethora of benefits, including the discovery of new reactivity patterns, improved reaction efficiency, enhanced safety, and scalability.^{16–20} Pioneering work by Yoshida²¹ encapsulates these benefits *via* the use of organolithiums in flow.²²

An excellent report by Kappe involving the continuous flow alkylation of esters has been reported.²³ Specific issues “especially in the case of enolates derived from ketones” was noted by Kappe. The pointed divergent reactivity of ketones and esters (related to the comparatively lower pK_a ²⁴ and higher electrophilicity²⁵ of ketones) requires new methodology/engineering development, and a scale-out for both reactions in flow has yet to be reported to the best of our knowledge.

Herein, we document a successful continuous flow methodology for the synthesis of α -alkylated ketones in good to excellent yields. Numerous advantages over the corresponding batch reaction are detailed and include: i) reduced reaction times; ii) elimination of cryogenic conditions, iii) increased safety profile; and iv) facile scale-out.

Results and discussion

Initially, deprotonation of propiophenone using LDA²⁶ and α -alkylation using benzyl bromide (BnBr) was chosen as the model system for our optimisation (Scheme 1). In batch, this transformation uses temperatures as low as -78°C , and reaction times of up to 20 hours. This is a problematic reaction and, in our hands, we achieve variable yields of 25–45% in batch.

Our initial continuous flow set-up consisted of two reaction zones: i) enolate formation and ii) electrophilic addition. The ketone substrate was delivered to the system *via* a commercially available HPLC/piston pump (Vapourtec R-series). With the aid of a second HPLC/piston pump, a solution of commercially available LDA was added to the system *via* a sample loop. The alkylating agent was introduced *via* a peristaltic pump (Vapourtec R-series). A 10 mL dual-core cooled reactor coil and a 10 mL heated reactor coil were used for all reactions. PFA reactor tubing was utilised, and the reagents were sequentially mixed using Teflon T-mixers (Table 1). An anhydrous, inert atmosphere and a pressure of 7 bar was maintained throughout.

Initially, RC 1 was set at a temperature of -15°C and RC 2 was set to room temperature (rt) (Table 1, entry 1). Disappointingly however, these conditions resulted in no observed α -benzylated product. Subsequently, we decreased the temperature of RC 1, and increased the temperature of RC 2 (Table 1, entry 2), which gave a steady state yield of 15%. Gratifyingly, a continual increase of the temperature of

Table 1 Optimisation parameters for the α -alkylation of propiophenone using benzyl bromide^a

Entry	RC 1 temp ($^\circ\text{C}$)	RC 2 temp ($^\circ\text{C}$)	Residence time (min)	Steady state ^b (yield%)
1	-15	rt	5	0
2	-70	75	5	15
3	-45	75	5	39
4	-30	75	5	53
5	-15	75	5	64
6	0	75	5	70


^a Unless otherwise noted, conditions are as follows: 1 equiv. of propiophenone, 1.5 equiv. of LDA, 1.2 equiv. of BnBr. ^b Determined by use of ^1H NMR with 1,3,5-trimethoxybenzene as internal standard.

RC 1 to 0°C (Table 1, entries 2–6) culminated in a yield of 70% of α -benzylated product, at steady state.

With these partially optimised reaction conditions in hand, we made two further alterations to our reaction conditions. Firstly, due to decreased volatility, we changed the alkylating agent employed to *p*-*tert*-butylbenzyl bromide (for comparison, in our hands, we achieved a 44% yield in batch using this electrophile). Secondly, we altered the configuration of the dual-core cooled reactor (RC 1) from (2 mL + 8 mL) configuration to (8 mL + 2 mL) configuration. This configurational swap allowed for a greater residence time for the enolate formation step, which we hoped would result in an increased yield of α -benzylated product. Using our previously optimised conditions, we initiated these reactions with the temperature of RC 1 set to 0°C , which resulted in a 60% yield of α -benzylated product at steady state (Table 2, entry 1). Further increasing the temperature of RC 1 to room temperature resulted in a slight increase in the yield (Table 2, entry 2). In addition, the yield was further increased by lowering the equivalents of LDA (Table 2, entry 3). Extending the residence time from 5 min to 7.5 min resulted in a significant increase in the yield, to 80%, of α -benzylated product (Table 2, entry 4). Prolonging the residence time further to 10 min, gave a 90% steady state yield of α -benzylated ketone (Table 2, entry 5). However, any further increase in the residence time did not result in any improvement in yield (Table 2, entry 6).

With the optimised reaction conditions in hand, we next sought to examine a small range of ketones and electrophiles tolerated within this methodology (Table 3). Initially, the reactions of a range of electrophiles, including benzyl and allylhalides were examined in the α -alkylation reaction of propiophenone (Table 3, entries 1–6). Pleasingly, in all cases, good to excellent yields (75–92%) of α -alkylated products



Table 2 Optimisation parameters for the α -alkylation of propiophenone using *p*-tert-butylbenzyl bromide^a


Entry	LDA (equiv.)	Electrophile (equiv.)	RC 1 temp (°C)	Residence time (min)	Steady state ^b (yield%)
1	1.5	1.2	0	5	60
2	1.5	1.2	rt	5	63
3	1.2	1.5	rt	5	70
4	1.2	1.5	rt	7.5	80
5	1.2	1.5	rt	10	90
6	1.2	1.5	rt	15	60


^a Unless otherwise noted, conditions are as follows: 1 equiv. of propiophenone, RC 2 temperature set to 75 °C. ^b Determined by use of ¹H NMR with 1,3,5-trimethoxybenzene as internal standard.

were obtained at steady state. Altering the ketone substrate proved equally successful, with excellent yields obtained at steady state (92% & 95%) for the reaction of 2-phenyl acetophenone with both benzyl and allylhalides (Table 3, entries 7 & 8). Finally, we examined the reactivity of 3-pentanone in this methodology. This is a particularly difficult substrate to undergo α -alkylation and can produce very low yields.²⁷ Gratifyingly, a good yield of 55% of the α -benzylated 3-pentanone was achieved at steady state (Table 3, entry 9). No evidence for the formation of additional side-products, for example, dialkylated product, was observed for this substrate. Finally, further purification is often not needed, but steady state yields translated very well to isolated yields (Table 3). In the case of cyclohexanone, the yield using flow chemistry is lower (34%) than that in batch (49%) (see ESI†), and investigations are ongoing to improve yields using symmetric ketones.

Having demonstrated the versatility of this protocol, our next challenge was to scale-out our reaction to generate an appreciable quantity of α -alkylated ketone using this methodology. The α -alkylation of 2-phenyl acetophenone was chosen as the reaction to conduct these investigations (Scheme 2). Our previously optimised reactor configuration was altered to include a 10 mL sample loop, allowing for a significantly increased loading of LDA to our system. All other reaction parameters remained unchanged. Pleasingly, a yield of 96% of α -alkylated ketone at steady state²⁸ was achieved for this reaction, over a 45 min collection time.

Conclusion

In conclusion, we provide an efficient methodology for the alkylation of ketones in continuous flow. Conveniently, commercial LDA can be used as a base in the deprotonation


Table 3 α -Alkylation substrate scope using optimised parameters


Entry	Ketone	Electrophile	Product	Steady state ^a (yield%)	Isolated ^b (yield%)
1	1a	2b	3b	90	81
2	1a	2c	3c	75	70
3	1a	2d	3d	85	72
4	1a	2e	3e	87	71
5	1a	2f	3f	92	75
6	1a	2g	3f	80	71
7	1b	2b	3g	92	85
8	1b	2f	3h	95	80
9	1c	2b	3i	55	53

^a Determined by use of ¹H NMR with 1,3,5-trimethoxybenzene as internal standard. ^b Isolated yield after purification by column chromatography on SiO₂.

of several exemplar ketones along with a good variety of alkylhalides. The continuous flow protocol with good to excellent yields, provides numerous advantages over the corresponding batch reaction, including the avoidance of cryogenic temperatures, reduction in reaction time, lessening of side product formation and a convenient scale-out (>3 g of material in 45 min).





Scheme 2 Continuous flow set-up for the scale out of 2-phenyl acetophenone α -allylation. ^aDetermined by use of ¹H NMR with 1,3,5-trimethoxybenzene as internal standard.

Conflicts of interest

Vapourtec flow company helped in the early development of these reactions.

Acknowledgements

Funding was provided through the IRC Enterprise Partnership Scheme (IRC EPSPG/2021/130) co-funded by Pfizer, Ringaskiddy, Ireland as the Industry Partner. We thank the Science Foundation Ireland (SFI/21/FFP-A/8784), and the Synthesis and Solid State Pharmaceutical Centre (SSPC) (SFI/12/RC/2275 and SFI/12/RC2275_P2). We thank D. Guthrie, C. Guthrie and R. C. Moses at Vapourtec for advice, and time on their instruments. We thank Dr Kishore Kumar for proof-reading this manuscript.

Notes and references

- 1 J. E. McMurry, *Organic Chemistry*, Cengage Learning, Boston, 2015.
- 2 (a) B. M. Trost and I. Flemming, *Comprehensive Organic Synthesis*, Paragamon, Amsterdam, 1991; (b) J. Plaquevent, D. Cahard, F. Guillen and J. Green, *Science of Synthesis*, Georg Thieme Verlag, 2005, vol. 26, pp. 463–511; (c) A. R. Katritzky and R. J. K. Taylor, *Comprehensive Organic Functional Group Transformations II*, Elsevier, Amsterdam, 2005.
- 3 L. R. Liou, A. J. McNeil, A. Ramirez, G. E. S. Toombes, J. M. Gruver and D. B. Collum, *J. Am. Chem. Soc.*, 2008, **130**, 4859–4868.
- 4 (a) R. W. Dugger, J. A. Ragan and D. H. B. Ripin, *Org. Process Res. Dev.*, 2005, **9**, 253–258; (b) V. Farina, J. T. Reeves, C. H. Senanayake and J. J. Song, *Chem. Rev.*, 2006, **106**, 2734–2793; (c) G. Wu and M. Huang, *Chem. Rev.*, 2006, **106**, 2596–2616.
- 5 T. J. Donohoe, B. S. Pilgrim, G. R. Jones and J. A. Bassuto, *Proc. Natl. Acad. Sci. U. S. A.*, 2012, **109**, 11605–11608.
- 6 B. M. Trost and E. Keinan, *Tetrahedron Lett.*, 1980, **21**, 2591–2594.
- 7 B. M. Trost and J. Xu, *J. Am. Chem. Soc.*, 2005, **127**, 2846–2847.
- 8 B. M. Stoltz, N. B. Bennett, D. C. Duquette, A. F. G. Goldberg, Y. Liu, M. B. Loewinger and C. M. Reeves, in *Comprehensive Organic Synthesis II*, ed. P. Knochel, Elsevier, Amsterdam, 2014, pp. 1–55.
- 9 F. Mo and G. Dong, *Science*, 2014, **345**, 68–72.
- 10 (a) E. J. Corey and D. Enders, *Tetrahedron Lett.*, 1976, **17**, 11–14; (b) E. J. Corey and D. Enders, *Tetrahedron Lett.*, 1976, **17**, 3–6; (c) E. J. Corey and S. Knapp, *Tetrahedron Lett.*, 1976, **17**, 4687–4690.
- 11 R. Lazny and A. Nodzevska, *Chem. Rev.*, 2010, **110**, 1386–1434.
- 12 G. Stork, R. Terrell and J. Szmuszkowicz, *J. Am. Chem. Soc.*, 1954, **76**, 2029–2030.
- 13 T. Noël, J. R. Naber, R. L. Hartman, J. P. McMullen, K. F. Jensen and S. L. Buchwald, *Chem. Sci.*, 2011, **2**, 287–290.
- 14 S. L. Poe, M. A. Cummings, M. P. Haaf and D. T. McQuade, *Angew. Chem., Int. Ed.*, 2006, **45**, 1544–1548.
- 15 F. Gomollón-Bel, *Chem. Int.*, 2019, **41**, 12–17.
- 16 M. B. Plutschack, B. Pieber, K. Gilmore and P. H. Seeberger, *Chem. Rev.*, 2017, **117**, 11796–11893.
- 17 R. Porta, M. Benaglia and A. Puglisi, *Org. Process Res. Dev.*, 2016, **20**, 2–25.
- 18 M. Colella, A. Nagaki and R. Luisi, *Chem. – Eur. J.*, 2020, **26**, 19–32.
- 19 M. Baumann, T. S. Moody, M. Smyth and S. Wharry, *Org. Process Res. Dev.*, 2020, **24**, 1802–1813.
- 20 A. Hafner, P. Filippini, L. Piccioni, M. Meisenbach, B. Schenkel, F. Venturoni and J. Sedelmeier, *Org. Process Res. Dev.*, 2016, **20**, 1833–1837.
- 21 J.-I. Yoshida, *Basics of Flow Microreactors Synthesis*, Springer, Tokyo, 2015.
- 22 M. Power, E. Alcock and G. P. McGlacken, *Org. Process Res. Dev.*, 2020, **24**, 1814–1838.
- 23 T. von Keutz, F. J. Strauss, D. Cantillo and C. O. Kappe, *Tetrahedron*, 2018, **74**, 3113–3117.
- 24 F. G. Bordwell and J. A. Harrelson Jr, *Can. J. Chem.*, 1990, **68**, 1714–1718.
- 25 H. Neuvonen, K. Neuvonen, A. Koch, E. Kleinpeter and P. Pasanen, *J. Org. Chem.*, 2002, **67**, 6995–7003.
- 26 We also generated LDA *in situ* in flow from *n*-BuLi and diisopropylamine and used it in the formation of α -benzylated propiophenone from propiophenone and BnBr. However the yield was lowered to 42%. Overall, it proved advantageous and more convenient to use titrated commercial LDA, as we observed no reliability issues.
- 27 G. A. Molander and C. del Pozo Losada, *J. Org. Chem.*, 1997, **62**, 2935–2943.
- 28 The product was sufficiently pure at this stage (see ESI† for details and spectra).

